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The aim of these studies was to identify circulating miRNAs that can be used as 
biomarkers in patients with paracetamol-induced liver injury. Whether the miRNAs 
discovered in humans could be back-translated to zebrafish with the aim of 
developing a liver toxicity model to replace rodent use was also investigated. 
First, the miRNA signature of DILI induced by paracetamol was defined. Plasma 
miRNAs were quantified in paracetamol overdose patients. A signature of 16 miRNAs 
was discovered that best separated patients with liver injury from those without liver 
injury. This signature was tested in a second cohort and resulted in the detection of 
paracetamol-induced liver injury with high specificity and sensitivity. At first 
presentation to hospital miR-122-5p was the most sensitive single miRNA and 
superior to ALT activity in predicting liver injury. 
In order to further qualify miR-122-5p, three detailed studies relevant to possible 
clinical scenarios were performed. The effect of acute alcohol ingestion (commonly 
co-ingested with paracetamol overdose) on circulating concentrations of miR-122-5p 
in healthy volunteers was investigated. Alcohol ingestion induced a small, non-
clinically relevant, increase in miR-122-5p. The effect of chronic kidney disease (CKD) 
and haemodialysis (HD) on circulating miR-122-5p concentrations was explored 
because kidney dysfunction has been associated with a reduction in the 
concentration of circulating miRNAs. HD patients had lower concentrations of miR-
122-5p compared to healthy volunteers and CKD patients. To facilitate miRNA 
measurement outwith hospitals, miR-122-5p was measured in a blood drop from a 
finger prick. miR-122-5p was readily measurable in finger prick samples and 
concentrations were significantly higher in the blood drop from DILI patients 
compared with healthy volunteers.  
To complement miR-122-5p as a marker of toxicity, circulating paracetamol 
metabolites were measured in plasma samples from paracetamol overdose patients. 
A higher percentage of circulating metabolites formed by cytochrome P450 enzymes 
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were present in patients with liver injury and these metabolites were superior to both 
ALT and paracetamol concentration with regard to early patient stratification.  
To reduce need for rodent studies, miRNAs were back-translated into zebrafish. In 
order to study circulating miR-122-5p in adult zebrafish, a bloodletting method by 
collecting blood retro-orbitally was developed. After studying different dosing 
regimens of paracetamol in adult and larvae zebrafish the model was determined to 
be too variable with regard to liver injury. A new drug, triptolide, originating from 
traditional Chinese medicine and responsible for DILI in China, was tested as an 
alternative model for drug-induced liver injury in zebrafish larvae. miRNA-122-5p 
decreased in zebrafish larvae after triptolide treatment and triptolide-induced liver 
injury could be tracked by fluorescent microscopy. Selective plane illumination 
microscopy was able to track the decrease in liver volume during triptolide exposure. 
In order to identify the toxic pathways involved in triptolide-induced liver injury, RNA-
sequencing was performed. This identified KEGG pathways including ribosome, 
spliceosome and notch signalling as pathways affected by triptolide. 
In summary, miRNAs can be used as highly sensitive biomarkers to detect acute liver 
injury in patients and zebrafish. Zebrafish may represent an alternative model species 





Liver injury is a disease that can be caused by using drugs and can be life-threatening. 
A common cause of liver injury is paracetamol overdose. In this study, molecules 
called microRNAs were measured in the blood from patients after paracetamol 
overdose. It was discovered that a specific microRNA (miR-122) is released from the 
injured liver into the blood in massive amounts. Subsequently, miR-122 was 
measured in 3 common clinical scenarios. The first scenario was acute alcohol 
consumption that increased the concentration of miR-122 in the blood by a small 
amount. The second scenario was the effect of kidney injury, a common event during 
paracetamol overdose. It was found that patients on hemodialysis had a lower 
concentration of miR-122 before dialysis compared to healthy volunteers, chronic 
kidney disease patients and patients that previously had received a kidney transplant. 
To be able to measure miR-122 outside the hospital, miR-122 was measured in a 
blood drop from a finger prick. The concentration of miR-122 in the blood drops from 
patients was higher compared to healthy volunteers. To reduce the need for rodents, 
miR122 were measured in zebrafish. In adult zebrafish exposed to paracetamol, miR-
122 was increased in the circulation. After studying different concentrations of 
paracetamol in adult and larvae zebrafish, the model was too variable.  
A new molecule, triptolide, originating from traditional Chinese medicine and 
responsible for liver injury in China, was tested. In zebrafish larvae triptolide induced 
reproducible liver injury. miR-122 decreased in zebrafish larvae after triptolide 
treatment and triptolide-induced liver injury could be seen with microscopy. In order 
to find out how triptolide toxicity works, we studied gene expression and found that 
the expression of many genes was changed after triptolide treatment. In summary, 
miR-122 can be used as highly sensitive blood measures to detect acute liver injury 
in patients and fish. Zebrafish represent an alternative experimental model species 
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Chapter 1: Introduction 
 
1.1 Acute liver failure 
 
Fulminant hepatic failure was first described in 1970 as “a severe liver injury, 
potentially reversible in nature and with onset of hepatic encephalopathy within 8 
weeks of the first symptoms in the absence of pre-existing liver disease” (1). Today, 
the main elements of this description remain relevant, but the classifications have 
changed. Modern classification systems for acute liver failure (ALF) recognize distinct 
disease phenotypes (2). The classification developed by O’Grady and colleagues 
classifies ALF into hyperacute, acute or subacute. The determinants for these 
classifications are time from jaundice to encephalopathy, severity of coagulopathy, 
severity of jaundice and the degree of intracranial hypertension (3). The classification 
developed by Bernuau and colleagues divides the disorder into fulminant and 
subfulminant classes, depending on the jaundice to encephalopathy interval (4).  
These classifications are clinically useful and can help to indicate the probable cause 
and prognosis of the disease. In the Western world, the incidence of ALF is less than 
ten cases per million people every year (5-7). Historically, the mortality has been over 
80% (8). However, in the recent years, the possibility of liver transplantation and 
improvement in multidisciplinary intensive care support has reduced the mortality 
rate. Currently, the short-term survival post transplantation is more than 65% (9). 
Early identification of patients that will not survive without transplantation is of great 
importance. Various prognostic evaluation systems, developed from analyses of 
historical patient cohorts, have been introduced. Of these evaluation systems, the 
King’s College Criteria (KCC), using age, cause, encephalopathy, bilirubin level and 
coagulopathy as risk factors, is most commonly used (10). The results from a meta-
analysis from 18 studies with data from 1105 patients indicates that the KCC has a 
sensitivity of 68 (57-79)%, specificity 81 (72-90)% which indicates that there is a lot 
of room for improvement (11).  
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The two main causes of ALF are viral infections and drug-induced liver injury (DILI) 
(12, 13). In the developing world, the main cause of ALF are hepatitis A, B and E, 
whereas DILI is the most common cause of ALF in the US and the UK (13). 
 
 
1.2 Drug-induced liver injury 
 
DILI is a frequent cause of liver injury that presents with a broad spectrum of clinical 
manifestations that can vary from acute hepatitis, cholestasis, nodular regenerative 
hyperplasia and sinusoidal obstruction syndromes with each pathology being able to 
occur in acute or chronic patterns (14). Many drugs that cause DILI can be categorised 
as either intrinsic liver toxins, with dose-dependent and predictable adverse effects, 
or idiosyncratic (15).  
Idiosyncratic reactions are non-predictable and occur at therapeutic doses in only 
one per 1000 to 100 000 patients who take the medication (16). The latency of 
idiosyncratic DILI varies from 5 days to 90 days after the start of drug therapy and the 
severity can vary from mild asymptomatic injury to ALF. Idiosyncratic liver toxicity is 
usually identified in late stages of drug development or after a new drug has already 
been released to the marketplace, making it the most frequent reason for the 
withdrawal from the market of an approved drug (15, 17). Some drugs cause 
idiosyncratic DILI more often than other drugs. Notorious for causing DILI are some 
antibiotics including amoxicillin, isoniazid, trimetroprim, fluoroquinolones, 
macrolides and minocycline. Other drugs that are relatively common causes of 
idiosyncratic DILI are non-steroid anti-inflammatory agents, valproate, methotrexate 
and anabolic steroids (18). Partly because of its rarity, the pathogenesis of 
idiosyncratic DILI is incompletely understood which makes it hard to predict in earlier 
drug development stages (19). 
The most widely used drug causing intrinsic DILI is Paracetamol (Acetaminophen - 
APAP). Paracetamol is used by millions of people worldwide as a safe analgesic drug 
at therapeutic doses. In overdose, it is well known to be toxic to the liver. Indeed, in 
the Western world, paracetamol is the commonest cause of acute liver injury (ALI) 
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with being responsible for 57% of ALF cases in the UK (20) and close to 50% in the US 
(9, 21). Paracetamol overdose is a very common reason for hospital attendance 
(around 100,000 UK patients each year) (22). In terms of UK hospital admission, the 
number of patients per year (around 50,000) is comparable to other ‘giants’ of 
emergency medicine such as heart failure and hip fracture (23).  
To improve patient care and reduce pressure on already stretched health care 
providers, new biomarkers are needed that identify or exclude liver toxicity soon 
after the drug is ingested. This introduction highlights the current state of 
paracetamol poisoning management and how novel biomarkers could improve 
patient care and save healthcare providers money. 
 
1.3 Mechanism of paracetamol-induced acute liver injury  
 
At therapeutic doses, the major route of paracetamol metabolism is through 
conjugation. Cellular injury is due to the reactive metabolite N-acetyl-p-
benzoquinone imine (NAPQI) that is produced by the cytochrome P450 enzymes 
CYP2E1, CYP1A2 and CYP3A4 (24-26). At therapeutic paracetamol doses, only low 
concentrations of NAPQI are formed and this metabolite is efficiently detoxified by 
conjugation with glutathione. At toxic doses, the paracetamol conjugation reaction 
becomes saturated and more paracetamol becomes oxidised by cytochrome P450 
into NAPQI. The cellular stores of glutathione become exhausted, which results in 
NAPQI covalently binding to sulfhydryl (SH-) groups in structural proteins, forming 
protein adducts leading to oxidative stress, mitochondrial injury, hepatocyte cell 
death by either apoptosis (minor pathway) or necrosis (major pathway), multi-organ 
failure and potentially patient death (Figure 1) (27). Antidote treatment with 
acetylcysteine (NAC) restores cellular glutathione concentrations. When 
administered soon after drug overdose (within about 8 hours), NAC is highly effective 
in preventing liver injury (28, 29). However, when NAC treatment is delayed, its 





Figure 1. Paracetamol metabolism. At therapeutic doses conjugation is the major 
route for paracetamol metabolism. Oxidation of paracetamol by cytochrome P450 is 
a minor route at therapeutic doses of paracetamol, forming N-acetyl-p-
benzoquinone imine (NAPQI) that quickly reacts with glutathione. When an overdose 
of paracetamol is taken, conjugation becomes saturated and more NAPQI is formed 
by oxidation. When the glutathione supply is exhausted, NAPQI binds to sulfhydryl 
(SH-) groups in structural proteins, resulting in cell injury.  
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1.4 Use of ALT to assess risk of hepatocyte injury after paracetamol 
overdose  
 
Serum alanine amino transferase (ALT) activity is the current, widely used, biomarker 
for hepatocyte injury after paracetamol overdose (and in many other settings). 
Although ALT has never been formally qualified against liver histology as a biomarker 
for drug-induced liver injury in humans, its utility has been qualified by decades of 
clinical experience (30). However, the majority of patients present to the emergency 
department soon after overdose with only around 10% presenting later than 12 hours 
post drug ingestion (31). To confidently exclude the development of liver injury, 
patients require an ALT measurement at least 24 hours after the overdose was 
ingested (32). This limits patient stratification in emergency care settings and 
potentially increases length of hospital stay. Apart from these time/kinetic issues, 
there are other important limitations of using ALT as a biomarker of liver injury. 
Changes in ALT activity do not only occur in paracetamol-induced ALI, but with a wide 
range of acute and chronic liver pathologies such as fatty liver disease, viral hepatitis 
and liver cancer which decreases the confidence in its utility for causality assessment 
of paracetamol induced liver injury (33). Increases in serum ALT activity can also be a 
result of myocardial damage or extreme exercise (34), which may generate false-
positive results. Because paracetamol-induced ALI cannot be confidently confirmed 
or excluded by using serum ALT activity as a biomarker at the hospital ‘front-door’, 
the decision to treat with NAC following an overdose is primarily based on the blood 
paracetamol concentration (35). To stratify patients as being ‘at-risk’ for 
hepatotoxicity after a single overdose (total ingestion of paracetamol taking less than 
around 1-2 hours) a nomogram is used that plots blood paracetamol concentration 
against time after overdose. This nomogram can only be confidently applied 4 hours 
after overdose ingestion, when absorption is believed to be complete (36). The 
utilisation of the blood paracetamol nomogram after overdose depends on the 
correct reporting of the time of overdose, small errors in timing can result in an 
incorrect treatment (27). When the paracetamol overdose is ingested over a longer 
time period (staggered overdose) or if the patient was exposed to a modified release 
or intravenous formulation (37) the nomogram cannot be used and the treatment 
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decision is based on the reported dose of paracetamol and the serum ALT activity. 
There is an unmet clinical need for new biomarkers that can guide treatment to 
patients at high-risk of paracetamol-induced ALI and identify patients with low-risk 
of liver injury that may require shorter, lower doses of NAC or even no treatment at 
all. To decrease the risk of developing ALI, the MHRA lowered the utility threshold of 
NAC by using a single ‘100 mg l-l’ treatment line, treating all staggered/uncertain 
ingestions, ceasing risk assessment and increasing the duration of the initial NAC 
infusion from 15 to 60 minutes (38). Recent health economic calculations have 
estimated that this change resulted in an increase of around £8M in the annual spend 
by UK healthcare providers (22), which further strengthens the case for new 




1.5 Target Biomarker Profile 
 
In order to identify new biomarkers that could add real value to the management of 
paracetamol poisoning desirable and acceptable properties – the target biomarker 
profile (TBP - table 1) are proposed. 
Table 1. Desired and acceptable biomarker attributes. 
 
  
Attribute Desired Acceptable 
Specific for paracetamol 
overdose 




Sensitivity for ruling out 
injury 
ROC-AUC 1 AUC ≥ 0.90 
Rapidly assayed At point of care 
<60 minutes 
turnaround time  
 Feasibility of assay 
Feasible in settings where 
resources are sparse 
(developing countries) 
Feasible in standard 
clinical labs (developed 
countries) 
Invasiveness / sample 
preparation time 
Whole blood Plasma/serum 
Conserved (translational) 
across in vitro models, in 
vivo models and humans 
Fully conserved between 
in vitro models, in vivo 
models and humans 
Conserved between 
rodent models and 
humans 
Time after overdose at 
which it is able to predict 
the onset of liver injury 
 4h  8h 
Signal to noise 
Single measure required 
to differentiate between 
healthy reference value 
and disease 
Requires measurement 
at two time points 
Quantitative relationship 
with disease severity 
Quantitative Qualitative 
Distinguish benign and 
clinical relevant increase 
in ALT 
Predicts liver failure Predicts ALT rise 
Mediator of liver injury 
Has existing therapeutic 
intervention 
Potential drug target 
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This approach is widely used in biomarker development to set criteria that will be 
used to define future success. For further background the US Food and Drug 
Administration have produced guidance (39). The suggested biomarker properties 
specifically relate to the clinical management of paracetamol overdose, what is 
desirable or acceptable in other settings may be different. For all biomarkers their 
diagnostic performance may change when they are measured on different validated 
assay platforms (for example, a new point-of-care platform in contrast with the 
laboratory gold standard), so the TBP could need to be re-assessed when new clinical 
assays become available and rigorously validated. It is also important to note that 
defined desirable and acceptable properties can assist with the development of 
prospective qualification studies in man to define the context of use for a putative 
biomarker (40). 
A biomarker specific for paracetamol toxicity is desired, as this test could not be 
misinterpreted due to a signal produced by other causes of liver injury. A biomarker 
diagnostic for paracetamol toxicity would be valuable when the aetiology of liver 
injury cannot be identified, reported to be the case in 17% of patients with ALI (9). 
However, a marker that reports liver injury due to any cause is acceptable, since in 
most cases it is known that the patient has ingested an overdose (proven by blood 
paracetamol measurement).  
Ideally, a new biomarker would differentiate disease from non-disease with 100% 
sensitivity and specificity (area under the receiver operator curve (ROC-AUC) of 1), 
but an acceptable performance as a ROC-AUC of 0.90 is proposed. This is a 
comparable accuracy to troponin T assays when they were first introduced into 
clinical medicine for acute myocardial infarction stratification (41). In real clinical 
practice the biomarker’s context of use, derived from prognostic qualification studies 
in man, may prioritise sensitivity or specificity and the acceptable criterion is a 
starting point for development.  
If the biomarker could be assayed rapidly at point-of-care it could be used outside of 
standard hospital laboratories, for example, in an ambulance, phase 1 clinical trial 
unit or in the developing world. An acceptable level of performance would be a 
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turnaround time of 60 minutes in a standard hospital laboratory, as per the guidance 
of the clinical biochemists/chemical pathologists and clinical biochemistry services 
regarding the measurement of commonly requested routine clinical biochemistry 
and haematology tests in emergency departments (42). Ideally, the assay would be 
performed on a drop of whole blood obtained from the fingertip, resulting in a 
minimally invasive test with short sample preparation time. Acceptable would be 
measuring the biomarker in plasma or serum. The biomarker assay is desired to be 
measurable in settings where resources are sparse, such as in developing countries. 
But acceptable would be the ability to perform the assay in standard hospital labs. 
Recently, data suggest that ALT can be measured using a robust point-of-care, finger 
stick test with a rapid turn around time (43). Despite the drawbacks of ALT, this 
technology might provide the clinician with a signal that triggers an improved 
sensitive and specific liver safety assessment. Furthermore, advances in these 
technologies also point to a pathway of development and validation of such 
methodologies to assess potential biomarkers with improved characteristics at the 
point-of-care. 
If the biomarker can report liver injury as early as 4 hours after paracetamol ingestion, 
it would complement the paracetamol blood concentration nomogram for making 
treatment decisions in patients presenting early after overdose. Acceptable would be 
the ability to predict liver injury at 8 hours after paracetamol ingestion, the time point 
after which NAC treatment loses efficacy (28, 44). 
A biomarker that is fully translational between in vitro models, animals and humans 
would aid the detection of hepatotoxic compounds in drug development. However, 
a biomarker being translational between rodents and humans would be acceptable.  
A biomarker with a high signal-to-noise ratio that only requires a single measurement 
is desirable. Serial measurement would be acceptable, as is the case with troponin 
for acute myocardial infarction (45). 
Ideally, the biomarker could distinguish between a benign ALT rise, the development 
of serious liver injury and imminent liver failure with higher sensitivity and specificity 
than “Hy’s Law”, the most commonly method for indicating the risk of a drug to 
10 
 
induce sever liver injury (46). Hy’s Law has been developed by clinical observations 
of Dr. Hyman Zimmerman(47) and later specified by Dr. Robert Temple of the U.S. 
Food and Drug Administration based on ALT or AST and total bilirubin (48).Acceptable 
would be the prediction of an ALT rise. The ability of a biomarker to have a 
quantitative relationship with the severity of the paracetamol toxicity would allow 
for different treatment strategies in patients with different severities of liver injury. 
Acceptable would be a biomarker that qualitatively discriminates injury from non-
injury. 
Should a biomarker also be a mediator of liver injury then the marker could represent 
a companion diagnostic that identifies patients for a novel therapeutic. Desirable 
criterion would be a marker that has a drug already approved for human use, 
acceptable would be a marker that mediates the disease process and has potential 
therapeutics in development.  
 
1.6 New biomarker candidates for paracetamol-induced liver injury and 
their performance compared with the target biomarker profile 
 
Currently there is huge investment into the development and qualification of novel 
biomarkers to improve the prediction and monitoring of drug-induced liver injury in 
preclinical species and in man (Figure 2). A number of public-private consortia exist 
such as the IMI (Innovative Medicine Initiative) funded SAFE-T (Safer And Faster 
Evidence-based Translation) project and the Critical Path institute supported PSTC 
(Predictive Safety Testing Consortium) with these objectives as specific goals. 
Although the efforts and achievements of these consortia have been previously 
reported, here the case for the TBP to improve treatment and to aid the 
understanding of the mechanistic basis of paracetamol overdose is presented. In the 
next section microRNAs, a selection of protein markers (Keratin-18, High-mobility 
group box-1 and glutamate dehydrogenase), mitochondrial DNA fragments, Kidney 
Injury Molecule-1 and paracetamol protein adducts will be introduced and its key 






Figure 2. Key properties of novel biomarkers for paracetamol-induced liver injury. 








 Specific for liver injury 
 Fully conserved (translational) across in vitro models, in vivo models and 
humans 
 Early marker for ALI with a ROC-AUC of >.90 
 Predicts ALT rise 
MicroRNAs (miRNAs) are small (~22 nucleotides long) non-protein coding RNA 
species involved in post-transcriptional gene product regulation found in viruses, 
plants and mammals. miRNAs affect many cellular pathways including development, 
differentiation, metabolism, haemostasis and apoptosis (50). Besides playing an 
important role in health, many miRNAs have been implicated in human diseases (50). 
The most recent release of mirBase annotated 2588 mature human miRNA species 
(51). 
The genomic sequences for miRNAs are distributed throughout the genome including 
exonic and intronic regions, as well as intergenic regions (52). The first step in miRNA 
biogenesis is the transcription by RNA polymerase II or RNA polymerase III resulting 
in a primary transcript known as pri-miRNA (53, 54). A pri-miRNA contains a ~80 
nucleotide stem-loop, a terminal loop and a single stranded sequence of a few 
hundred bases which is capped at the 5’ end and polyadenylated at the 3’ end (55). 
The pri-miRNA is next processed by the microprocessor complex existing out of 
Drosha (an RNase III enzyme) and (DiGeorge critical region 8) DGCR8. Drosha contains 
two RNAse domains that cleave the 5’and 3’ arms of the pri-miRNA hairpin (56). 
DGCR8 determines the precise cleavage site by stably interacting with the pri-miRNA 
molecule (57). The resulting pre-miRNA is transported out of the cell nucleus into the 
cytoplasm by Exportin-5-Ran-GTP (58).  
In the cytoplasm, the RNA-induced silencing complex (RISC) loading complex, 
including the RNAse III Dicer, the double-stranded RNA-binding protein (TRBP), 
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protein activator of PKR (PACT) and Argonaute-2 (Ago2), cleaves the pre-miRNA into 
its mature length (59-61). After cleavage, the mature miRNA, attached to Ago2 forms 
the active RISC (Figure 3).  
 
Figure 3. The miRNA biosynthesis pathway and modes of export out of the cell. 
 
Complementary base-pairing of the miRNA guides RISC to its target mRNA. In plants, 
the miRNAs usually have perfect or near perfect base paring with its target mRNA 
which promotes cleavage by RISC and subsequent degradation of the mRNA (62). In 
mammals, inhibition of protein translation occurs by partial complementary pairing 
between miRNAs and mRNAs. In this case miRNAs are complementary for 6-8 
nucleotides at the 5’end of the miRNA which is called the seed sequence (63). Many 
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alternative detours and crossroads have been found in the biogenesis of miRNAs 
which are comprehensively described by Winter and colleagues (64). 
Although miRNAs fulfil their biological functions inside cells, miRNAs are transported 
out of cells where they are very stable due to protection from RNAses by being 
encapsulated in exosomes, microparticles (65) and protein complexes (Figure 3) (66). 
Although most miRNAs are expressed in many tissues, certain miRNAs appear to be 
highly organ specific (67). Liver tissue expresses a number of distinct miRNAs, 
especially miR-122-5p, the most abundant hepatic miRNA that has very low to no 
expression in other healthy tissues, which makes this marker highly liver specific (67). 
miR-122-5p is a multifunctional RNA species that modulates multiple pathways 
involved in stress response (68), fatty-acid metabolism (69), cholesterol synthesis 
(70) and hepatocellular carcinoma (71). 
The potential of circulating miRNAs to serve as biomarkers for ALI was first reported 
in mice treated with a toxic dose of paracetamol (72). miR-122-5p was the miRNA 
species that had the largest fold change between control and paracetamol treated 
mice (72). Subsequently circulating miR-122-5p has been reported as a marker for ALI 
in rats (73), dogs (74), zebrafish (75) and pigs (76). 
In patients with established ALI circulating miR-122-5p is around 100 fold higher 
compared to healthy controls and overdose patients without ALI (77). Furthermore, 
miR-122-5p has also been shown to provide utility at reporting liver injury in 
paediatric populations of paracetamol overdose (78). At first presentation to 
hospital, in a UK cohort of 129 patients from Edinburgh and Newcastle Upon-Tyne, 
miR-122-5p was measured at a median of 8 hours post-overdose in patients requiring 
subsequent NAC therapy ('Edinburgh and Newcastle study') (79). In this first sample 
miR-122-5p correlated significantly with peak hospital stay ALT activity and INR. miR-
122-5p was significantly higher in those patients that developed subsequent ALI. ROC 
analysis revealed that miR-122-5p had an AUC value (sensitivity at 90% specificity, 
95% CI) of 0.93 (0.83, 0.86-1.0, P < 0.0001) suggesting that miR-122-5p could 
accurately separate patients with and without ALI at an early time when ALT activity 
was still normal.  
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 Conserved between rodent models and humans. 
 Mechanism-based (apoptosis vs necrosis) 
 Early marker for ALI with a ROC-AUC of >.90 
 Predicts ALT rise  
 Prognostic marker 
 
Keratins are intermediate filament proteins, expressed by epithelial cells, that are 
responsible for cell structure, differentiation, mitosis and apoptosis (80, 81). Keratin 
18 (K18) is abundantly expressed in the liver and other digestive epithelial cells (82). 
During apoptosis, phosphorylation and cleavage of K18 results in cellular 
rearrangement. Full-length K18 is passively released from necrotic cells whereas 
cleaved K18 fragments are released from apoptotic cells once membrane integrity is 
lost (83). Circulating cleaved K18 (apoptosis) and full-length K18 (necrosis) can be 
measured using ELISA-based assays to report apoptosis and necrosis (84, 85). 
Cleaved K18 and full-length K18 have been reported to be circulating mechanistic 
biomarkers for apoptosis and necrosis in mouse models of paracetamol-induced ALI 
(86, 87). Full-length and cleaved K18 were measured in a mixed UK and US cohort of 
paracetamol-induced ALI patients - they were increased in the circulation of 
paracetamol-induced ALI patients compared to paracetamol overdose patients 
without ALI and healthy controls. 
In patients with established ALI full-length and cleaved K18 were significantly higher 
in patients that subsequently reached the King's College Criteria (KCC) for liver 
transplant (10). Further analysis revealed that the percentage of total circulating K18 
derived from cleaved K18 (from apoptotic cells) was relatively lower in patients that 
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reached the KCC compared to those that did not (87). ROC analysis confirmed that 
full-length K18 had a higher AUC than ALT for predicting patients that met KCC and 
for the outcome of liver transplant/death (87). Another research group has recently 
confirmed the ability of circulating cleaved and full-length K18 to report liver injury 
after paracetamol overdose (88). In this study both cleaved and full-length K18 
correlated with poor outcome (death or liver transplant).  
At first presentation to hospital - In the Edinburgh and Newcastle first presentation 
study - cleaved and full-length K18, measured in the first sample, correlated with 
peak ALT activity and INR during hospital stay. ROC analysis revealed that full-length 
K18 had an AUC value (sensitivity at 90% specificity, 95% CI) of 0.94 (0.9, 0.87-1.0, P 
< 0.0001) suggesting that this form of K18 could accurately separate patients with 
and without ALI at an early time when ALT activity was still normal. The performance 
of the cleaved form of K18 was less accurate with regard to reporting ALI at first 
presentation to hospital (AUC: 0.77; sensitivity at 90% specificity 0.21) (79). This is 
consistent with necrosis being more prominent than apoptosis in the 





 Prognostic marker 
 Mechanism-based (DAMP – inflammatory mediator) 
 Early marker for ALI with a ROC-AUC of >.90 
 Predicts ALT rise 
 Conserved between rodent models and humans 
 Potential drug target 
High-mobility group box-1 (HMGB1) is an evolutionary conserved chromatin-binding 
protein expressed in the nucleus of virtually all cells. HMGB1 is passively released into 
the extracellular space by cells that are undergoing necrosis and plays a key role in 
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alerting the immune system to dying cells and thus works as a damage-associated 
molecular pattern (DAMP) molecule (90-92). HMGB1 stimulates an immune response 
by activating toll-like receptors (TLRs) and the receptor for advanced glycation end 
products (RAGE) (93-95). Besides being passively released, HMGB1 is actively 
released as a cytokine in a hyper-acetylated form by various immune cells such as 
monocytes and macrophages after activation by inflammatory stimuli (96). Whether 
the extracellular cytokine activity of HMGB1 functions as a chemo attractant or pro-
inflammatory mediator depends on the redox state of three key cysteine residues 
(95, 97). HMGB1 can be measured in the circulation and increased levels are related 
to increased disease activity in sepsis (98), pancreatitis (99) and rheumatoid arthritis 
(100). In a mouse model of paracetamol toxicity circulating total and acetylated forms 
of HMGB1 displayed temporal kinetics that correlated with the onset of necrosis and 
inflammation respectively, confirming the potential of HMGB1 as an indicator of cell 
death processes (101). HMGB1 is a potential mediator of paracetamol-induced 
hepatotoxicity – anti-HMGB1 antibodies and knocking out HMGB1 in the liver 
reduced hepatic inflammation and liver injury in mouse models of paracetamol 
poisoning (90, 102, 103). A partly humanized chimeric antibody targeting HMGB1 was 
reported to be successful in reducing paracetamol induced ALI in mice. This confirms 
progress in the endeavour to bring HMGB1 specific therapy to future clinical 
development (104).  
In patients with established ALI total and acetylated HMGB1 was increased in the 
circulation compared to paracetamol overdose patients without ALI and healthy 
controls (87). Acetylated HMGB1 was significantly increased in patients that reached 
KCC compared to patients that did not. ROC analysis demonstrated that HMGB1 
(both total and acetylated) had a higher AUC than ALT for predicting patients that will 
reach KCC and predicting liver transplant/death (87). 
At first presentation to hospital HMGB1 had an AUC value (sensitivity at 90% 
specificity, 95% CI) of 0.97 (0.91, 0.91-1.0, P < 0.0001), suggesting that HMGB1 could 
accurately identify patients with ALI at the time when ALT activity was still normal 
(79). Comparing ROC curves suggests that HMGB1 may be the most accurate 
biomarker at first presentation, but this needs to be tested in larger studies.   
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1.6.2.3 Glutamate dehydrogenase 
 
Key properties: 
 Conserved between rodent models and humans. 
 Predicts ALT rise 
Glutamate dehydrogenase (GLDH) is a mitochondrial enzyme that catalyses the 
reversible deamination of glutamate to α-ketoglutarate plus free ammonia by using 
NAD or NADP as a co-factor (105). Circulating GLDH has been suggested to be a 
specific mechanistic marker for mitochondrial damage. Mitochondrial damage 
releases GLDH into the cytosol from where it can be leaked into the circulation with 
cell necrosis. When the cellular content is released from necrotic cells into the 
circulation, intact injured mitochondria are released. For this reason, freshly drawn 
blood needs to be centrifuged at > 14,000 x g for 20 min to pellet the intact 
mitochondria (106). It was reported that mice treated with furosemide, a loop 
diuretic deemed to cause centrilobular liver necrosis without affecting mitochondrial 
function (107), produced a significant increase in serum ALT activity with only a non-
significant increase in serum GLDH activity (108). By contrast, paracetamol treated 
mice had a substantial increase in GLDH along with ALT suggesting that the increase 
of circulating GLDH is indicative of paracetamol-induced mitochondrial damage and 
not simply caused by leakage of the enzyme from necrotic cells (108). 
In patients with established ALI circulating GLDH is elevated. At first presentation to 
hospital GLDH is less accurate than miR-122-5p, K18 and HMGB1 with regard to 
identifying patients with subsequent ALI despite NAC with an AUC value (sensitivity 
at 90% specificity, 95% CI) of 0.80 (0.19, 0.68-0.93, P = 0.0003) (79).  
 
1.6.3 Mitochondrial DNA fragments 
 
Circulating mitochondrial DNA (mtDNA) has been reported to act as a DAMP 
molecule via TLR mediated activation of inflammatory cells (109, 110). Increased 
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concentrations of circulating mtDNA have been associated with the systemic 
inflammatory response syndrome, multiple organ dysfunction syndrome and 
mortality in patients admitted to intensive care (111, 112). 
In patients with established ALI circulating mtDNA was increased as measured by 
absolute quantification of mtDNA encoding NADH dehydrogenase and cytochrome c 
oxidase. The plasma concentration of mtDNA in patients with abnormal liver function 
increased over time and peak levels correlated with peak ALT (108). As is the case 
with GLDH, circulating mtDNA may be a mechanistic marker for paracetamol-induced 
mitochondrial injury (108). 
 




 Translational between humans and rodents 
 Point of care tested developed with rapid turn around 
 Formally qualified by regulatory authorities for the investigation of drug-
induced renal injury in preclinical drug development 
Kidney Injury Molecule-1 (KIM-1) is a transmembrane glycoprotein that confers 
phagocytic activity on the proximal tubule cells of the kidney. During AKI, KIM-1 is 
rapidly up-regulated and its ecto-domain is shed into urine and blood where it is a 
sensitive and specific biomarker of acute kidney injury. Furthermore, KIM-1 has been 
formally qualified by regulatory authorities for its use to monitor acute kidney injury 
in the preclinical setting (113). In patients with paracetamol overdose, secondary 
injury to the kidney and specifically the proximal tubule epithelia is a major 
determinate of mortality. Indeed, biomarkers such as serum creatinine are often 
incorporated into prognostic algorithms. However, serum creatinine is delayed in its 
onset and data from animal models and in humans has repeatedly demonstrated the 
ability of KIM-1 to increase earlier following acute kidney injury (114, 115). In patients 
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with established ALI circulating KIM-1 has been reported to be elevated, particularly 
in those patients who subsequently died or required a liver transplant compared to 
spontaneous survivors (116). The fold change in KIM-1 in this poor prognostic group 
was higher than creatinine and KIM-1 outperformed creatinine in a ROC analysis. 
Furthermore, circulating KIM-1 was an independent predictor of outcome in a logistic 
regression model (116). 
 
1.7  Paracetamol protein adducts 
 
Key properties: 
 Conserved between rodent models and humans. 
 Exclusively selective for paracetamol overdose 
 Reflective of the initial molecular initiating event (MIE) 
 Point of care tested developed with rapid turn around 
When NAPQI is formed during paracetamol metabolism it covalently binds with 
proteins forming paracetamol-protein adducts, of which cysteine adducts are the 
most common (117). After the binding of NAPQI with cysteine, the structure of NAPQI 
reverts to that of paracetamol resulting in paracetamol-cysteine (paracetamol-CYS). 
In mouse models of paracetamol-induced ALI, immunohistochemical methods report 
that paracetamol-CYS adducts are formed in the liver in a temporally progressive, 
central to peripheral pattern (118). Experiments in mice also report paracetamol-CYS 
adducts in serum, suggesting that injured liver cells release paracetamol-CYS adducts 
into the circulation. Notably, serum paracetamol-CYS adducts were only detectable 
after toxic doses of paracetamol (119).  
More recently, a high-performance liquid chromatography with electrochemical 
detection (HPLC-ECD) assay has been developed. This assay has been used to detect 
paracetamol -CYS adducts in liver and serum after hepatotoxic dosing of paracetamol 
to mice (120) and in both adult and paediatric human serum samples with 
paracetamol-induced ALI (121-123). In the sample preparation for this assay, dialysis 
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is performed to remove potential contaminating free paracetamol-CYS metabolites 
so that only the protein bound paracetamol-CYS adducts are measured. The protein 
fraction is then isolated for analysis (120). Due to the relatively long plasma half time 
of 1.7±0.3 days in adults (124) and 1.5 ± 0.3 days in children and adolescents (125), 
paracetamol-CYS adducts can be detected up to 7 days after a large overdose (121). 
By contrast, the plasma half-life for paracetamol is 1.5-2.5h (126). The longer half-life 
of paracetamol-CYS adducts could potentially allow risk assessment/diagnosis in 
patients who present when paracetamol has been cleared from the circulation. When 
the aetiology of ALI is known, paracetamol-CYS adducts have no defined advantage 
over ALT because kinetic changes in paracetamol-CYS adducts track ALT activity (121). 
A point-of-care immunoassay for measuring paracetamol-CYS adducts, AcetaSTAT, is 
currently in early clinical development and it was reported that it identified patients 
with established paracetamol-induced ALI with a positive predictive value (PPV) of 
89.2% and negative predictive value (NPV) of 100% (127). 
 
1.8 Current biomarker performances and future challenges 
 
Table 2 gives an overview of the characteristics of each marker. Each of the 
characteristics has at least one biomarker that meets the acceptable or desired 
specifications. However, all these biomarkers have only been measured in a relatively 
small numbers of patients and large multi-centre trials are required to qualify current 
findings and further explore and confirm the attributes of these biomarkers. These 
studies should confirm at which time after paracetamol overdose the biomarker is 
able to predict liver injury and the sensitivity for ruling out injury. These studies 
should also determine the signal-to-noise ratio of each marker, identify which 
markers (if any) can distinguish between a benign and clinically relevant increases in 
ALT, and establish if there is a quantitative relationship between biomarker level and 
outcome. There is considerable scope for improvement in the “rapidly assayed” and 
“feasibility of assay” characteristics in the TBP. At the time of writing, only the 
calorimetric assay for GLDH fulfils the characteristic “feasibility of assay” as it has 
been validated in automated modern clinical chemistry labs within a turnaround time 
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of less than 1 hour. The point of care test, AcetaSTAT, is the only test in clinical 
development that could potentially be “rapidly assayed” (127). Large validation 
studies are required to test its performance. All other biomarkers are typically 
measured manually in research laboratories with time consuming and expensive kits. 
There is an urgent need for standardized and validated commercial assays that can 
be used at point-of-care to stratify paracetamol overdose patients for entry into trials 
of new therapeutic approaches. In order to have the driver for introducing one or 
more of these biomarkers into clinical practice their measurement must add value to 
patient care (128). In the setting of paracetamol overdose, a normal test result might 
add value by giving the treating clinician more confidence in discharging a patient. 
Given the large number of patients, this could reduce the pressure on acute hospital 
beds and save the health provider money. Conversely, an abnormal test result might 
trigger entry into a stratified clinical trial, indicate need for different treatment with 
a new therapy or referral for specialist care. To further fill the ‘toolbox’ of markers in 
the TBP, the large pool of circulating miRNAs and advances in sensitive profiling 
technologies, offer a promising opportunity (51). When miR-122-5p was discovered 
to be a sensitive marker for liver injury in mice the technology used to profile miRNAs 
in the circulation only resulted in 53 unique miRNA species in treated mice versus 43 
miRNAs in control mice (72). There is a need for comprehensive profiling of all 
circulating miRNA species in humans with paracetamol overdose to identify a panel 
of the most sensitive miRNAs that can detect paracetamol induced liver injury in 





 Table 2. Comparative biomarker profiles. 
 
  
Attribute Desired Acceptable 
Specific for paracetamol 
overdose 
paracetamol-CYS adducts miR-122-5p, GLDH 





Rapidly assayed paracetamol-CYS adducts GLDH, KIM-1 
Feasibility of assay GLDH? GLDH 




HMGB1, GLDH, mtDNA 
Conserved (translational) 
across in vitro models, in 
vivo models and humans 
miR-122-5p 
Keratin-18, HMGB1, 
GLDH, mtDNA, KIM-1 
Time after overdose at 
which it is able to predict 




Signal to noise 
miR-122-5p, Keratin-18, 
paracetamol-CYS 




with disease severity 
- miR-122-5p, HMGB1 
Distinguish benign and 
clinical relevant increase 
in ALT 
Keratin-18, HMGB1 miR-122-5p, GLDH 
Mediator of liver injury - HMGB1 
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1.9 Test systems for studying drug induced liver injury 
 
In order to better understand DILI and find new biomarkers, the establishment of a 
reliable research model remains a key challenge.  
 
1.9.1 In vivo models 
 
In 1991 Terblanche and Hickman introduced the requirements of an ideal animal 
model for studying acute liver failure (129). Up until today, no ideal animal model 
exists that fulfils all these requirements. Even though each animal model has 
limitations, they play a fundamental role in current and future studies. Most widely 
used models related to DILI use paracetamol due to its clinical significance (130). 
Other frequently used drugs in animal models are D-galactosamine and 
thioacetamide (131).  
Due to high costs and low throughput, animal models are not ideally suited for early 
phase drug screens. Large animals such as pigs and dogs are usually only used for the 
development of new therapeutic approaches for ALF (129). In most cases the 
preclinical species of choice are rats and mice. Rats are still required for standard 
safety evaluation of new drugs, however in the case of paracetamol-induced liver 
injury, the rat is unsuitable since they do not develop mitochondrial oxidant stress or 
JNK activation resulting in minimal liver injury (132).  
The mouse model for paracetamol induced liver injury has been used since the 1970s 
(133). This model has had great importance in understanding the mechanism of 
paracetamol induced liver injury (134). Due to mechanistic similarities with humans, 
mice are currently the most widely used model species (108). Another advantage of 





1.9.2 In vitro test systems 
 
To reduce animal usage, cost and the ability to test a high number of compounds in 
a short time, numerous in vitro test systems have been developed and applied (135). 
The use of these in vitro systems have multiple advantages compared to using animal 
models including the reduced cost of animal maintenance and care, and the ability to 
test small amounts of compound in a high throughput fashion.  
Immortalised liver cell lines, primary hepatocytes and precision cut liver slices have 
remained the main models for toxicity testing with each having advantages and 
disadvantages (136). 
 
1.9.2.1 Immortalised liver cell lines 
 
The most common immortalised liver cell lines include HepG2, Fa2N-4, Hep3B, HBG 
and HepaRG (137, 138). Immortalised liver cell lines mainly originate from tumours 
and have to advantage of indefinite proliferative capacity (139). 
The human hepatoma HepG2 line stems back from the 1970s. It retained the 
expression of many liver specific genes, however it lacks the expression of important 
genes including cytochrome P450 genes, membrane transporters, phase II enzymes 
and nuclear receptors (137). The human hepatoma HepaRG line appears to be a good 
alternative with high proliferative capacity, the ability to differentiate into 
hepatocytes and biliary cells and the much greater expression of the major P450 
enzymes as well as other liver-specific functions (139). 
 
1.9.2.2 Primary hepatocytes 
 
Primary hepatocytes isolated from humans have the advantage of expressing the 
typical hepatic biochemical functions and containing the entire hepatic drug-
metabolizing enzyme system (140). However, as soon as 24 hours after isolation, 
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there is significant down regulation of many important enzymes involved in drug 
metabolism (141). This decline in metabolic capacity can be reduced by culturing 
hepatocytes in a sandwich format in which the hepatocytes form a monolayer 
inbetween two collagen layers mimicking the extracellular layer (142, 143). Another 
strategy for partially preventing the decline in CYP activity is by introducing a mixture 
of CYP inducers to the cell medium (144). 
A major disadvantage of these cell systems is that only one cell type is present. This 
makes these systems unsuitable for detecting toxicities in which non-hepatocyte cell 
functions are involved. DILI is often a complex multi-cellular process in which not just 
hepatocytes but many other cell types can play a role and have an important 
contribution to the toxicity (145, 146). 
 
1.9.2.3 Precision cut liver slices 
 
A multicellular approach is the use of precision cut liver slices. Precision cut liver slices 
present small slices of liver with all the different cell types, cell-cell contacts and 
extracellular matrix of the liver present in its natural architecture (147). Precision cut 
liver slices could be prepared from multiple organs, allowing for multi organ 
incubations enabling studies on the gut-liver axis (148). 
In human precision cut liver slices, gene expression changes after culturing for 24h, 
however these changes mainly reflect extracellular matrix and cytoskeletal 
remodelling. Importantly, genes involved in stress, toxicity, drug metabolism and 
transport hardly change (135). Although precision cut liver slices can be cultured for 
up to 7 days, some important functions, such as metabolic capacity, decline after 3 
days (149). In order to perform longitudinal studies, culture conditions of precision 
cut liver slices need to be further improved.  
Precision cut liver slices are a promising model for studying DILI, but the main 
disadvantage of human precision cut liver slices is that the supply of intact human 
tissue is limited (140). 
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Another promising model organism with many in vitro model advantages but the 
complexity of in vivo models are zebrafish. 
 
1.10 Zebrafish as model organisms for studying drug induced liver injury 
 
The zebrafish is a promising animal for assessing drug-induced toxicity in a variety of 
organ systems (150). Well-established zebrafish assays have frequently been utilised 
for measurement of cardiac function, CNS assessment, gastrointestinal function and 
developmental toxicity (151, 152). The zebrafish liver can also be used to study drug 
toxicity, however in comparison to other organs, the zebrafish model of liver toxicity 
has been utilised less frequently.  
The use of this model has the potential to identify new biomarkers, drug targets for 
the treatment of DILI and play a role in pre-clinical drug development. Also, the use 
of zebrafish is in line with the 3R’s (reduce, refine, and replace) approach of animal 
use for scientific purposes by replacing higher order animals with lower order 
zebrafish (particularly zebrafish embryos). 
 
1.11 Potential advantages of zebrafish as a model for studying DILI 
 
Histopathology and clinical chemistry have been traditionally used to report liver 
toxicity in established animal models. To decrease the cost and time of toxicity 
studies, alternative test systems have been developed. These include liver slices 
(153), cultured primary hepatocytes (154), immortal hepatic cell lines such as the 
human hepatoblastoma-derived HepG2 line (155) and the recently derived human 
hepatocyte HepaRG line (139). The advantage of these ex vivo and in vitro approaches 
is that they can be used efficiently for high throughput screening. However, the 
usefulness of these approaches for toxicological testing of compounds can be 
questioned based on differences in gene expression between the different systems 
(156) and the low sensitivity of the cytotoxicity assays, which can be less than 25% 
for the detection of hepatotoxic agents (157). 
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In order to perform liver toxicity testing with a higher degree of sensitivity, in vivo 
assessment is necessary. This allows study of the dose-dependent toxicity of a drug 
within the complex physiology of a whole organism. Higher vertebrate organisms 
(e.g. rodents and pigs) are physiologically similar to humans and have been used for 
this approach. However, smaller, lower-order vertebrates, such as the zebrafish, have 
similar molecular and cellular processes that can accurately model human physiology 
(150). In addition, the zebrafish offers significant advantages in comparison to 
rodents (Table 3) and other larger animals. The zebrafish embryo is optically 
transparent and grows outside the uterus. This makes it possible to detect and 
monitor developmental changes easily from the single-cell stage. For example, the 
zebrafish embryo has allowed researchers to study embryonic lethal phenotypes; 
something that was not possible with mammalian models(158). Additionally, an early 
zebrafish embryo, at 3 days post fertilisation (dpf), is ∼3.5 mm long. This allows 
zebrafish embryos to be grown at high stocking densities in multi-well plates. The 
high fecundity of the zebrafish (each female can lay ∼200 eggs per week) can 
generate hundreds of embryos for screening, each of which has very rapid 
development. This reduces the cost of zebrafish husbandry significantly, when 
compared with larger laboratory animals. Furthermore, the Wellcome Trust Sanger 
Institute has sequenced the genome of the zebrafish, and many of these sequences 
have been annotated (http://vega.sanger.ac.uk/Danio_rerio/Info/Index) (159). 






Table 3. Comparative advantages of using zebrafish and mice to model DILI. 
Zebrafish vs Mouse   
Advantages of zebrafish Advantages of mice 
Optically large and transparent 
embryos 
Characterized inbred strains, including 
knock-out and knock-in strains 
Ex utero development More complementary with mammalian 
organs and closer physiological 
similarity to humans 
Similar cellular and sub-cellular 
processes to humans 
Easier to draw blood 
Rapid development of liver ~72-96 hpf Feasible to perform pharmaco/toxico 
kinetic studies 
High fecundity (~200 
eggs/female/week) 
Genome duplication of fish results in 
multiple copies of genes 
Large numbers of fish can be easily 
maintained 
 
Embryonic fish can survive up to 7 days 
without a Cardiovascular system 
Low overall cost 
Easy drug delivery by dissolving in the 
tank water, with possibility of drug 
delivery by microinjection 
Feasibility of high throughput screens 
N numbers available per study, 
allowing improved statistical analysis 
Lower order mammal (in line with 3R 
principle) 
 
1.12 Zebrafish liver anatomy is different to rodents and humans 
 
Studies examining the zebrafish organs, specifically the liver, have revealed multiple 
similarities with higher vertebrates (163). When liver budding starts at 28 hours post 
fertilisation (hpf), growth factor and gene expression similar to those of humans and 
rodents has been reported in zebrafish (164). When hepatic organogenesis is 
completed at 72 hpf, the liver is perfused with blood and is functional (165). At 
120 hpf, the zebrafish is actively seeking food and the yolk sac reserves have become 
exhausted. By this time, larvae already have a fully functional liver. In comparison, in 
the embryonic mouse the primary liver bud starts to grow around embryonic day 8.5–
9 and the liver is mature at embryonic day 18.5, just before birth (166). The tri-lobed 
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liver of the zebrafish is similar to the liver of mammals with regard to biological 
function; this includes processing of lipids, vitamins, proteins and carbohydrates and 
the synthesis of serum proteins (163). The main difference between the mammalian 
and zebrafish liver is the structural organisation of the liver tissue. Instead of having 
the large bile ducts, portal veins and hepatic arteries organised in portal tracts, these 
are randomly allocated throughout the liver parenchyma in the zebrafish. 
Hepatocytes in the mammal liver are arranged in plates, whereas in the zebrafish 
liver they are arranged in tubules. In zebrafish, the bile canaliculi radiate centripetally 
between hepatocytes to anastomose with a single ductular cell, forming a ductule at 
the centre of the tubule. These ductules form a network that transports the bile 
secreted by hepatocytes. Downstream, these ductules merge into intrahepatic bile 
ducts, converging at the cystic duct, which exits the liver at the hilum to connect with 
the gallbladder. Subsequently, the gallbladder empties into the intestine through the 
common bile duct (Figure 4) (164, 167). The above-mentioned lack of lobular 
arrangement impairs morphological differentiation between venules from the portal 






Figure 4. Schematic transverse representations of mammalian and zebrafish liver 
architecture. (A) The mammalian liver lobule, arranged with plates of hepatocytes 
radiating outward from a central vein (CV). At the corners of each lobule are portal 
tracts (PT), containing a portal vein (PV), a hepatic artery (HA) and a bile duct (BD). 
(B) Mammalian bilayered hepatocyte plate. Bicellular canaliculi (CA) are located 
adjacent to the hepatocytes (H) in the hepatocyte plate (HP). A basal hepatocyte 
membrane allows transport of oxygen, proteins and different macromolecules to 
the hepatocytes. Blood enters the liver through the portal vein and hepatic artery, 
after which it enters the central vein through sinusoid vessels, located between the 
plates. (C) The zebrafish liver architecture. The portal vein (PV), hepatic artery (HA), 
bile duct (BD), hepatocyte tubule (HT) and the central vein (CV) are scattered 
throughout the parenchyma. (D) Zebrafish hepatocytes (H) are arranged in tubules 
around small bile ducts, which receive bile from the hepatocyte canaliculi (CA). 
Sinusoids are located at the periphery of these tubules. (E) Histological image of 
male zebrafish liver (haematoxylin and eosin staining at ×200 magnification). Note 
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the presence of several biliary ducts (arrows), bile ductules (arrowheads) and blood 
vessels (*), with lack of lobular arrangement. (F) Histological image of female 
zebrafish liver (haematoxylin and eosin staining at ×400 magnification). This high-
power image displays sinusoidal spaces between hepatocytes (arrows) and an 
instance of the tubular arrangement of hepatocytes (encircled), which is frequently 
not visible histologically. Note the difference in staining of male and female 
zebrafish liver. From Vliegenthart et al, 2014. (75). 
 
1.13 Zebrafish drug metabolism is similar to rodents and humans 
 
One of the key physiological functions of the liver is oxidative catalytic 
transformation, which leads to activation or inactivation of many endogenous and 
exogenous compounds. This metabolism is mainly performed by the cytochrome 
P450 (CYP) enzymes, which are predominantly localized in the liver. The metabolic 
reactions performed by the CYP enzymes include oxidation, reduction and hydrolysis. 
The CYP enzymes can be divided into two major groups. The first group of enzymes, 
with generally narrow substrate specificity, are predominantly involved in synthesis, 
activation or inactivation of endogenous regulatory molecules. The second group 
predominantly metabolize xenobiotics, but may also metabolize endogenous 
compounds (168, 169).  
These reactions are divided in two phases. In phase I, the metabolized compound is 
oxidized, reduced or hydrolysed. These phase I reactions are predominantly 
mediated by CYP enzymes. In phase II, conjugation takes place (not CYP enzyme 
mediated). The rate of these reactions is controlled by expression levels and activity 
of the specific enzymes (170).  
When selecting an animal model for toxicity testing, characterization of the metabolic 
properties of the selected species is very important. These properties influence DILI, 
for example, by creating reactive metabolites, and this will determine whether a 
compound is toxic (171).  
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Therefore, the application of zebrafish as a model of human (hepatic) endogenous 
and exogenous compound metabolism requires the full range of CYP genes; these 
have been identified in zebrafish and annotated with regard to their phylogenetic 
relationships to human CYP enzymes. This essential study was reported by Goldstone 
and colleagues, who characterised a total of 94 CYP genes in the zebrafish genome 
(168). Based on homologous amino-acid sequences, they reported that these genes 
fitted into 18 CYP gene families that are also present in humans and other mammals. 
The CYP enzyme families 1–4, which predominantly metabolize exogenous 
compounds, are more diverse in zebrafish than in humans. However, analysis of 
shared synteny demonstrates an evolutionary relationship between human and 
zebrafish CYP genes. In the CYP families 5–51, zebrafish have single genes like 
humans, and there is a high degree of conservation between human and zebrafish 
sequences (168).  
Metabolic experiments demonstrate that drugs are metabolized when exposed to 
zebrafish embryos by similar reactions to those in humans. An overview of reported 
metabolic experiments is presented in Table 4. The metabolic degradation of the 
widely used nonsteroidal anti-inflammatory drug ibuprofen is well studied in 
different mammals (172, 173). The compound is metabolized by different reactions, 
including oxidation of the parent compound to hydroxyl-ibuprofen and carboxy-
ibuprofen, as well as glucuronic acid conjugation of both parent and metabolite 
compounds (174). In humans, the oxidation of ibuprofen is catalysed by the CYP2C8/9 
isoforms (175). When ibuprofen is exposed to zebrafish embryos, hydroxylated 
ibuprofen can be detected in the zebrafish extracts and water samples, suggesting 
that zebrafish have an analogous metabolic system to the human CYP2C8/9 (176).  
Following exposure to high dose paracetamol, in humans, rat and mice, the reactive 
metabolite NAPQI is formed by phase I metabolism of paracetamol by predominately 
CYP3A4 (177-179). Recently, Chng and colleagues used a glutathione trapping assay 
for NAPQI to determine that zebrafish generate the same reactive metabolite as 
humans. The same authors reported that the zebrafish CYP3A65, orthologue for the 
human CYP3A4, contributed to the formation of NAPQI, as well as the phase I 
hydroxylation of testosterone (180).  
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Alderton and colleagues (181) confirmed that zebrafish embryos are able to perform 
the metabolic phase I reactions, oxidation, N-demethylation, O-demethylation and 
N-dealkylation, as well as the metabolic phase II metabolic reactions, sulfation and 
glucuronidation. The metabolites of three compounds, namely cisapride, verapamil 
and chlorpromazine, were profiled. With cisapride, the mammalian phase I reactions 
(piperidine N-delakylation and fluorophenyl ring oxidation) and phase II reactions 
(glucuronidation, resulting in glucuronide conjugates) were not observed in zebrafish 
(183). However, following exposure of zebrafish to verapamil, a number of 
metabolites were formed by N-dealkylation and hydroxylation; these reactions are 
also present in mammals (184). Three major metabolites of chlorpromazine, which 
are excreted in human urine, were also excreted by zebrafish; these metabolites were 
formed by hydroxylation, oxidation, N-demethylation, glucuronidation and sulfation. 
Alderton and colleagues also reported that zebrafish embryos were able to de-
Drug metabolism in zebrafish   
  








Ibuprofen Hydroxylation Yes CYP2C8/9 (174) 
Paracetamol Hydroxylation Yes CYP3A4 (180) 
Testosterone Hydroxylation Yes CYP3A4 (180) 
Cisapride Sulfate conjugation No CYP3A4 (181) 














Phenacetin De-ethylation Yes CYP1A2 (181) 
Dextromethorphan Demethylate Yes CYP2D6 (181) 
Bupropion Hydroxylation Yes CYP2B6 (181) 
Ethanol Oxidation Yes CYP2E1 (182) 
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ethylate phenacetin, demethylate dextromethorphan and hydroxylate bupropion 
(181).  
The nuclear receptor, pregnane X receptor (PXR), is involved in the transcriptional 
regulation of cytochrome P4503A (CYP3A) and the multidrug resistance 1 transporter 
(MDR1) (185, 186). Studies have confirmed that CYP enzymes can be induced and 
inhibited in zebrafish as reported in mammals. Bresolin and colleagues (187) studied 
the in vivo expression of PXR, CYP3A and MDR1 genes in the liver of zebrafish treated 
with the synthetic steroid pregnenolone 16α-carboninitrile, a potent PXR agonist 
(188). The liver of the fish treated with pregnenolone 16α-carboninitrile had a 1.9-
fold increase in PXR, followed by a 1.8-fold increase of CYP3A and 1.6-fold increase in 
MDR1. This suggests that the regulation of PXR, CYP3A and MDR1 is conserved in 
zebrafish and similar to mammals (187).  
Tseng and colleagues (189) found that CYP3A65 expression was upregulated in the 
embryo (84 hpf) intestine by rifampicin and dexamethasone. In addition to the PXR 
pathway, the aryl hydrocarbon receptor 2 (AHR2) has a role in the pathway that 
regulates gene expression and is activated by endogenous and exogenous 
compounds, such as drugs and xenobiotics (190). Orthologues genes of the aryl 
hydrocarbon receptor are present in different mammals, such as humans, mice and 
rats, and regulates expression levels of enzymes involved in phase I metabolism, 
including CYP1A2, CYP1B1 and aldehyde dehydrogenase 3A1 (ALDH3A1), as well as 
phase II metabolism, including NAD(P)H dehydrogenase quinone 1 (NQO1), UDP 
glucuronosyltransferase 1A2 (UGT1A2) and glutathione S-transferase α1 (STA1) 
(191). Expression of CYP3A65 was increased by exposing fish to 2,3,7,8-tetrachloro-
dibenzo-p-dioxin, a AHR2 ligand (192), during early embryonic stages, and inhibition 
of AHR2 translation by antisense morpholino oligonucleotides inhibited both normal 
and 2,3,7,8-tetrachloro-dibenzo-p-dioxin-stimulated CYP3A65 transcription in 
embryonic intestine. These data suggest that AHR2 regulates CYP3A65 expression in 
zebrafish (189). 
 
In summary, the zebrafish liver contains enzymes that metabolize a variety of 
endogenous and exogenous compounds in a similar manner to human liver. 
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Additionally, these enzymes are subject to similar regulation mechanisms to those 
reported in humans. These findings support the potential of the zebrafish as an 
animal model for DILI. 
 
1.14 The zebrafish immune system is similar to rodents and humans 
 
Hepatic inflammation is commonly reported in various liver diseases, including DILI. 
Liver toxic drugs can have a direct effect on liver cells to release DAMPS that stimulate 
immune cell secretion of chemokines and cytokines. Various immune cells such as 
lymphocytes, neutrophils and macrophages can subsequently infiltrate the liver. This 
complex immune response has been widely described by several authors (193-195). 
Additionally, specific genetic backgrounds can be a risk factor for idiosyncratic DILI in 
humans (196, 197). For example, a variety of leukocyte antigen (HLA) haplotypes are 
associated with immunological drug hypersensitivity (e.g. amoxicillin/clavulanate and 
abacavir) (198-201). 
Many similarities exist between the zebrafish and the mammalian immune systems. 
Different studies of haematopoiesis in zebrafish have demonstrated that most, if not 
all, cell types of the human immune system have zebrafish counterparts, although 
the sites of origin differ (202). There is a variation in the repertoire of chemokine 
receptors in different species, regardless of the specific evolutionary position. 
Despite this, the expression and function of orthologous chemokine receptors in 
lower and higher vertebrates are highly similar (203). While the zebrafish metabolizes 
drugs using similar pathways to humans, whether a similar immune response takes 
place with DILI in zebrafish is yet to be confirmed. 
 
1.15 A range of drugs induce liver toxicity in zebrafish 
 
Different methods have been used to assess liver toxicity in zebrafish, for example, 
visual assessment of gross and microscopic morphological changes, serum enzyme 
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and biomarker tests, hepatic excretory tests, and assessment of alterations in 
chemical constituents of the liver. 
 
1.15.1 Gross/subgross visual phenotypic assessment 
 
The ability to perform assays for liver toxicity with visually assessable phenotypic end-
points enables transparent zebrafish larvae to be used in high-throughput screening. 
A comparative toxic screen of 50 different compounds classified to be hepatotoxic by 
the US FDA, and non-toxic controls, was performed in zebrafish embryos. The 
compounds were screened in a researcher-blinded fashion for evaluation of three 
specific phenotypic end-points of liver toxicity, i.e. change in liver size, liver 
morphological abnormality and yolk-sac retention. A sensitivity for hepatotoxic drugs 
of 86% and specificity for nonhepatotoxic drugs of 77% was reported, which resulted 
in an overall correlation of 84% with mammalian in vivo data (204). However, when 
four compounds were excluded from the analysis because of low uptake into the 
embryo from the tank water, an increased sensitivity, specificity and overall 
predictability of 97, 77 and 91%, respectively, was reported (205). 
He and colleagues (206), exposed zebrafish embryos at 120 hpf to six known 
mammalian hepatotoxic drugs (paracetamol, aspirin, tetracycline hydrochloride, 
sodium valproate, cyclophosphamide and erythromycin) and two nontoxic 
compounds (sucrose and biotin), after which three phenotypic visual end-points of 
liver toxicity were assessed quantitatively. These end-points were liver degeneration 
score, changes in liver size and shape and yolk-sac retention. These end-points were 
easily measured under a light microscope without the need for dissection. All six 
hepatotoxic compounds induced liver degeneration, reduced liver size and led to 
yolk-sac retention, which suggested that this assay could be predictive for liver 
toxicity. Zhang and colleagues (207) have developed a transgenic zebrafish line 
(LiPan) that expresses a liver-specific fluorescent protein (DsRed) under the fabp10a 
promoter. They reported that the LiPan line could identify hepatotoxic drugs by 
detecting changes in both liver red fluorescence and liver size in a dosage-dependent 
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fashion. This was demonstrated by exposing the LiPan line to the hepatotoxic drugs 
paracetamol, aspirin, isoniazid and phenylbutazone. 
Nadanaciva and colleagues (208), exposed 72 hpf zebrafish embryos to a panel of 11 
NSAIDs (flufenamic acid, tolfenamic acid, mefenamic acid, diclofenac, meloxicam, 
sudoxicam, piroxicam, diflunisal, acetylsalicylic acid, nimesulide, and sulindac). At 120 
hpf all fish were assessed for lethality and morphology. The effects on fish were 
compared to the effects of the NSAIDs on the respiration of rat liver mitochondria 
and other mechanistic endpoints in rat hepatocytes. It was found that all three assays 
were complementary and able to correctly identify “toxic”from “non-toxic” drugs in 
accordance to the safety profile in human. 
 
1.15.2 Liver histopathology  
 
Specific changes in zebrafish liver histology have been reported: North and colleagues 
reported widespread necrosis and sinusoidal haemorrhage after adult zebrafish were 
exposed to 10 mM paracetamol for 12 hours. Paracetamol exposure (10 mM) to fish 
concurrently to NAC (10 µM) improved survival, serum ALT activity and histology 
(209). As described in other mammals, exposing zebrafish to hexachlorocyclohexane 
results in specific histological changes such as hepatic macrovesicular triglyceride 
droplets, glycogen depletion and the presence of club-shaped mitochondria (210). 
Exposure of zebrafish to thioacetamide induces steatohepatitis, which is 
accompanied by the accumulation of fatty droplets and apoptosis (211). Zebrafish 
exposed to ethanol display histological changes such as steatosis, as seen in alcoholic 
liver disease in human (212). In conclusion, both embryonic and adult zebrafish are 
amenable to study of the histological changes that accompany different liver 
pathologies, such as steatosis, apoptosis and necrosis.  
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1.15.3 Circulating biomarkers 
 
Whilst zebrafish embryos offer a range of advantages that facilitate high throughput 
screening, adult zebrafish are needed if circulating biomarkers are to be measured. 
Murtha and colleagues determined multiple serum biochemical values in zebrafish 
(±1 year old), such as total bilirubin concentration (mean ± SD, 0.38 ± 0.1 mg dl−1; 
range, 0.2–0.6 mg dl−1) and serum alanine transaminase (ALT) activity (mean ± SD, 
376 ± 25.3 U l−1; range, 343–410 U l−1) (213). In a paracetamol-induced liver toxicity 
model in adult zebrafish, North and colleagues demonstrated that ALT activity 
increased in zebrafish in a dose- and time-dependent fashion (209). Injury was 
reduced by acetylcysteine treatment of paracetamol exposed zebrafish, as is the case 
in humans (214). Cox and colleagues reported that after paracetamol exposure, 
inhibition of the enzymic regulator S-nitrosoglutathione reductase (GSNOR) 
minimized liver toxicity in zebrafish. A GSNOR-specific inhibitor improved survival and 
histology and lowered ALT activity through the cytoprotective Nrf2 pathway. 
Paracetamol toxicity studies in GSNOR-deficient mice confirmed conservation of the 
hepatoprotective properties of S-nitrosothiol signalling across vertebrates (215). This 
supports use of the zebrafish as a translational model of human paracetamol toxicity 
and biomarker research. 
 
1.16 Challenges in using zebrafish as a new model for DILI 
 
Although a substantial amount of research demonstrates the potential of zebrafish 
as a model of liver toxicity, there are a number of challenges. 
Zebrafish are often exposed to a drug by dissolving the drug in the water, which 
enables easy and fast drug administration. This is an advantage of the model that 
allows for high-throughput phenotypic screening, especially if transgenic lines are 
used (216). The problem with this method of drug administration is that, although 
the concentration of drug in water is known, the amount taken up by the fish is 
imprecise and variable, which limits the study of toxicokinetics. Berghmans and 
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colleagues (217) studied the uptake of nine compounds in zebrafish embryos by 
dissolving the compounds in the water and found a large variability in the 
bioavailability of the different compounds. This was because the physiochemical 
properties of different compounds determine the absorption of the compounds into 
the fish through the gills and intestine, rather than simply their aqueous 
concentration. If required, drugs can be injected into the yolk sac of embryonic fish, 
and this method can therefore quantify the administered dose at the expense of 
being time consuming (218).  
The relationship between the drug’s lipophilicity and the amount of compound 
penetrating the zebrafish has been determined (217) however no single 
physiochemical property can accurately predict the uptake of different types of 
compounds (219). Therefore, bioanalysis should be performed to correlate the 
amount of drug in the fish (the real body burden) and the observed toxic effects (220). 
For instance, sodium valproate, a potential liver toxic drug in humans did not cause 
liver toxic effects in zebrafish embryos, possibly due to poor uptake of this drug. In 
contrast, valproic acid did cause liver toxicity in zebrafish embryos with higher blood 
concentrations, indicating increased uptake (204). To overcome the possible problem 
of absorption, the amount of drug taken up by the fish can be determined by using 
radio-labelled compound and liquid scintillation counting or radio high-performance 
liquid chromatography. Other methods that determine the uptake of drug into fish 
include lysing embryos and then using liquid chromatography–tandem mass 
spectrometry (LC-MS) analysis (221). Recently this approach was able to determine 
the pharmacokinetics of paracetamol in zebrafish larvae. It was reported that the 
larvae had an uptake of 0.290 pmole/min and clearance of 2.96 x 107 L/h that scaled 
reasonably well with clearance rates in higher vertebrates (222). 
 In adult zebrafish, the uptake of compounds can be determined by drawing blood 
from adult zebrafish and measuring the concentration of the compound in blood 
plasma. However, because of the low blood yields obtained from zebrafish, typically 
3–20 μl of whole blood (223-227), 10–20 fish may have to be pooled. Zang and 
colleagues (227) described a recovery method that allows for serial blood sampling 
from adult zebrafish, but it takes 1–2 weeks for fish to recover normal haemoglobin 
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values after taking a small blood sample of 2 μl. This delayed recovery may limit the 
application to toxicity studies. 
Goldstone and colleagues (168) demonstrated that 66 of the 88 studied CYP genes in 
zebrafish embryos have a differential level of expression during development 
between 3 and 48 hpf. This stresses the importance of age on toxicity when zebrafish 
embryos are used. In liver toxicity studies, embryos must be >3 dpf (168). Circadian 
rhythms will influence an organism's susceptibility and responses to xenobiotic 
exposure. It is established that ATP binding cassette (ABC) transporters have a 
significant impact on bio-availability, metabolism and excretion of drugs. The gene 
expression of some transporters, including P-glycoprotein, could be under circadian 
transcriptional regulation in zebrafish, as reported in mice (228). Therefore, age-
related and circadian-related gene expression profiles will impact on the relative 
higher amount of toxic metabolite, which might influence susceptibility. It is for this 
reason that standardization of protocols when using embryonic stages is an 
important consideration in high-throughput screens. 
 
Early identification of hepatotoxic compounds would accelerate the process of drug 
discovery and development and reduce the enormous costs. The zebrafish appears 
to be a model that may complement established models. However, before the model 
can be applied on wider scale more validation is needed to confirm the translatability 
of the model to humans. This may include testing established human hepatotoxic and 
nonhepatotoxic compounds, comparing dose responses between fish and humans 
and developing translational biomarkers that bridge between fish, rodents and 
humans. Furthermore, the immunological response observed with DILI in humans has 
to be studied in zebrafish to confirm mechanistic similarity. Ultimately, use of the 
zebrafish as a model for DILI is promising and may enable better decision making in 




Hypothesis and Aims 
 
The hypotheses investigated in this study are: 
1) miRNAs can be used as specific markers for hepatotoxicity in humans. 
2) Zebrafish can be used as a pre-clinical model for drug induced liver injury. 
 
In order to test these hypotheses, the aims of the studies described in this thesis are: 
 Identify the circulating miRNAs that are most sensitive to detect paracetamol 
induced liver injury in humans. 
 Develop the leading miRNA candidate by determining the effect of alcohol 
consumption and renal dysfunction. Furthermore, determine whether 
microRNA measured in capillary blood obtained from a finger prick could be 
used as biomarker for DILI. 
 Explore the toxicokinetics of circulating paracetamol metabolites.Develop a 
blood letting method in adult zebrafish and test if circulating miRNA is 
increased with paracetamol induced liver injury in zebrafish.Develop a 





Chapter 2: Comprehensive microRNA profiling in paracetamol toxicity 





In humans, a miRNome subset of 372 miRNAs has been quantified in 49 patients with 
paracetamol hepatotoxicity or ischemic hepatitis (229). This study confirmed that 
miRNAs were increased and decreased and suggested that certain species could 
distinguish between these distinct aetiologies of liver injury (229). Changes in 
circulating miRNAs have also been reported in small numbers of hepatotoxicity 
patients analysed by high-throughput sequencing (78, 230). These studies did not 
address the unmet clinical need for improved patient stratification, back translate to 
pre-clinical models or identify signals of kidney toxicity. In the present study we 
recruited over 200 patients and assayed all miRNAs annotated in miRBase (version 
18), a biological database that acts as an archive of miRNA sequences and 
annotations (51), to identify which miRNAs were differentially expressed in plasma 
from overdose patients with and without paracetamol toxicity. Selected miRNA 
candidate biomarkers were tested for liver and kidney specificity in humans and mice, 
and sensitivity with regard to patient stratification at first presentation to hospital. 
The results of this chapter were published as: 
Vliegenthart AD, Shaffer JM, Clarke JI, Peeters LE, Caporali A, Bateman DN, Wood DM, 
Dargan PI, Craig DG, Moore JK, Thompson AI, Henderson NC, Webb DJ, Sharkey J, 
Antoine DJ, Park BK, Bailey MA, Lader E, Simpson KJ, Dear JW. Comprehensive 
microRNA profiling in acetaminophen toxicity identifies novel circulating biomarkers 
for human liver and kidney injury. Sci Rep 2015;5:15501. (231) 
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Comprehensive microRNA 
profiling in acetaminophen 
toxicity identifies novel circulating 
biomarkers for human liver and 
kidney injury
A. D. B. Vliegenthart1, J. M. Shaffer2, J. I. Clarke3, L. E. J. Peeters1, A. Caporali1, 
D. N. Bateman1, D. M. Wood4,5, P. I. Dargan4,5, D. G. Craig6, J. K. Moore6, A. I. Thompson7, 
N. C. Henderson7, D. J. Webb1, J. Sharkey3, D. J. Antoine3, B. K. Park3, M. A. Bailey1, 
E. Lader2, K. J. Simpson6 & J. W. Dear1
Our objective was to identify microRNA (miRNA) biomarkers of drug-induced liver and kidney injury 
by profiling the circulating miRNome in patients with acetaminophen overdose. Plasma miRNAs 
were quantified in age- and sex-matched overdose patients with (N = 27) and without (N = 27) organ 
injury (APAP-TOX and APAP-no TOX, respectively). Classifier miRNAs were tested in a separate 
cohort (N = 81). miRNA specificity was determined in non-acetaminophen liver injury and murine 
models. Sensitivity was tested by stratification of patients at hospital presentation (N = 67). From 
1809 miRNAs, 75 were 3-fold or more increased and 46 were 3-fold or more decreased with APAP-
TOX. A 16 miRNA classifier model accurately diagnosed APAP-TOX in the test cohort. In humans, 
the miRNAs with the largest increase (miR-122-5p, miR-885-5p, miR-151a-3p) and the highest rank 
in the classifier model (miR-382-5p) accurately reported non-acetaminophen liver injury and were 
unaffected by kidney injury. miR-122-5p was more sensitive than ALT for reporting liver injury at 
hospital presentation, especially combined with miR-483-3p. A miRNA panel was associated with 
human kidney dysfunction. In mice, miR-122-5p, miR-151a-3p and miR-382-5p specifically reported 
APAP toxicity - being unaffected by drug-induced kidney injury. Profiling of acetaminophen toxicity 
identified multiple miRNAs that report acute liver injury and potential biomarkers of drug-induced 
kidney injury.
Acetaminophen (paracetamol) is a safe analgesic drug when taken at therapeutic doses. However, in 
overdose acetaminophen is hepatotoxic and is the most common cause of acute liver failure in the United 
States and Europe1,2. After overdose, the reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI) 
is generated in excess, depleting cellular glutathione (GSH) then binding covalently to cellular pro-
teins resulting in oxidative stress and hepatocyte death, predominately by necrosis3. Cell death releases 
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intra-cellular molecules into the extra-cellular milieu and this is reflected by changes in circulating pro-
tein and RNA4. The current antidote, acetylcysteine (NAC), replenishes cellular GSH and is highly effec-
tive at preventing liver injury if administered soon after overdose5. However, NAC treatment takes at 
least 21 hours to complete so resulting in substantial hospital bed occupancy and commonly producing 
adverse drug reactions; 65% of NAC-treated patients vomited, retched or needed antiemetic therapy in 
a recent randomised controlled trial6. To selectively target treatment to those who stand to benefit and 
facilitate early safe hospital discharge of low risk patients there is an unmet need for new biomarkers 
that stratify patients by their risk of liver injury at first presentation to hospital, soon after overdose, an 
early time point when current markers such as serum alanine transaminase (ALT) activity lack sensitivity 
and specificity7.
Acetaminophen can also induce kidney tubular cell death resulting in acute kidney injury (AKI)8 and, 
in the presence of liver injury, AKI is one of the key predictors of need for urgent liver transplantation to 
avoid death. Kidney injury is currently quantified by serum creatinine. However, patients with AKI are 
not in steady-state with regard to kidney function and serum creatinine is slow to report cellular damage. 
Serum creatinine also lacks specificity, becoming elevated by non-renal pathologies such as dehydration 
and muscle injury9. New biomarkers are needed to report drug-induced kidney injury with enhanced 
sensitivity and specificity.
MicroRNAs (miRNAs) are small (~22 nucleotide-long) non-protein coding RNA species involved in 
post-transcriptional gene-product regulation10. In blood, miRNAs are stable because they are protected 
from degradation by extra-cellular vesicles (such as exosomes), RNA binding protein complexes (such as 
argonaute 2 – Ago2) and high-density lipoproteins11,12. The different circulating carriers for miRNA may 
reflect different pathways of release from cells; exosomal miRNAs may represent physiological release 
whereas miRNAs bound to Ago2 are increased with cell necrosis. As they are amplifiable and some are 
tissue restricted, miRNAs represent a reservoir for biomarker discovery. Liver-enriched miR-122-5p is 
released by injured hepatocytes and is a circulating biomarker for liver toxicity in zebrafish13, rodents14 
and humans15. In patients with acetaminophen-induced liver injury circulating miR-122-5p has been 
reported to be increased around 100-fold compared to controls15,16. However, it is not known whether 
other miRNAs can out-perform miR-122-5p with regard to patient stratification.
The field of profiling multiple circulating miRNAs to discover signatures of toxicity is relatively new. 
In rodent models of acetaminophen toxicity there have been profiling studies of relatively small num-
bers of circulating miRNAs - these studies demonstrate that multiple miRNA species change with liver 
injury17,18. In humans, a miRNome subset of 372 miRNAs was quantified in 49 patients with acetami-
nophen hepatotoxicity or ischemic hepatitis17. This study confirmed that miRNAs were increased and 
decreased and suggested that certain species could distinguish between these distinct aetiologies of liver 
injury17. Changes in circulating miRNAs have also been reported in small numbers of hepatotoxicity 
patients analysed by high-throughput sequencing18,19. These studies did not address the unmet clinical 
need for improved patient stratification, back translate to pre-clinical models or identify signals of kidney 
toxicity. In the present study we recruited over 200 patients and assayed miRBase version 18 to identify 
which miRNAs were differentially expressed in plasma from overdose patients with and without aceta-
minophen toxicity (APAP-TOX and APAP-no TOX, respectively). Selected miRNA candidate biomarkers 
were tested for liver and kidney specificity in humans and mice, and sensitivity with regard to patient 
stratification at first presentation to hospital.
Results
Circulating miRNAs that were differentially expressed with acute liver injury. The experi-
mental design used to identify differentially expressed miRNAs is presented in Fig. 1. In phase 1 of this 
discovery study, randomly selected APAP-TOX and APAP-no TOX samples were pooled and expressed 
miRNAs were identified. From 1809 miRNA species, 359 miRNAs fulfilled our criteria of expression (Ct 
value < 35 with a single, sharp melt peak) in at least one of the 4 sample pools (2 x APAP-TOX and 2 x 
APAP-no TOX). The patient demographics and clinical chemistry results from APAP-TOX and APAP-no 
TOX patients in the training set and test set are presented in supplementary Table 1. In Phase II, these 
359 miRNAs were quantified in each of the 54 patient samples of the training set using a bespoke PCR 
array. The PCR results from phase II for each microRNA are presented in supplementary file 1. The PCR 
results from 1 sample in the APAP-TOX group did not have any amplification curves and this sample 
was excluded from further analyses. The phase II PCR profiling results: 75 miRNAs were 3-fold or more 
increased in the APAP-TOX patient group compared to the age- and sex-matched APAP-no TOX group. 
46 miRNAs were 3-fold or more decreased in the APAP-TOX patient group. These data are presented 
in Fig. 2A as a volcano plot. The largest median (IQR) increased circulating miRNAs were miR-122-5p 
68 (11–277), miR-885-5p 57 (17–372) and miR-151a-3p 57 (16–360) (Fig.  2B). A heatmap with clus-
ter analysis of > 3-fold increased/decreased circulating miRNAs in the APAP-no TOX and APAP-TOX 
patients from the training set is displayed in supplementary Figure 1. This heatmap demonstrates that 
APAP-TOX patients can be clustered into sub-groups based on the expression of miRNA panels. There 
was a group of patients with lower miR-30b-5p, miR-186-5p, miR-382-5p, miR-27a-3p, miR-15a-3p and 
miR15a-5p. These APAP-TOX patients were more unwell (INR 2.0 (16-3.4) v 1.4 (1.2–1.5) in rest of 
APAP-Tox group P = 0.003; serum creatinine 152 mg/dl (64–289) v 61 mg/dl (58–67) P = 0.01). The larg-
est fold increase miRNAs (miR-122-5p and miR-885-5p) were highly correlated across patients in the 
www.nature.com/scientificreports/
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training set (Fig. 3A). miR-122-5p has been reported to circulate in a protein fraction of plasma rather 
than in extra-cellular vesicles although this has not been characterized in humans. After antibody-medi-
ated pull down of Ago2 (corrected by IgG control), acetaminophen toxicity induced a significant increase 
in the amount of miR-122-5p and miR-885-5p specifically bound to Ago2 (Fig.  3B,C), consistent with 
both miRNAs being released bound to this protein. Interestingly there was no increase in miR-151a-3p, 
which suggests different mechanisms of release across miRNA species (Fig.  3D). In situ hybridization 
for miR-122-5p and miR-885-5p was performed on liver explants removed following acetaminophen 
overdose. Both these miRNAs localised to hepatocytes and their expression was reduced in the areas of 
centrilobular necrosis, consistent with release from injured cells (Fig. 3E).
Development and testing of miRNA diagnostic panels. In Phase III random forest statistics were 
used to identify which miRNAs separate APAP-TOX from APAP-no TOX. The analysis demonstrated 
that 16 miRNAs (‘classifier model’) had the lowest prediction error - the largest marginal decrease in 
prediction accuracy when their values are randomly permuted (Fig. 4A). This classifier model was tested 
in an independent test set of 81 patient samples (Fig.  4B). The probability of a sample being correctly 
classified by the miRNA model as APAP-TOX was significantly higher when the true classification was 
APAP-TOX (median percent probability (IQR): 75 (63–77) for true APAP-TOX; 44 (43–47) for true 
APAP-no TOX; P < 0.0001). For an APAP-TOX classification probability cut-off of 50% (i.e. higher prob-
ability of APAP-TOX than APAP-no TOX) the classifier series sensitivity was 90% (95% CI: 76 to 97) 
and specificity was 90% (77 to 97) (Fig. 4B).
Specificity of candidate miRNA biomarkers. The 3 largest fold increase miRNAs (miR-122-5p, 
miR-885-5p and miR-151a-3p) and the miRNA with the lowest prediction error from the classifier model 
(miR-382-5p) were taken forward and tested for specificity and sensitivity.
Human specificity studies. In patients with acute liver injury (ALI) due to a diverse range of 
non-acetaminophen causes, all 4 miRNA species were significantly changed in their circulating 
Figure 1. Study design. Phase I identified the expressed microRNAs (miRNAs) in pooled samples from 
acetaminophen toxicity (APAP-TOX) patients and acetaminophen overdose with no toxicity (APAP-no 
TOX) patients. In Phase II, expressed miRNAs were quantified in 27 APAP-TOX and 27 APAP-no TOX 
patients. For data processing, Ct values were calibrated for RNA recovery using the cel-miR-39-3p assay 
(which detects a synthetic miRNA spiked in to each sample during sample prep). In Phase III, random forest 
analysis was performed to develop the classifier model that was subsequently tested in the test set.
www.nature.com/scientificreports/
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concentration to levels comparable with the APAP-TOX group (Fig.  5A–D). The kidney is commonly 
injured in the setting of ALI so could be the tissue of origin for circulating miRNAs and kidney dysfunc-
tion could affect the circulating concentration of liver-derived miRNAs by altering their clearance. Two 
complementary approaches were used to determine miRNA liver specificity in the presence of kidney 
Figure 2. Differentially expressed circulating microRNAs (miRNAs) with toxicity. (A) Volcano plot of 
miRNA data when acetaminophen toxicity (APAP-TOX) patients were compared with age and sex matched 
acetaminophen no toxicity (APAP-no TOX) patients. The negative logarithm base 10 of the P-value is 
plotted against log 2 difference in estimated relative expression values. Respectively, the triangles and squares 
correspond to miRNAs that were more than 3 fold increased or decreased in the APAP-TOX patients 
relative to the APAP-no TOX patients. (B) Box-and-whisker plots displaying the top 15 highest fold increase 
miRNAs and 5 highest fold decrease miRNAs. The fold regulation was calculated using the 2−ΔΔCt method. 
Statistically significant differences were determined by Wilcoxon matched-pairs signed rank test using 2−ΔCt. 
Ct values were normalized using global Ct mean. Statistically significant differences were determined by 
Mann Whitney Test using Δ Ct values. ***P < 0.001; **P < 0.01; *P < 0.05.
www.nature.com/scientificreports/
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injury. APAP-TOX patients without and with kidney dysfunction (serum creatinine concentration 
> 110 μ mol/L) were compared across the training and test sets (supplementary Table 2). There was an 
increase in the median PCR-array Ct value with kidney dysfunction, consistent with a overall reduction 
Figure 3. miR-122-5p and miR-885-5p are released from human hepatocytes bound to the carrier 
protein Ago2. Figure (A) Pearson correlation plot of circulating miR-885-5p and miR-122-5p across APAP-
TOX and APAP-no TOX patients. Figure (B–D) represent the relative Ago2 fraction for miR-122-5p, miR-
885-5p and miR-151a-5p respectively in APAP-TOX (N = 6) and APAP-no TOX (N = 6) patients. The Y axis 
represents the 2−ΔCt value obtained from the Ago2 pull-down minus the 2−ΔCt value obtained from the IgG 
pull-down from the same sample, both normalised by spiked-in synthetic miR-39. Statistically significant 
differences were determined by Mann Whitney Test. Figure (E) presents liver tissue from 2 patients whom 
underwent liver transplantation for severe acute liver failure due to acetaminophen overdose. Images from 
hematoxylin and eosin (H&E) and in situ hybridization for miR-122-5p and miR-885-5p are presented.
www.nature.com/scientificreports/
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in circulating miRNAs (APAP-TOX no AKI: 16.55 (15.78–17.49); APAP-TOX AKI: 18.01 (16.84–19.02). 
P = 0.0007). However, there was no difference in miR-122-5p, miR-885-5p, miR-151a-3p or miR-382-5p 
(Table 1). The miRNAs that were significantly changed with kidney dysfunction are presented in Table 1.
Mouse specificity studies. Mouse models of acetaminophen and cisplatin toxicity were compared 
with regard to miRNA circulating concentrations, cisplatin toxicity being a well-established model of 
drug-induced AKI. Acetaminophen induced liver injury was confirmed by a median (IQR) serum ALT 
activity of 7230IU/L (5355–23615, N = 8) and histologically by centrilobular hepatic necrosis. By contrast 
with vehicle treated controls (N = 7), acetaminophen toxicity in mice resulted in increased miR-122-5p 
and miR-151a-3p, and decreased miR-382-5p, in line with our human data (Fig. 5E–H). However, miR-
885-5p was not translatable across species and did not change. Cisplatin-induced AKI was demonstrated 
by significant elevations in urinary KIM-1 concentration (control: 1322 pg/mgUCr (766–1460); cisplatin 
10,964 pg/mgUCr (4493–16003). N = 7, P = 0.0003) and histologically, there were apoptotic proximal 
tubular cells, sloughing and an overall reduced number of epithelial cells. Cisplatin had no effect on 
miR-122-5p, miR-885-5p, miR-151a-3p or miR-382-5p (Fig. 5E–H).
Human case report. To further define temporal changes, miRNA candidate biomarkers were measured 
in serial samples from a 49 year-old man who presented to hospital soon after a large overdose (4 hour 
acetaminophen concentration: 405 mg/L) with initially normal serum ALT activity (28 U/L) and kidney 
function (serum creatinine: 83 μ mol/L). Despite prompt NAC treatment (started 6 hours after overdose), 
the patient subsequently developed significant liver injury (peak ALT: 12,353 U/L) with coagulopathy 
(peak INR: 2.8) and kidney injury (peak creatinine: 151 μ mol/L) (Fig. 6F–H). The patient’s liver injury 
recovered with continued NAC treatment, providing an opportunity to track miRNA concentrations 
from no apparent injury, into significant organ injury and through to liver recovery. The temporal pro-
files of the individual miRNAs were different; miR-122-5p concentration was elevated but decreased 
earlier than ALT (Fig. 6A). miR-885-5p remained elevated longer than miR-122-5p (Fig. 6B). In line with 
the array data, both miR-382-5p and miR-19a substantially decreased in concentration and, interestingly, 
they remained below the hospital admission level (Fig. 6C,D). miR-34a initially increased but then fell 
to below the admission concentration, a decrease which corresponded temporally with increased serum 
creatinine concentration (Fig. 6E).
Identification of endogenous miRNA normalizers. To identify which miRNAs were most stably 
expressed across APAP-TOX and APAP-no TOX patients NormFinder analysis was performed on the 
training set data. miR-1287 was the most stably expressed with a stability value of 1.22*10− 5. All results 
from the NormFinder assessment are reported in supplementary Table 3. miR-1913, miR-671, miR-1287, 
Let-7d, miR-1260 and miR-324 were taken forward and measured in the APAP-early patient samples 
using RT-PCR. The demographics and standard clinical chemistry for this patient cohort are presented 
in supplementary Table 4. In accordance with the NormFinder assessment, miR-1287 was most stably 
expressed across the different samples with a coefficient of variation (CV) of 1.71% (supplementary 
Figure 2).
Sensitivity - comparison of leading microRNA discriminators with ALT as a diagnostic of early 
ALI. In the 67 APAP-early patients, miR-122-5p identified subsequent liver injury when normalized by 
BA














AUC = 0.96 (0.92-1.01)
P < 0.0001
Figure 4. Random forest statistics analysis. Figure (A) presents the top 16 miRNAs that separate APAP-
TOX from APAP-no TOX in the training set. miRNAs were ranked according to the marginal decrease in 
out-of-bag prediction accuracy when the gene’s expression measurements are scrambled. Figure (B) Receiver 
operator characteristic curve displaying the performance of the top 16 miRNAs from the training set with 
regard to distinguishing APAP-TOX from APAP- no TOX in the test set.
www.nature.com/scientificreports/
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any of the 6 endogenous miRNA normalizers described above (miR-122-5p area under ROC curve nor-
malized by miR-1913, 0.97 (95% CI 0.92–1.01); miR-671, 0.96 (0.92–1.01); miR-1287, 0.95 (0.90–1.00); 
let7-d, 0.94 (0.89–1.00); miR-1260, 0.93 (0.88–1.00); miR-324, 0.93 (0.87–1.00) miR-122-5p ROC-AUC 
significantly larger than all other miRNAs – P < 0.05). miR-885-5p, miR-151a-5p and miR-382-5p were 
inferior to ALT for early prediction of liver injury (Fig. 7). When the largest fold increase and decrease 
phase II miRNAs were combined (miR-122-5p and miR-483-3p, respectively) there was a modest increase 
in the area under the ROC curve compared with miR-122-5p alone. No other miRNA combination 
improved predictive accuracy (data not shown).
Discussion
To date, this is the largest and most comprehensive study of the circulating miRNome in humans with 
acetaminophen toxicity. We identified multiple miRNA species that separated APAP-TOX from APAP-no 
TOX in a training set of patients, then tested the panels in a separate patient cohort. The large number of 
Figure 5. Biomarker specificity for liver injury. Figure (A–D) present circulating miR-122-5p, miR-885-5p, 
miR-151a-3p and miR-382-5p in APAP-no TOX patients and patients with acute liver injury (ALI) induced 
by APAP overdose or another aetiology (non-APAP). Figure (E–H) present miR-122-5p, miR-885-5p, miR-
151a-3p and miR-382-5p in control mice, APAP overdose mice and cisplatin-induced acute kidney injury 
(AKI) mice. Values represent 2−ΔCt normalised by miR-1287 in human samples and spiked in synthetic miR-






CI) P value SENS (95% CI)
miR-19a-3p − 3.76 <0.0001 0.76 (0.66–0.86) <0.0001 0.51 (0.35–0.67)
miR-19b-3p − 4.10 0.001 0.73 (0.61–0.85) 0.001 0.27 (0.12–0.46)
miR-192-5p − 1.66 0.001 0.73 (0.61–0.85) 0.001 0.20 (0.08–0.39)
miR-34a-5p − 5.71 0.003 0.71 (0.58–0.83) 0.003 0.20 (0.08–0.39)
miR-3187-3p − 5.30 0.005 0.70 (0.58–0.83) 0.005 0.47 (0.28–0.66)
miR-122-5p 1.28 0.92 0.51 (0.36–0.65) 0.92 0.27 (0.12–0.46)
miR-885-5p 1.25 0.73 0.53 (0.38–0.67) 0.72 0.33 (0.17–0.53)
miR-151a-3p 1.28 0.27 0.58 (0.44–0.72) 0.27 0.10 (0.02–0.27)
miR-382-5p 1.46 0.67 0.53 (0.39–0.68) 0.67 0.17 (0.06–0.35)
Table 1.  Comparison of circulating miRNAs in acetaminophen-induced acute liver injury patients with 
and without kidney dysfunction. ROC-AUC (area under the curve with 95% CI), sensitivity (SENS with 
95% CI) at 90% specificity and statistical significance are given. Negative fold change means lower with 
kidney dysfunction.
www.nature.com/scientificreports/
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miRNAs that were screened in this study (1809) allowed the identification of novel miRNA species that 
report toxicity. The largest fold change miRNAs (miR-122-5p, miR-885-5p and miR-151-3p) and the best 
discriminating miRNA (miR-382-5p) were taken forward and tested for specificity. Although variable, 
they report acute liver injury across patients and mouse models, even in the presence of kidney injury. 
Kidney injury resulted in significantly decreased miRNAs that represent new circulating biomarker can-
didates. The most stable internal miRNA normalizers were discovered and used to normalize miRNAs 
to compare with ALT activity with regard to sensitivity (the stratification of patients at first presentation 
to hospital). miR-122-5p very accurately predicted liver injury at first presentation to hospital, especially 
when combined with the largest decrease miRNA.
This study reported that 75 circulating miRNA species were more than 3-fold increased with acute 
liver injury, demonstrating the potential of multiple miRNA species as biomarkers. miRNAs identified 
in the training set of patients were validated in a separate patient cohort from a separate clinical unit. 
This 16-miRNA ‘signature’ of acute liver injury accurately identified toxicity. The most abundant miRNA 
Figure 6. Timeline of current and novel miRNA biomarkers following a large acetaminophen overdose 
in a 49 year-old male. Values for miRNA represent 2−ΔCt normalised by spiked-in synthetic miR-39.
www.nature.com/scientificreports/
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species in the liver20, miR-122-5p, was the highest increased circulating miRNA but other species were 
elevated to comparable degrees (miR-885-5p, miR-151-3p) or were ranked higher by random forest anal-
ysis in terms of ability to report injury (miR-382-5p). Circulating miRNAs are stable because they are 
either bound to proteins or encapsulated in extra-cellular vesicles (or both). The presence of miRNA in 
vesicles such as exosomes is controversial, with some studies reporting very low amounts in the exosomal 
cargo21. Also extra-cellular vesicles contain Ago2 suggesting there is not a clear division between the two 
circulating fractions. For the first time we demonstrate that human miR-122-5p circulates bound to the 
protein Ago2 and this fraction increases with liver injury. Ago2-bound miR-885-5p also increases with 
injury and both these miRNAs were localised to hepatocytes by in situ hybridization on human liver 
explants removed at transplantation for acetaminophen toxicity. These data suggest release of miR-122 
and miR-885 from the same cells attached to the same carrier protein.
The 3 highest fold increase miRNAs and the leading discriminator in our model were tested for 
specificity. Across all our human array studies and in mice models miR-382-5p decreased in circulating 
Figure 7. Biomarker sensitivity - ROC curve analysis supports the potential for miR-122-5p to predict 
the development of ALI. ROC analysis was calculated to determine the potential for plasma miRNAs 
and serum ALT activity to predict the development of TOX at first presentation to hospital following 
acetaminophen overdose. TOX was defined as > 3xULN ALT activity during hospital admission. The ROC 
curves of the 4 most accurate predictors are presented. AUC (area under the curve with 95% CI), sensitivity 
(SENS at 90% specificity) with 95% CI, positive and negative predictive values (PPV and NPV) and 
statistical significance for AUC value is presented in table. The miRNAs are normalized by miR-1287.
www.nature.com/scientificreports/
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concentration with liver injury. The mechanism of this circulating decrease of miR-382-5p is unknown, 
but conceptually could be either a decrease in production (such as reduced gene transcription in the 
injured liver) or increased clearance. Given that more miRNAs increase than decrease in the circula-
tion with acute liver injury it would require a highly selective process of altered clearance to explain 
the specific decrease in miR-382-5p and decreased tissue expression seems more plausible. miR-122-5p, 
miR-885-5p, miR-151-3p and miR-382-5p reported acute liver injury due to causes other than acetami-
nophen, which is consistent with them being liver specific and demonstrates that this panel has utility 
in the diagnosis of acute liver injury due to multiple causes. Furthermore, none of this panel changed 
with kidney injury in humans or mice, which also supports liver specificity and validates their use in 
patients with liver and kidney injury, which commonly co-exist in life-threatening acute liver failure. 
There were miRNA species that changed with kidney dysfunction and they consistently decreased in cir-
culating concentration. A general fall in circulating miRNA concentrations has been reported in chronic 
kidney disease and suggested to be due increased blood RNAase activity22. Our data would suggest AKI 
also reduces most, but not all, circulating miRNAs. In the present study the performance of the lead-
ing miRNA, miR-19a, was modest with regard to separating liver injury from liver and kidney injury 
(ROC-AUC 0.76). However, human diagnostic performance may be improved when multiple time points 
post-drug exposure are analysed in larger studies. This is supported by the case reported in this paper, 
which demonstrated a decrease in miR-19a before serum creatinine was elevated. By definition, the 
patients with kidney dysfunction had more severe acetaminophen toxicity and differences in circulating 
miRNAs could reflect more severe liver injury rather than kidney injury per se. Whether miRNA species 
such as miR-19a are truly kidney specific or represent liver toxicity prognosis markers is an important 
area for further development.
It is widely reported that miRNAs translate across species; for example, we have reported that miR-
122-5p reports liver injury in cell models, zebrafish, rodents and humans. Our array data are consistent 
with smaller acetaminophen studies performed in rodents: 586 miRNA species were measured in mice14 
and 750 miRNA species were measured in rats23. In addition to miR-122-5p, the miRNA species miR-22, 
miR-29b, miR-29c, miR-130a and miR-193 were increased in both mice and humans. In rats, in addition 
to miR-122-5p, the increase of miR-22, miR-193 and miR-194 was in accordance with our human data23. 
This demonstrates the translational potential of miRNAs across rodents and humans. However, the data 
presented in this study clearly demonstrate that miR-885-5p does not increase with acetaminophen tox-
icity in mice, an important limitation. Comparative biomarker profiles for miR-122-5p, miR-885-5p, 
miR-151-3p and miR-382-5p are summarized in supplementary Table 5.
Although miR-122-5p had the highest fold increase in APAP-TOX patients, it was ranked 11th place 
in the miRNA panel, suggesting that other microRNA species may have greater clinical utility. As a first 
step in determining the clinical utility of our miRNA panel, the performance of selected members was 
compared with ALT with regard to patient stratification at first presentation to the ED. These patients 
were recruited from a different hospital to the training and test patient sets (London as compared to 
Edinburgh). ROC analysis revealed that miR-122-5p was superior to ALT activity with regard to pre-
dicting APAP-TOX in early APAP patients. This observation confirms our previous investigation, in 
which miR-122-5p displayed superior predictive value over ALT activity at the hospital ‘front door’, in a 
separate cohort of patients from a different hospital16. miRNA species were identified which were stable 
across patients with and without organ injury. These internal normalizers can be used to report sample 
degradation and failed miRNA extraction from plasma. Therefore, they are of value for future studies of 
acute liver injury providing their stability is confirmed in each specific clinical study. When normalized 
by any of the stable miRNAs, miR-122-5p was superior to ALT. At first presentation, miR-122-5p was 
also superior to other miRNAs with regard to prediction of subsequent liver injury. This important result 
may reflect the high abundance of miR-122-5p within the hepatocyte compared to other miRNAs, its 
high degree of tissue selectivity, potential different pathways of release from injured cells (although miR-
885-5p is also bound to same protein), different stability in the circulation or miR-122-5p having a higher 
baseline circulating concentration. Interestingly, combining miR-122-5p with miR-483-3p resulted in 
an increase in predictive accuracy (as judged by the largest area under the ROC curve). While this is 
hypothesis generating, it may be that combining miRNAs that increase and decrease represents the opti-
mal biomarker qualification strategy.
In conclusion, miRNA panels are associated with liver and kidney toxicity in patients with acetami-
nophen overdose. These panels include novel miRNAs not previously described as toxicology biomark-
ers. For patient stratification at first presentation to hospital miR-122-5p is the lead miRNA candidate for 
clinical development, possibly in combination with miR-483-3p. Use of miRNA biomarkers could allow 
earlier prediction of patients at risk of organ injury and enable targeted intervention in these patients; 
furthermore they could allow earlier prediction of patients at low risk and enable shorter antidotal treat-
ment regimens and reduce length of hospital stay.
Patients and Methods
Patient Cohorts. The local research ethics committee approved the study and informed consent was 
obtained from all patients before entry into the study. The study was carried out in accordance with the 
approved relevant guidelines.
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Acetaminophen toxicity (APAP-TOX) patients. A total of 68 adult patients (aged 16 years and 
above) admitted to the Royal Infirmary of Edinburgh (RIE), UK with ALI, secondary to acetaminophen 
ingestion, were entered into the study. ALI was defined as a sudden deterioration in liver function in the 
absence of a history of chronic liver disease with a clear history of excess acetaminophen ingestion. All 
patients received intravenous NAC treatment.
There were two separate cohorts within this APAP-TOX group. First, patients admitted to the Clinical 
Toxicology Unit at RIE with a peak serum ALT activity greater than 3 x upper limit of normal (> 150 U/L) 
formed the training set (N = 27). Second, patients admitted to the Scottish Liver Transplantation Unit 
at RIE with peak ALT > 150 U/L formed the test set (N = 41). There was no patient overlap between 
training and test sets. Blood samples with peak hospital stay ALT activity were analysed in both training 
and test sets.
Acetaminophen no toxicity (APAP-no TOX) patients. 67 patients were recruited from RIE. The 
entry criterion was a history of acetaminophen ingestion in overdose that required treatment with NAC 
as per UK guidelines at the time of hospital admission24. All patients had a plasma acetaminophen con-
centration above the Prescott nomogram, which confirmed potentially toxic exposure. Blood was col-
lected at the end of the intravenous NAC infusion for measurement of serum ALT activity and absence 
of liver injury was confirmed by a normal serum ALT activity (< 50 U/L). APAP-no TOX patients were 
age- and sex-matched with the training and test set APAP-TOX patients. There was no patient overlap 
between training and test set. Blood from the end of NAC treatment was used in this study.
Acute liver injury not due to acetaminophen (Non-APAP ALI). Samples from 5 subjects with 
ALI not due to acetaminophen were recruited to this study. The causes of injury were autoimmune 
hepatitis, primary graft non-function, small-for-size syndrome, malignancy and clarithromycin-induced 
liver injury.
First presentation to hospital patients (APAP-early). These patients (total N = 67) were all 
recruited from St Thomas’ Hospital, London UK. Inclusion criteria were: adult with a clear history of 
excess acetaminophen ingestion and a timed blood acetaminophen concentration that was judged by the 
treating physician to necessitate hospital admission for intravenous NAC therapy, as per UK guidelines 
at the time of study. All patients completed the full course of NAC treatment. For all study participants, 
demographic data and blood results were recorded. ALI was defined as peak serum ALT activity greater 
than 3x the upper limit of the normal range (> 150 IU/L), the UK indication for continuing NAC therapy 
after completion of the initial regimen. The first blood sample at presentation to hospital was collected 
for the APAP-early cohort.
In all groups, blood samples were centrifuged at 1000 × g for 15 minutes at 4 °C. The supernatant was 
then separated into aliquots and stored at − 80 °C until analysis.
MicroRNA profiling of training set. In the training set 27 APAP-TOX samples were compared with 
27 APAP-no TOX samples. The methods for profiling are described in the supplemental methods.
MicroRNA profiling of test set. In the test set 41 APAP-TOX samples were compared with 40 
APAP-no TOX samples. miRNA species were selected based on fold change from the training set results. 
Sample processing was as described for the training set and real-time PCR was again performed on a 
Fluidigm BioMark HD.
Ago2-associated miRNA isolation. Magna Bind goat anti-mouse IgG magnetic bead slurry, 100 μ L, 
(Thermo Scientific, Waltham, USA) was incubated with 10 μ g of mouse monoclonal anti-Ago2 (Abcam, 
Cambridge, UK) or mouse normal IgG (Santa Cruz Biotechnology, Dallas, US) antibodies for 2 h at 4 °C. 
The antibody-coated beads were then added to plasma and incubated overnight at 4 °C with rotation. 
Beads were washed and each sample then eluted in RNAse free water before QIAzol was added for RNA 
isolation. Ago2 isolation was determined by western blot analysis.
Targeted miRNA measurement. Selected miRNAs were quantified in plasma samples by RT-qPCR 
as described in the supplemental methods. In situ hybridisation was performed on human liver removed 
at the time of transplantation (explant) using methods described in our previous study13. The patients 
had severe acute liver failure secondary to acetaminophen overdose.
Mouse models of liver and kidney toxicity. Mouse studies were in accordance the Animals 
(Scientific Procedures) Act 1986 and approved by the local Animal Ethics Committee. In brief, male CD1 
mice (28–33 g) were treated with either 0.9% saline, cisplatin (20 mg/kg) or acetaminophen (350 mg/kg) 
IP. At 24–72 hours after treatment, blood was collected via cardiac puncture and allowed to clot before 
isolation of serum which was stored at − 80 °C. Tissue samples were collected and either snap frozen or 
fixed in neutral buffered formalin (10%).
www.nature.com/scientificreports/
1 2Scientific RepoRts | 5:15501 | DOi: 10.1038/srep15501
Statistical analysis. Data are presented as median and range or interquartile range (IQR). Each 
dataset was analysed for normality using a Shapiro-Wilk test. For nonparametric datasets, comparisons 
were made using the Mann-Whitney U test or Wilcoxon matched-pairs signed rank test. All calcula-
tions and receiver operator characteristic (ROC) curves were performed using GraphPad Prism software 
(GraphPad Software, La Jolla, CA). Profiling data were analysed by random forests to give an estimate 
of how well we can classify individuals in a new data set into each group. Random forests create a set of 
classification trees based on continual sampling of the experimental units and compounds. Each obser-
vation is then classified based on the majority votes from all of the classification trees. Details of random 
forest analysis can be found in the supplemental methods.
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2.2 Contributions by the candidate 
 
Measurement of the miRNA panel and 6 endogenous miRNA normalisers in the 67 
Paracetamol overdose patient samples collected directly after presenting to the 
hospital; Argonaut pulldown with subsequent miRNA measurements in a selection of 
patient samples; Measurement of miRNAs in samples from the case report for 
producing the timeline; miRNA measurements in the mouse samples from 
Paracetamol overdose mice and cisplatin-induced kidney injury mice; All statistical 
analyses apart from the Random forest analysis; Producing all figures apart from 






To date, this is the largest and most comprehensive study of the circulating miRNome 
in humans with paracetamol toxicity. We identified multiple miRNA species that 
separated APAP-TOX from APAP-no TOX in a training set of patients, then tested the 
panels in a separate patient cohort. The large number of miRNAs that were screened 
in this study (1809) allowed the identification of novel miRNA species that report 
toxicity. The largest fold change miRNAs (miR-122-5p, miR-885-5p and miR-151-3p) 
and the best discriminating miRNA (miR-382-5p) were taken forward and tested for 
specificity. Although variable, they reported acute liver injury across patients and 
mouse models, even in the presence of kidney injury. Kidney injury resulted in 
significantly decreased miRNAs that represent new circulating biomarker candidates. 
The most stable internal miRNA normalizers were discovered and used to normalize 
miRNAs to compare with ALT activity with regard to sensitivity (the stratification of 
patients at first presentation to hospital). miR-122-5p very accurately predicted liver 
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Chatper 3: Further qualification of miR-122-5p as a marker of 




Because miR-122-5p was the most sensitive miRNA for predicting ALI in the previous 
study, it was chosen to further qualify and explore this marker in three clinically-
relevant scenarios. 
Since co-ingestion of ethanol is common in overdose patients (232, 233), the effect 
of acute ethanol ingestion had to be defined. For this reason, healthy volunteers were 
recruited and blood was collected up to 48 hours before they intended to drink 
ethanol, and again 3-5h after the participants had consumed ethanol in order to 
measure circulating miR-122-5p concentration. 
The results from this study are published as: 
McCrae JC, Sharkey N, Webb DJ, Vliegenthart AD, Dear JW. Ethanol consumption 
produces a small increase in circulating miR-122 in healthy individuals. Clin Toxicol 
(Phila) 2016;54:53-55. (234) 
 
Kidney dysfunction is one of the key predictors of death and need for urgent liver 
transplantation in the presence of significant liver injury, with serum creatinine 
concentration being a component of the King’s College Criteria (KCC) (10). Renal 
dysfunction has been reported to affect the circulating concentration of microRNAs. 
In patients with chronic kidney disease (CKD) Neal et al. reported significantly 
reduced total plasma microRNA and reductions in certain specific species (miR-16, -
21, -210, -638) (235). In the previous chapter, the patients with acute liver injury also 
had a global reduction in circulating miRNA (231). Patients with ALI may need short-
term haemodialysis (HD), for example, as a bridge to possible liver transplantation. 
For this reason, the effect of HD in patients with end-stage renal disease (ESRD) on 
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circulating miR-122-5p was determined and compared with healthy controls, patients 
with CKD and patients with successful renal transplant. 
Findings from this study are published as: 
Rivoli L*, Vliegenthart AD*, de Potter CM, van Bragt JJ, Tzoumas N, Gallacher P, Farrah 
TE, Dhaun N, Dear JW. The effect of renal dysfunction and haemodialysis on 
circulating liver specific miR-122. Br J Clin Pharmacol 2016. (236) *co-first authors. 
 
Up until now, all studies involving miR-122-5p serum or plasma venous samples have 
been analysed in specialist laboratories with time-consuming and expensive kits. 
There is an unmet need for assays that can rapidly and accurately measure miRNA at 
the point-of-care (POC). Ideally, a POC assay would measure miR-122-5p in a single 
blood drop from a finger prick, be affordable for use in resource-limited settings and 
suitable for use near, or actually in, a patient’s home (43). Such an assay could provide 
an early signal of DILI in patients at elevated risk, for instance, following prescription 
of antimicrobials with a significant DILI liability (7, 9, 237). With development, serial 
monitoring of miR-122-5p could improve patient safety by allowing medication 
change before life-threatening liver failure develops and by supporting safe 
reintroduction of treatment after interruption. In commercial drug development, 
measurement of miR-122-5p using a finger prick could reduce the need for 
venepuncture, which is especially advantageous in certain groups such as children 
and when multiple serial measurements in the same person are required. For this 
reason, in this project it was determined if miR-122-5p could be measured in a 
capillary blood drop from a finger prick and to compare the concentration to venous 
blood and plasma; to assess the intra-individual variability of capillary miR-122-5p 






Findings from this study are published as: 
Vligenthart AD, Berends C, Potter CMJ, Kersaudy-Kerhoas M, Dear JW. Capillary miR-
122 represents a sensitive and specific biomarker for human drug-induced liver 
injury. Br J Clin Pharmacol (238) 
 
3.2 Contributions by the candidate 
 
Paper 2: Recruiting the volunteers; Measurement of miRNAs in all samples; The 
statistical analysis of data; Producing the figures; Preparation and revision of the 
manuscript. 
Paper 3: miRNA measurements in plasma samples from the healthy volunteers, CKD 
patients, ESRD patients and kidney transplant patients; Performing the Argonaut 
pulldown and isolating the exosomes with subsequent miRNA measurements; 
Statistical analysis of the data; Producing the figures; Preparation and revision of the 
manuscript. 
Paper 4: miRNA measurements in the blood samples and blood drops; Statistical 
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ABSTRACT
Introduction: MicroRNA 122 (miR-122) is a new circulating biomarker for liver injury, which increases
earlier than conventional markers in patients with acetaminophen hepatotoxicity. However, as co-
ingestion of ethanol is common with drug overdose, a confounding effect of acute ethanol
consumption on serum miR-122 must be examined. Methods: Blood was collected from healthy
volunteers before and after recreational consumption of ethanol. Routine biochemistry and
haematology measurements were performed, and serum miR-122 was measured by qPCR. The
primary outcome was the difference in serum miR-122 with ethanol consumption. Results: We
recruited 18 participants (72% male). Their mean serum ethanol concentration was 113 mg/dl (95%
confidence interval [CI] 91–135 mg/dl) after consuming ethanol. Serum miR-122 increased from a
mean of 71.3 million (95% CI 29.3–113.2 million) to 139.1 million (95% CI 62.6–215.7 million) copies/
ml (2.2-fold increase). There was no significant difference in serum alanine aminotransferase activity
before and after ethanol consumption. Conclusion: miR-122 increased with moderate ethanol
consumption, but the fold change was modest. As increases with acetaminophen toxicity are 100-
to 10 000-fold, moderate ethanol intoxication is unlikely to confound the use of this biomarker of
hepatotoxicity.
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MicroRNAs are short (22 nt) RNA species that do not code
for proteins, but affect gene expression via binding to
messenger RNA (mRNA) and blocking translation to pro-
tein.[1,2] Some are tissue-specific and stable in the circulation
which has led to microRNAs being developed as organ injury
biomarkers.[3–5]
miR-122 is abundant and liver-specific, representing over
70% of all hepatocyte microRNA.[2] It has been implicated in
liver pathologies, such as viral hepatitis, hepatocellular carcin-
oma, drug-induced liver injury and alcoholic liver disease.[2–4]
Recently, we reported that miR-122 is a biomarker of liver
injury in paracetamol (acetaminophen – APAP) poisoning. In
patients requiring acetylcysteine (NAC) treatment for APAP
overdose, circulating miR-122 rose more quickly than alanine
aminotransferase (ALT), and could accurately predict subse-
quent liver injury at first presentation to hospital.[6]
If miR-122 is going to have clinical utility as a marker for
acute liver injury in APAP poisoning, the effect of acute ethanol
ingestion needs to be defined, as co-ingestion of ethanol is
common in overdose patients.[7] This study is an examination
of circulating miR-122 before and after ethanol ingestion in
healthy volunteers.
Methods
We prospectively recruited healthy volunteers in the age group
of 18–65 years, with pre-existing plans to consume ethanol
recreationally. Ethical approval was obtained from the South
East Scotland research ethics committee and informed consent
obtained from all participants. Exclusion criteria were: previous
liver disease or hepatobiliary surgery; previous viral hepatitis;
recent viral infection; recent strenuous exercise; consumption
of cytochrome P450-inducing medication; past medical history
of epilepsy, cancer, diabetes mellitus or alcoholism; psychiatric
disease; pregnancy or the possibility of pregnancy and direct
connection to clinical staff involved in the study.
We collected blood up to 48 h before, and again 3–5 h after
the participants had consumed ethanol. The amount of
ethanol to be consumed was not specified in advance. In
serum the following parameters were measured: full blood
count, urea and electrolytes, bilirubin, ALT, alkaline phosphat-
ase, gamma-glutamyl transferase, coagulation profile, ethanol
and miR-122. Samples were refrigerated immediately and
prepared for analysis within 24 h.
miR-122 was measured by PCR as previously described.[8]
Absolute quantification of miR-122 was achieved by generating
a standard curve using synthetic target. All other analyses were
CONTACT Jame C. McCrae jcmccrae@gmail.com Room 3.08, Ashworth Laboratories, King’s Buildings, University of Edinburgh, West Mains Road, Edinburgh EH9
3JT, Scotland, UK
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performed by laboratory services at the Royal Infirmary of
Edinburgh.
The primary outcome was difference in serum miR-122
before and after ethanol consumption. We calculated the
sample size as follows: alpha-level 0.05; beta-level 0.9; standard
deviation 0.203 (calculated from the first five participants’ pre-
consumption serum miR-122); we estimated that to determine
a minimal difference in miR-122 delta-Ct of 0.165 (correspond-
ing to a 2-fold increase in copy number per millilitre) we would
require 18 participants. Statistical analysis was performed using
Graphpad Prism (GraphPad Software, La Jolla, CA).
Results
Eighteen healthy subjects were recruited to the study as per
the power calculation, of whom 13 (72%) were male. Table 1
summarises the clinical parameters at baseline and after
ethanol consumption. Notably, there was no significant differ-
ence between ALT measurements, which were all in the normal
range. Several blood parameters were significantly different
after alcohol consumption. There were small but statistically
significant changes in the leucocyte count, creatinine, urea,
potassium and bilirubin.
At baseline no participants had a detectable serum ethanol.
After consuming ethanol, their mean serum ethanol concen-
tration was 113 mg/dl (range 20–175). There was a 2.2-fold
increase of miR-122 from a mean value of 71.3 (95% confidence
interval [CI] 29.3–113.2 million) to 139.1 million (95% CI 62.6–
215.7 million) copies/ml (Fig. 1; p¼ 0.006).
Discussion
ALT is a serum marker used to detect hepatocellular injury that
has been in common practice for several decades.[9] Despite
this, there are several issues with its use: low-level insults may
not affect ALT, and there is a considerable delay between the
insult to the liver and a subsequent rise in serum. miR-122 is
one of a panel of new biomarkers that appear to have
increased sensitivity and specificity compared with ALT with
regard to detecting liver injury.[5,6]
Co-ingestion of ethanol is common in overdose,[7,10] and
so its effects on new biomarkers must be determined. We have
identified a small but statistically significant increase in miR-
122 after consumption of recreational levels of ethanol by
healthy young adults. The mean increase in serum ethanol in
this study (113 mg/dl) represents a moderate level of inebri-
ation, but well above the drink–drive limit in many countries
(e.g. 80 mg/dl in USA, England, Wales; 50 mg/dl in Scotland).
In previous studies miR-122 has increased 100- to 10 000-
fold in response to hepatocellular injury.[5,8] It is doubtful,
therefore, in mixed overdoses of APAP and ethanol that
elevations of miR-122 above around 2-fold could be due to
ethanol ingestion alone. These data indicate that ethanol co-
ingestion is unlikely to be a significant contributor to the
massive increases in miR-122 seen after APAP overdose. This is
essential information for the further development of miR-122
as a biomarker of APAP-mediated hepatocellular injury.
Our study has a few limitations: first, though the data set is
sufficient to address our primary outcome, it does not have
sufficient power to determine any relationship between level
of ethanol ingestion and miR-122 level. Furthermore, patients
taking mixed ethanol/APAP overdoses can present with serum
ethanol levels greater than the range covered by our study and
we cannot fully exclude the possibility that these might
increase mir-122 more substantially. This will need further
research in the clinical setting.
The participant groups had some differences in their blood
parameters before and after ethanol consumption. Although
statistically significant, the authors feel that these changes
would not be considered clinically important as they were all
modest and within their respective normal ranges. Finally, our
participants were healthy individuals with no history of liver
disease; it is unknown how applicable our findings are to
patients with pre-existing hepatic illness, and further explor-
ation in this patient group is required.
Conclusion
Acute ethanol ingestion leads to a significant rise in miR-122.
This increase is small compared with the biomarker signal with
APAP-mediated liver injury.[6] This study contributes to the
Table 1. Clinical parameters before and after ethanol consumption.
Before After
Clinical parameter Mean (SD) Mean (SD) p Value
Haemoglobin (g/l) 148 (7) 146 (8) 0.17
Leucocyte count (x109/l) 7.2 (2.9) 8.4 (1.7) 0.04
Platelets (x109/l) 261 (51) 261 (44) 0.98
INR 1.0 (0.1) 1.0 (0.1) 0.07
APTT Ratio 1.0 (0.1) 1.0 (0.1) 0.72
C-fibrinogen (g/l) 2.3 (0.3) 2.2 (0.3) 0.22
Urea (mmol/l) 5.0 (1.4) 4.6 (0.9) 0.04
Creatinine (micromol/l) 74.9 (6.4) 79.9 (12.3) 0.03
Sodium (mmol/l) 140 (1) 141 (3) 0.08
Potassium (mmol/l) 4.5 (0.5) 4.1 (0.2) 0.01
Bilirubin (micromol/l) 15.6 (12.0) 11.3 (10.0) 0.00
ALT (U/ml) 31.9 (25.0) 31.4 (23.7) 0.56
ALP (U/ml) 70.8 (13.2) 73.7 (14.2) 0.06
GGT (U/ml) 22.2 (16.8) 22.2 (17.0) 0.87
Ethanol (mg/dl) 0 (0) 113.4 (44.1) 50.001
Statistically significantly different parameters are highlighted in bold. ALP,
alkaline phosphatase; APTT, activated partial thromboplastin time; GGT,
gamma-glutamyl transpeptidase; INR, international normalized ratio; SD,
standard deviation.
Fig 1. Serum miR-122 before and after ethanol consumption.
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ongoing clinical development of miR-122 as a liver injury
biomarker for use in clinical toxicology.
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AIMS
microRNA-122 (miR-122) is a hepatotoxicity biomarker with utility in the management of paracetamol overdose and in drug
development. Renal dysfunction and haemodialysis have been associated with a reduction in circulating microRNA. The objective
of this study was to determine their effect on miR-122.
METHODS
Blood samples were collected from 17 patients with end-stage renal disease (ESRD) on haemodialysis, 22 healthy controls, 30
patients with chronic kidney disease (CKD) and 15 patients post-kidney transplantation. All had normal standard liver function
tests. Samples from ESRD patients were collected immediately pre- and post-haemodialysis. Serum alanine transaminase activity
(ALT), miR-122 and miR-885 (liver enriched) were compared.
RESULTS
Circulating miR-122 was substantially reduced in ESRD patients pre-haemodialysis compared with the other groups (19.0-fold
lower than healthy controls; 21.7-fold lower than CKD). Haemodialysis increased miR-122 from amedian value of 6.7 × 103 (2.3 ×
103–1.4 × 104) to 1.6 × 104 (5.4 × 103–3.2 × 104) copies ml1. The increase in miR-122 did not correlate with dialysis adequacy.
miR-122 was reduced in the argonaute 2 bound fraction pre-haemodialysis; this fraction was increased post-dialysis. There was no
change in miR-122 associated with extracellular vesicles. miR-885 was also reduced in ESRD patients (4-fold compared to healthy
subjects) and increased by haemodialysis.
CONCLUSION
miR-122 is substantially lower in ESRD compared to healthy controls, patients with CKD and transplanted patients. Haemodialysis
increases the concentration of miR-122. These data need to be considered when interpreting liver injury usingmiR-122 in patients
with ESRD on dialysis, and specific reference ranges that define normal in this setting may need to be developed.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• microRNA-122 (miR-122) is a sensitive and specific biomarker for drug-induced liver injury that is being qualified for use
in clinical medicine and drug development.
• Renal dysfunction and haemodialysis can affect circulating microRNA concentrations.
WHAT THIS STUDY ADDS
• miR-122 is substantially lower in the circulation of patients with end-stage renal disease on haemodialysis.
• This decrease is specifically in the miR-122 fraction bound to the microRNA carrier protein argonaute 2.
• Haemodialysis increases the circulating concentration of miR-122.
• Reference ranges that define normality may need to take into account renal function.
Introduction
MicroRNAs are small (~22 nucleotide-long) non-protein
coding RNA species involved in post-transcriptional gene-
product regulation [1]. In blood, microRNAs are stable
because they are protected from degradation by extracellular
vesicles (ECVs), such as exosomes, RNA binding protein com-
plexes, such as argonaute 2 (Ago2), and high-density lipopro-
teins [2, 3]. As they are amplifiable and some are tissue
restricted, circulating microRNAs represent a reservoir for
biomarker discovery. Liver-enriched miR-122 is released by
injured hepatocytes, primarily bound to Ago2, and is a trans-
lational circulating biomarker for liver injury in zebrafish [4],
rodents [5] and humans [6]. In patients with drug-induced
liver injury (DILI), circulating miR-122 is increased around
100-fold [6, 7] and accurately predicts hepatotoxicity when
all current hepatotoxicity biomarkers are still normal [7]. In
the context of DILI there is a strong correlation between
circulating concentrations of miR-122 and miR-885, another
microRNA with a large fold increase following DILI. miR-885
is released directly from hepatocytes as reported by in situ hy-
bridization studies of human liver DILI explants [8]. miR-122
is currently undergoing qualification as a clinical biomarker
for stratification of patients at risk of paracetamol-induced
liver injury and as a translational safety biomarker for use in
preclinical and clinical drug development.
In the presence of liver injury, kidney function is one of
the key predictors of death and need for urgent liver trans-
plantation, with serum creatinine concentration being a
component of the King’s College Criteria [9] and the Model
for End-Stage Liver Disease [10] scoring systems that are used
for prognostic stratification. Circulating kidney injury
molecule-1 (KIM-1) is a marker of kidney tubular injury that
predicts outcome in patients with acute liver injury with
higher sensitivity than creatinine and other common
prognostic tools [11]. Renal dysfunction has been reported
to affect the circulating concentration of microRNAs. Neal
et al. reported significantly reduced total plasma microRNA
and reductions in certain specific species (miR-16, -21, -210,
-638) in patients with chronic kidney disease (CKD) [12].
We recently profiled the circulating miRNome in patients
with paracetamol-induced acute liver injury and also demon-
strated a global reduction in circulating microRNA with renal
dysfunction [8]. In our profiling study there was no change in
miR-122; however, an effect of renal dysfunction may have
been undetectable given the high plasmamiR-122 concentra-
tions that accompany acute liver injury.
Patients with DILI may need short-term haemodialysis
(HD), for example, as a bridge to possible liver transplanta-
tion. The effect of HD on circulating microRNAs depends on
the species studied, with no effect being reported for some
species (miR-21, -210) [13] but a significant decrease after
HD being reported for miR-499 [14]. In the current study we
measured circulating miR-122 concentrations in patients
with end-stage renal disease (ESRD) before and after HD and
compared them with healthy controls, patients with CKD
and patients with a successful renal transplant. These data




In total, 84 subjects were recruited to this study, 17 with sta-
ble ESRD on maintenance HD from the outpatient dialysis
unit at the Royal Infirmary of Edinburgh, UK (numbers as
per power calculation), 22 healthy volunteers, 30 with CKD
and 15 patients post-transplantation. Healthy controls and
patients with ESRD and kidney transplantation were prospec-
tively recruited for this study. Samples from patients with
CKD were taken from a previously published study [15]. The
study was approved by the local research ethics committee
(Tayside Committee on Medical Research Ethics B) and per-
formed in accordance with the Declaration of Helsinki.
Informed consent was obtained from all participants.
ESRD patients
Inclusion criteria were: age 18 or over, treated with HD for
over 3 months. Patients affected by liver disease or with a his-
tory of hepato-biliary surgery were excluded; other exclusion
criteria were consumption of cytochrome P450-inducing
medications, past medical history of epilepsy, cancer, alcohol-
ism and/or psychiatric disease.
All patients were treated with HD for 4–5 hours per
session, three times per week. Data collected included
demographic characteristics, cause of ESRD, dialysis age and
current medications. All patients were dialysed without hepa-
rin to prevent inhibition of polymerase chain reaction (PCR).
CKD patients
Patients with CKD stages I–V (estimated glomerular filtration
rate 6–91 ml min1/1.73 m2 calculated using the MDRD
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equation) were matched with ESRD patients for age, gender,
body mass index (BMI) and blood pressure (BP). In brief, sub-
jects were recruited from the renal outpatient clinic at the
Royal Infirmary of Edinburgh. The inclusion criteria were:
male or female CKD patients, 18–65 years old and clinic BP
≤ 160/100 mmHg, whether or not on anti-hypertensive med-
ication. We excluded patients with a renal transplant or on
dialysis, patients with systemic vasculitis or connective tissue
disease, those with a history of established cardiovascular dis-
ease, peripheral vascular disease, diabetes mellitus, respira-
tory disease, or neurological disease, and those with current
alcohol abuse or pregnancy.
Renal transplantation patients
Patients entered the study if their transplant was performed
six or more months prior, their renal function was stable
and their estimated glomerular filtration rate (eGFR) was
greater than 60 ml min1/1.73m2. Patients with abnormal
liver functions tests or a history of liver disease were
excluded.
Healthy volunteers
Age, gender, BMI and BP matched adults with no medical
complaints and no medication use were recruited.
Blood collection
In healthy subjects blood was collected into three EDTA
plasma tubes (2.7 ml) and processed without delay – centrifu-
gation at 1200 g for 10 min at 4°C. Then one sample was im-
mediately frozen at 80°C. To test miR-122 stability, the
remaining plasma samples were left unprocessed at room
temperature or 4°C for 24 h or 7 days.
Two blood plasma samples were collected from each HD
patient, one immediately before and one after a single dialy-
sis session, directly from dialysis needles. For CKD and trans-
plant patients, samples were collected on the study day.
ESRD, CKD and transplant patient blood plasma samples
were immediately processed by centrifugation at 1200g for
10 min at 4°C and then supernatant frozen at 80°C.
Biochemical analysis
The following parameters were measured: full blood count,
urea and electrolytes, creatinine, bilirubin, alanine amino-
transferase (ALT), alkaline phosphatise (ALP) and gamma-
glutamyl transferase (GGT).
MicroRNAs were measured by PCR using SYBR green-
based detection as previously described [8]. RNA was isolated
from 50 μl plasma samples using themiRNeasy Serum/Plasma
Kit (Qiagen, Venlo, Netherlands). RNA was eluted in a fixed
volume of 14 μl, after which 2.5 μl of each eluate was reverse
transcribed into cDNA using the miScript II RT Kit (Qiagen,
Venlo, Netherlands) following manufacturer’s instructions.
The synthesized cDNA was ten-fold diluted and used for
cDNA template in combination with the miScript SYBR
Green PCR Kit (Qiagen, Venlo, Netherlands) using the spe-
cific miScript assays (Qiagen, Venlo, Netherlands). Real-time
PCR was performed on a Light Cycler 480 (Roche, Basel,
Switzerland) using the recommended miScript cycling
parameters.
Where indicated, results were confirmed by TaqMan-
based PCR. The small RNA eluate was reverse transcribed
using the Taqman assay containing specific stem-loop
reverse-transcription RT primers (Applied Biosystems, Foster
City, CA, USA) for each target miRNA species, following the
manufacturer’s instructions. In the reverse transcription reac-
tion, 1 μl of RNA was used to produce the complementary
DNA (cDNA) template. Then, 1 μl of cDNA was used in the
PCR mixture with specific PCR primers (Applied Biosystems,
Foster City, CA) in a total volume of 10 μl. Levels of miRNA
were measured using the Light Cycler 480 (Roche, Basel,
Switzerland).
Absolute quantification of microRNA was achieved by
generating a standard curve using synthetic target. Standard
curves were generated by reverse transcribing known concen-
trations of miScript miRNA mimics (Qiagen, Venlo, The
Netherlands) in 0.1X TE buffer spiked with 10 ng μl1 Poly-
C (Sigma-Aldirch, Gillingham, UK). The resulting cDNA was
measured using serial dilutions on three different plates to
demonstrate minimal variability.
The Agilent 2100 Bioanalyzer Small RNA kit was used ac-
cording to the manufacturer’s instructions to quantify RNAs
in the 6–150 nucleotide size range.
Extra-cellular vesicle isolation
Human plasma was fractionated by differential centrifuga-
tion to isolate microRNA containing ECVs. Plasma (1 ml)
was centrifuged at 2000g for 30 min then 12 000g for
45 min. The supernatant was then ultracentrifuged at
110 000g for 1.5 h to pellet ECVs. The pellet was resuspended
in 2 ml PBS, after which an additional ultracentrifugation
step of 110 000g for 1.5 h was performed. The vesicles were
re-suspended for miRNA analysis. ECV presence and number
was quantified by nanoparticle tracking analysis as previ-
ously described [16].
Ago2 isolation
Magna Bind goat anti-mouse IgGmagnetic bead slurry, 100 μl
(Thermo Scientific,Waltham, USA), was incubated with 10 μg
of mouse monoclonal anti-Ago2 (Abcam, Cambridge, UK) or
mouse normal IgG (Santa Cruz Biotechnology, Dallas, US)
antibodies for 2 h at 4°C. The antibody-coated beads were
then added to plasma and incubated overnight at 4°C with
rotation. Beads were washed three times and each sample
then eluted in RNAse-free water before QIAzol was added for
RNA isolation.
Statistical analysis
The primary outcome was difference in serummiR-122 before
and after HD. Out of five microRNA species, the smallest dif-
ference between ESRD and control that was reported by Neal
et al. was a two-fold reduction [12]. Therefore, this cutoff was
used as the minimal effect size for the power calculation. We
calculated the sample size as follows: alpha-level 0.05;
beta-level 0.8; standard deviation 0.203; we estimated that
to determine a minimal difference in miR-122 ΔCt of 0.165
(corresponding to a two-fold change in copy number/ml)
we would require 17 participants. All data are presented as
median with interquartile range as D’Agostino & Pearson
omnibus normality test failed to demonstrate a normal
microRNA-122 in renal failure
Br J Clin Pharmacol (2016) •• ••–•• 3
distribution for the data. Statistical analysis was performed
using Graphpad Prism (GraphPad Software, La Jolla,
California, USA). Nominal statistical significance was set at
P < 0.05.
Results
Firstly, the stability ofmiR-122was determined. After process-
ing human blood into plasma, storage at room temperature or
4°C for 24 h or 7 days had no significant effect on miR-122
concentration (Figure 1). Subject demographics and medica-
tions are shown in Table 1. As expected, the patient groups
had significantly lower haemoglobin concentrations and
were prescribed multiple medications. Erythropoietin, iron,
1α-calcidol, phosphate binders and calcimimetics were more
commonly used in the ESRD group. The aetiologies of CKD
were polycystic kidney disease (n = 8), glomerulonephritis
(n = 6), obstructive uropathy (n = 5), Alport Disease (n = 1),
with one unknown cause. The aetiologies of ESRD were
obstructive uropathy (n = 5), diabetic nephropathy (n = 4),
glomerulonephritis (n = 3), polycystic kidney disease (n = 1),
pyelonephritis (n = 1), hypertensive nephropathy (n = 1), in-
terstitial nephritis (n = 1) and one unknown cause. The dis-
eases that resulted in need for transplantation were IgA
nephropathy (n = 3), hypertensive nephropathy (n = 1), inter-
stitial nephritis (n = 1), nephrolithiasis (n = 2), adult polycys-
tic kidney disease (n = 1), Alport syndrome (n = 2), reflux
nephropathy (n = 3), diabetic nephropathy (n = 1) and focal
segmental glomerulosclerosis (n = 1). In the transplanted pa-
tient group the median eGFR was 80 ml min1/1.73m2 (IQR:
67–95; range: 60–97), as calculated by the MDRD equation.
Total circulating microRNA was lower in patients with
CKD (Figure 2). Serum ALT activity was lower in CKD and
ESRD compared with healthy controls and transplanted
patients (healthy ALT: median 18 IU l1 (IQR16–30); CKD
11 IU l1 (6–13); ESRD 12 IU l1 (9–19); transplant 23 IU l1
(14–38)). (Figure 3A). Haemodialysis induced a statistically
significant, but clinically insignificant, increase in ALT from
12 (9–19) to 13 (11–21) IU l1. By contrast with ALT,
miR-122 was not different when healthy controls were
compared with CKD (Figure 3B). Pre-HD miR-122 circulating
concentration was 19-fold lower compared with healthy con-
trols (pre-HD median value of 6.7 × 103 (2.3 × 103–1.4 × 104);
healthy controls 1.3 × 105 (7.6 × 104–3.8 × 105) copies ml1;
P < 0.0001). Compared with healthy subjects, miR-122 was
5.0-fold lower pre-HD when PCR was performed using
Taqman (Supplementary Figure S1). HD induced a 2.4-fold
increase in miR-122 (post-HD: 1.6 × 104 (5.4 × 103–3.2 ×
104) copies ml1). In patients with renal transplantation,
miR-122 was comparable to the healthy controls (post-trans-
plant: 4.7 × 104 (2 × 104–2.3 × 105) copies ml1). miR-885 was
also reduced in ESRD patients (4-fold compared to healthy
subjects) and increased by haemodialysis (from a median
value of 5 (2–14) to 10 (5–18) copies ml1) and renal trans-
plantation (294 (224–436) copies ml1) (Figure 3C). In the
30 patients with CKD, there was no significant correlation be-
tween eGFR and miR-122 (Figure 4). In ESRD there was no
correlation between change in miR-122 and fluid removed
by HD, urea reduction ratio (URR) or change in ALT. There
was a significant correlation with change in miR-885
(Figure 5).
miR-122 circulates bound to Ago2 and encapsulated in
ECVs. ECVs were isolated from plasma (Figure 6); there was
no difference in miR-122 when ESRD patient samples were
compared to healthy controls (Figure 6). By contrast, when
Ago2 was isolated from plasma, the miR-122 fraction bound
to this protein was significantly lower in ESRD patients
pre-HD compared to healthy controls and post-HD samples
(Figure 6).
Discussion
An essential part of biomarker development is the definition
of normal reference ranges that allows patients with disease
to be identified with a level of accuracy that is fit for purpose
given the biomarker’s context of use. In this paper we demon-
strate that Ago2-bound miR-122 is substantially reduced in
patients with ESRD on HD who have standard liver function
tests (such as ALT) within the normal range. Furthermore,
HD increases miR-122, which may reflect hepatocyte injury
given the concomitant increase in ALT and miR-885 and the
lack of correlation with measures of dialysis adequacy. These
data need to be considered when interpreting miR-122 con-
centrations in patients with ESRD on dialysis, and specific ref-
erence ranges that define normal in this setting may need to
be developed.
Before commencing recruitment into this study, we con-
firmed that miR-122 was stable in plasma. This is consistent
with the general view in the literature that microRNAs are sta-
ble in the circulation, a property that makes them attractive
biomarker candidates. This stability is believed to be due to
their binding to carrier proteins or encapsulation in vesicles.
In the specific case of miR-122 we have recently
Figure 1
miR-122 is stable in plasma. Plasma samples were collected from
healthy volunteers (n = 3) and immediately centrifuged to isolate
plasma. One plasma sample was stored at 80°C without delay
and the remaining tubes were left at room temperature (RT) or 4°C
for 24 h or 7 days. Data presented as a Tukey plot
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demonstrated that this microRNA species circulates predom-
inantly bound to the carrier protein Ago2 [8].
The total circulating microRNA concentration was re-
duced in patients with CKD. This is consistent with data from
Neal et al. who also reported a significant decrease [12]. Neal
et al. presented data supporting a possible mechanism for this
global reduction: patients with CKD have increased RNAse
activity in their blood. The primary objective of our study
was to explore miR-122 concentrations in patients with im-
paired kidney function. This liver-specific biomarker was re-
duced in the group with the worst kidney function, patients
with ESRD. This is clinically important, as normal reference
ranges may need to take into account the patient’s GFR.
Patients with CKD had miR-122 concentrations that were
no different to controls. This is consistent with our previous
published data that demonstrated no reduction in miR-122
in patients with CKD [6]. However, in the present study pa-
tients with CKD had lower serum ALT activity. This demon-
strates a disconnect between ALT and miR-122 (which
typically track each other, albeit with miR-122 having more
rapid kinetics), and possibly reflects differences in the effect
of renal dysfunction on mechanisms of ALT cellular release
and clearance. Our published data demonstrate that miR-
122 and miR-885 are related; both species are released from
injured hepatocytes and their circulating concentrations are
tightly positively correlated [8]. When compared with
healthy controls, miR-885 was also substantially lower in
patients with ESRD but not those patients with CKD.
Table 1
Subject characteristics
Healthy controls CKD Haemodialysis Post-transplant
Number of patients 22 30 17 15
Age (years) 55 ± 10 48 ± 10 58 ± 13 43 ± 10
Sex M, % (n) 55 (12) 50 (15) 47 (8) 73 (11)
BMI (kg m2) 26 ± 5 26 ± 6 27 ± 6 25 ± 4
SBP (mmHg) 128 ± 13 123 ± 14 129 ± 19 129 ± 15
ALT (U l1) 22 ± 10 11 ± 7 15 ± 8 37 ± 44
Bil (μmol l1) 9 ± 4 9 ± 3 9 ± 3 13 ± 6
CRP (mg dl1) 1 ± 2 2 ± 2 10 ± 15 6 ± 6
Haemoglobin mg dl1) 146 ± 13 134 ± 16 115 ± 12 135 ± 16
Medications, n (%)
ACE-I 12 (40) 4 (20) 5 (33)
ARB 5 (17) 1 (6) 0 (0)
Βeta-blockers 13 (43) 8 (47) 4 (27)
Statins 9 (30) 8 (47) 2 (13)
Antiplatelets 6 (20) 6 (35) 1 (7)
Warfarin 1 (3) 3 (18) 0 (0)
CCBs 14 (47) 4 (20) 7 (47)
Diuretics 1 (3) 0 (0) 0 (0)
Corticosteroids 0 (0) 0 (0) 10 (67)
Calcineurin inhibitor 0 (0) 0 (0) 15 (100)
Mycophenolate mofetil 0 (0) 0 (0) 12 (80)
Erythropoietin 2 (7) 17 (100) 0 (0)
Oral iron supplement 8 (27) 16 (99) 0 (0)
1-α calcidol 8 (27) 16 (99) 9 (60)
Phosphate binders 4 (13) 11(65) 4 (27)
Calcimimetics 0 (0) 3 (18) 0 (0)
alpha blockers 0 (0) 0 (0) 2 (13)
Age, gender; haemoglobin and medications of the 84 enrolled subjects (Healthy Controls, Chronic Kidney Disease (CKD) Haemodialysis and
Post-transplant) are shown. ACE-I, ACE inhibitors; ARB, angiotensin receptor blockers; ALT, alanine aminotransferase; Bil, bilirubin; BMI, body mass
index; CCB, calcium channel blockers; CRP, C-reactive protein; SBP, systolic blood pressure. Values are expressed as mean ± SD.
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HD has been reported to reduce the circulating concentra-
tion of certain microRNA species, which could relate to their
being cleared in the dialysate fluid [14]. The data presented in
this article are the first to demonstrate an increase in
microRNA after HD. The increase in miR-122 did not corre-
late with parameters of dialysis adequacy or fluid removal,
which argues against volume changes being the explanation
for the increase. Serum ALT activity and miR-885 also in-
creased after HD, which suggests that there is mild hepato-
cyte injury during the HD session.
In the field of drug-induced liver injury, miR-122 has sig-
nificant promise as a new sensitive and specific biomarker of
hepatocyte injury. More broadly, across a wide range of dis-
ease areas, circulating microRNAs are being proposed as bio-
markers. However, their kinetics in the circulation are
poorly defined, specifically their clearance. Following acute
liver injury miR-122 is elevated in concentration earlier than
ALT and decreases before ALT. However, this kinetic profile is
not consistent across all microRNAs that change significantly
following liver injury, with some changing later and having
longer ‘half-lives’ in the circulation [8]. Future studies should
investigate the clearance mechanisms of microRNA when
combined with their different circulating carriers. Such stud-
ies would include defining the contribution of the kidney.
The present study clearly demonstrates that the Ago2-bound
form of miR-122 is substantially reduced in patients with
ESRD. Mechanisms that underlie this are yet to be defined
but may include reduced production of microRNA. However,
if this were the case, the ECV-bound fraction would also be
expected to fall. Neal et al. have reported that ESRD is associ-
ated with increased circulating RNAse activity [12]. The
Ago2-bound form of miR-122 may be more sensitive to enzy-
matic digestion compared with ECV-encapsulated miR-122.
A priori it could be hypothesized that the ECV fraction would
differ between patients with ESRD and healthy controls be-
cause work by our group [17], and others [18], has clearly
demonstrated that systemically injected ECVs are excreted
in urine. This would suggest that their clearance may be
altered in ESRD. However, the miR-122 concentration in this
fraction did not change. Defining the kinetics of miR-122 will
be a priority if it is to be adopted into clinical practice and
drug development.
Figure 2
Total circulating microRNA is lower in chronic kidney disease (CKD)
stage IV. microRNA in plasma was quantified by Agilent 2100
Bioanalyzer. Patient groups were healthy controls (n = 17), CKD
(n = 20), and end-stage renal disease immediately before and after
haemodialysis (pre-HD and post-HD, respectively, both n = 17)
Figure 3
miR-122 is lower in end-stage renal disease and is increased by
haemodialysis. Plasma was isolated from healthy controls (n = 22),
chronic kidney disease (CKD) stage IV (n = 30), end-stage renal
disease immediately before and after haemodialysis (pre-HD and
post-HD, respectively, both n = 17) and patients with renal
transplantation (n = 15). Serum ALT activity (A), miR-122 (B) and
miR-885 (C) were measured. Data are presented as Tukey plots
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miR-122 is being qualified as a biomarker for a range of
diseases. In patients with established paracetamol-induced
acute liver injury, miR-122 is increased on average around
100-fold [6]. In patients with ESRD, our study demonstrates
a reduction in miR-122 of 19-fold compared with matched
healthy controls. Therefore, the miR-122 signal associated
with established ALI may still be appreciable even if the pa-
tient’s baseline miR-122 concentration were lower than
normal due to ESRD. An important future clinical applica-
tion of miR-122 may be the stratification of patients at
first presentation to hospital after paracetamol overdose
with regard to their risk of subsequent ALI. In this
‘pre-injury’ context of use, the fold difference in miR-122
between high- and low-risk groups is smaller (around
17-fold) [7]. Therefore, pre-existing severe renal impair-
ment may have a significant impact on the interpretation
of miR-122. We propose that future qualification should
include defining reference ranges in patients with reduced
renal function.
There are some limitations to our study. Although recruit-
ment was based on our pre-study power calculation, this is a
discovery study that needs to be built on in larger patient co-
horts. As is to be expected, patients with ESRD were pre-
scribed multiple medications, which could potentially affect
circulating microRNA concentrations. Such confounding by
medication has been demonstrated for platelet-derived
microRNAs and anti-platelet agents [19]. There are no data re-
garding the effect of anti-hypertensives on miR-122. Liver
toxicity with ACE inhibitors, angiotensin receptor blockers
and beta blockers is rare and all the patients in this study
had normal standard liver function tests. Furthermore, our
study included a CKD group who were prescribed similar
Figure 4
Circulating miR-122 is not related to the estimated glomerular
filtration rate (eGFR) in patients with CKD. Each point represents a
patient with CKD. eGFR calculated by the MDRD equation. Pearson
correlation data are presented
Figure 5
Haemodialysis-induced change in circulating miR-122 correlates with change in miR-885. In patients with end-stage renal disease,
haemodialysis increased plasma miR-122. This increase did not have a significant relationship with volume of fluid removed during dialysis
(A), urea reduction ratio (URR) (B) or change in ALT (C). There was a significant relationship with the dialysis-induced increase in plasma
miR-885 (D)
microRNA-122 in renal failure
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cardiovascular medications but had substantially higher
circulating miR-122 in comparison with ESRD patients.
There is no evidence in the literature to suggest that the
medications used more in the ESRD group (erythropoietin,
iron, 1α-calcidol, phosphate binders and calcimimetics)
have any effect on the liver or microRNA, at least in ther-
apeutic doses.
In summary, miR-122 is lower in ESRD and haemodialysis
restores the concentration of circulating miR-122 to healthy
levels, which may reflect dialysis-induced hepatocyte injury
given the concomitant increase in ALT and miR-885. These
data need to be considered when interpreting liver injury
using miR-122 in patients with ESRD on dialysis, and specific
reference ranges that define normal in this setting may need
to be developed.
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blood which facilitates point-of-care testing
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AIMS
Liver-enriched microRNA-122 (miR-122) is a novel circulating biomarker for drug-induced liver injury (DILI). To date, miR-122 has
been measured in serum or plasma venous samples. If miR-122 could be measured in capillary blood obtained from a finger prick
it would facilitate point-of-care testing, such as in resource-limited settings that have a high burden of DILI.
METHODS
In this study, in healthy subjects, miR-122 was measured by polymerase chain reaction in three capillary blood drops taken from
different fingers and in venous blood and plasma (n = 20). miR-122 was also measured in capillary blood obtained from patients
with DILI (n = 8).
RESULTS
Circulating miR-122 could be readily measured in a capillary blood drop in healthy volunteers with a median (interquartile range)
cycle threshold (Ct) of 32.6 (31.1–34.2). The coefficient of variation for intraindividual variability across replicate blood drops was
49.9%. Capillary miR-122 faithfully reflected the concentration in venous blood and plasma (Pearson R = 0.89, P < 0.0001; 0.88,
P < 0.0001, respectively). miR-122 was 86-fold higher in DILI patients [median value 1.0 × 108 (interquartile range 1.89 × 107–
3.04 × 109) copies/blood drop] compared to healthy subjects [1.85 × 106 (4.92 × 105–5.88 × 106) copies/blood drop]. Receiver
operator characteristic analysis demonstrated that capillary miR-122 sensitively and specifically reported DILI (area under the
curve: 0.96, P = 0.0002).
CONCLUSION
This work supports the potential use of miR-122 as biomarker of human DILI when measured in a capillary blood drop. With
development across DILI aetiologies, this could be used by novel point-of-care technologies to produce aminimally invasive, near-
patient, diagnostic test.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Drug-induced liver injury (DILI) is a major healthcare challenge in western countries and in resource-limited settings.
• microRNA-122 (miR-122) has substantial promise as a sensitive and specific biomarker of hepatocyte injury when
measured in venous samples.
WHAT THIS STUDY ADDS
• miR-122 can be quantified reliably in a capillary blood drop from a finger prick.
• Capillary miR-122 faithfully reflects the plasma and venous whole blood concentration.
• Capillary miR-122 can identify patients with DILI with high sensitivity and specificity.
• If combined with a novel point-of-care detection platform, capillary miR-122 could allow near patient testing for DILI.
Introduction
Drug-induced liver injury (DILI) presents a major burden to
clinical medicine and is a common cause of drug failure
during clinical development [1]. In western clinical medicine,
about half of the cases of acute liver failure are caused by DILI
[2]. In the developing world, cotreatment of human
immunodeficiency virus (HIV) and tuberculosis (TB) is a
major cause of DILI. Globally, an estimated 37 million people
are HIV-positive, with eastern and southern Africa carrying
the highest burden with an estimated 19 million people
infected [3]. The South African, TB incidence is particularly
high; new diagnoses being 834 per 100 000 per annum [4].
TB prevalence is high in people coinfected with HIV, with
42% of HIV-positive TB cases receiving both TB and
antiretroviral treatment [5]. DILI complicates TB treatment
in up to 33% of cases [6], and in South Africa the in-hospital
mortality from DILI has been reported to be around 30% [5].
MicroRNAs (miRNAs) are small (~22 nucleotides long)
nonprotein-coding RNAs involved in post-transcriptional
gene regulation [7]. In the circulation, miRNAs are protected
from degradation by binding to RNA protein complexes
(such as argonaute 2) and high-density lipoproteins, and
being encapsulated in extracellular vesicles such as exosomes
[8, 9]. AsmiRNAs are amplifiable and some are tissue enriched
[10], they have emerged as a reservoir for the discovery of
biomarkers that report organ injury [11].
The liver enriched miRNA-122 (miR-122) is a circulating
biomarker of DILI. miR-122 is released into the circulation
when hepatocytes are injured and is a translational safety
biomarker across zebrafish [12], rodents [13] and humans
[14–16]. In humans, miR-122 is around 100-fold higher in
paracetamol overdose patients with DILI compared to those
patients without liver injury [17] and is able to report DILI
soon after overdose when serum alanine transaminase (ALT)
activity is still in the normal range [14, 15, 18]. Circulating
miR-122 is not DILI specific but is specific for hepatocyte
injury. It is also increased in patients with cholestyramine-
induced liver injury [19], ischemic hepatitis [20], viral
hepatitis [21] and cholestatic liver injury [22]. In these
published studies serum or plasma venous samples have been
analysed in specialist laboratories with time-consuming and
expensive kits. There is an unmet need for assays that can
rapidly and accurately measure miRNA at the point-of-care
(POC) [23]. Ideally, a POC assay would measure miR-122 in
a single blood drop from a finger prick, be affordable for use
in resource-limited settings and suitable for use near, or
actually in, a patient’s home [24]. Such an assay could provide
an early signal of DILI in patients at elevated risk, for instance,
following prescription of antimicrobials with a significant
DILI liability [25–27]. With development, serial monitoring
of miR-122 could improve patient safety by allowing
medication change before life-threatening liver failure
develops and by supporting safe reintroduction of treatment
after interruption. In commercial drug development,
measurement of miR-122 using a finger prick could reduce
the need for venepuncture, which is especially advantageous
in certain groups such as children and when multiple serial
measurements in the same person are required.
The aims of this study were to determine if miR-122 can
be measured in a capillary blood drop from a finger prick
and to compare the concentration with venous blood and
plasma; to assess the intraindividual variability of capillary
miR-122 concentration and to establish proof of concept as
to whether capillary miR-122 can report DILI in patients.
Material and methods
The study was approved by the research ethics committee
(East Midlands – Nottingham 1 Research Ethics Committee)
andperformed in accordancewith theDeclarationofHelsinki.
Informed consent was obtained from all participants.
Healthy volunteers
Healthy volunteers were eligible if they had no history of liver
disease, were taking no medications and were willing to give
blood samples by venepuncture and finger prick.
Drug-induced liver injury patients
A total of eight adult patients (age 24–82 years) admitted to
the Royal Infirmary of Edinburgh, UK with DILI were entered
into the study. In each patient, causality of liver injury was
scored as definitive by the Roussel Uclaf Causality Assessment
Method [28].
Blood collection
Blood was collected in EDTA tubes by venepuncture.
Immediately, a 50 μL aliquot was collected in 1 mL of Qiazol
(Qiagen, Venlo, Netherlands) for whole blood analysis. The
remaining blood was centrifuged at 11 000 × g for 15 min at
4°C after which the supernatant was separated into aliquots
and frozen at –80°C until miRNA extraction.
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Three finger-prick blood drops (BD1: index finger, BD2:
middle finger, BD3: ring finger) per healthy volunteer were
obtained using disposable lancets that are used in routine
clinical practice for glucosemeasurement (Accu-Chek, Roche,
Basel, Switzerland – adjustable depth settings 1.8 mm). In
DILI patients, one blood drop from the index finger was
collected. After blood drop collection, Qiazol (1 ml) was
added to each sample. All samples were stored at –80°C until
analysis.
MicroRNA extraction
MicroRNA was extracted using miRNeasy Serum/Plasma kit
(Qiagen), following the manufacturer’s instructions. For
venous blood and plasma, 50 μl of sample was used in
combination with 150 μl nuclease free water. For capillary
blood, 200 μl nuclease free water was added to the Qiazol
containing each blood drop.
Real-time polymerase chain reaction
From each sample, 2.5 μl of RNA eluate was reverse
transcribed into cDNA using the miScript II RT Kit (Qiagen)
following manufacturer’s instructions. The synthesized
cDNA was 5-fold diluted and used for cDNA template in
combination with the miScript SYBR Green polymerase
chain reaction (PCR) Kit (Qiagen) using the specific miScript
assays (Qiagen). Real-time PCR was performed in duplicate
on a Light Cycler 480 (Roche) using the recommended
miScript cycling parameters.
Absolute quantitation of miRNA was achieved by
generating a standard curve using synthetic target. Standard
curves were generated by reverse transcribing known
concentrations of miScript miRNA mimics (Qiagen, Venlo,
The Netherlands) in 0.1X TE buffer spiked with 10 ng μl–1
Poly-C (Sigma–Aldrich, Gillingham, UK). The resulting cDNA
was measured using serial dilutions on three different plates
on 3 different days to demonstrate minimal variability
[interassay coefficient of variation (CV): 3.4%]. The calibra-
tion curve was linear in the cycle threshold (Ct) range of
20.0–36.1. A Ct value of 37.1 was obtained in water control.
Statistical analysis
Statistical differences, correlations and receiver operator
characteristic (ROC) curve analyses were performed using
Graphpad Prism (GraphPad Software, La Jolla California,
USA). Nominal statistical significance was set at P < 0.05.
Table 1
Copy numbers of capillary miR-122 per blood drop (BD1: index finger; BD2: middle finger; BD3: ring finger) in healthy volunteers. The coefficient
of variation (CV) across the three blood drops is presented
Healthy volunteer
number BD1 (copy/drop) BD2 (copy/drop) BD3 (copy/drop) CV (%)
1 0.45 × 106 0.40 × 106 1.53 × 106 81.13
2 3.39 × 106 11.5 × 106 4.11 × 106 71.14
3 0.29 × 106 0.41 × 106 0.11 × 106 54.52
4 0.24 × 106 0.11 × 105 0.20 × 106 37.15
5 0.59 × 106 0.17 × 106 0.42 × 106 54.17
6 1.25 × 106 0.91 × 106 0.69 × 106 29.85
7 0.11 × 106 0.20 × 106 0.28 × 106 43.24
8 2.85 × 106 5.20 × 106 1.18 × 106 65.70
9 1.53 × 106 0.89 × 106 0.69 × 106 42.28
10 0.29 × 106 0.23 × 106 4.45 × 106 146.1
11 0.13 × 106 0.14 × 106 0.19 × 106 20.47
12 1.37 × 106 2.81 × 106 1.93 × 106 35.53
13 2.09 × 106 0.64 × 106 1.20 × 106 56.18
14 1.53 × 106 6.40 × 106 5.52 × 106 57.85
15 5.06 × 106 9.52 × 106 8.79 × 106 30.74
16 10.6 × 106 9.07 × 106 10.3 × 106 8.00
17 7.61 × 106 9.37 × 106 5.70 × 106 24.26
18 1.81 × 106 3.00 × 106 5.18 × 106 51.21
19 4.70 × 106 2.69 × 106 2.79 × 106 33.44
20 36.6 × 106 36.3 × 106 10.3 × 106 54.38
Mean 4.12 × 106 5.00 × 106 3.28 × 106 49.87
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Results
Capillary miR-122 can be measured in a finger
prick blood drop
A total of 20 adults (14 females, median age 24 years; range
21–31 years) were recruited to this study. First it was
determined whether a capillary blood drop yields sufficient
miR-122 for robust quantification. Capillary blood Ct
values (obtained by quantitative PCR) were all within the
linear range of the calibration curve [mean (range) 32.6
(29.1–35.4)]. Copy numbers of miR-122 per blood drop in
the healthy controls are presented in Table 1. Across the
replicate drops fromdifferent fingers themeanCV (± standard
deviation) was 49.9 ± 28.9%. The CV ± standard deviation of
duplicate PCR measurements of the same blood drop was
0.94 ± 1.29%.
Capillary miR-122 correlates with venous
blood and plasma
Across the healthy volunteers, the relationship between copy
numbers of miR-122 per blood drop and copy numbers of
miR-122 per mL of venous blood and plasmawas determined.
Copy number of miR-122 per blood drop significantly
correlated with miR-122 measured in venous blood and
plasma (P< 0.0001, Figure 1A, B). The correlation coefficients
(R2) were 0.80 and 0.78 and the Pearson R values [95%
confidence interval (CI)] were 0.89 (0.75–0.96) and 0.88
(0.72–0.95), both P < 0.0001, in venous blood and plasma,
respectively. As would be expected there was a significant
correlation between venous blood and plasma miR122
(Figure 1C).
Liver-enriched miRNA-122 is higher in ALI
patients
Capillary miR-122 was measured in blood drop samples
obtained from patients with DILI (n = 8) and compared with
healthy volunteers (n = 20). Clinical parameters of the DILI
patient cohort are summarized in Table 2, along with their
capillary miR-122 concentrations. In the single case of
nonparacetamol DILI (induced by nitrofurantion) other
causes of liver disease such as viral hepatitis (A–E) were
excluded. miR-122 was increased 86 fold in DILI patients
[median 1.58 × 108 (interquartile range 4.67 × 106–4.51 ×
109) copies/blood drop] compared to healthy volunteers
[1.85 × 106 (1.53 × 105–2.77 × 107) copies/blood drop]
P = 0.004 (Figure 2). ROC analysis was performed to determine
the sensitivity and specificity of miR-122 for detecting DILI
(Figure 3). Capillary miR-122 had high sensitivity and
specificity (area under the curve; 0.96 (95%CI 0.89–1.04),
P = 0.0002, sensitivity: 86% at 90% specificity).
Discussion
This study has demonstrated, for the first time, that capillary
miR-122 can be measured in a single blood drop to report
DILI. This facilitates point-of-care measurement out with
hospital, such as in the developing world where the burden
of DILI is substantial.
Figure 1
Scatter graphs. Correlation between copy numbers of miR-122 per
mL (A) venous blood or (B) plasma and copy numbers of miR-122
per capillary blood drop. (C) correlation between copy numbers of
miR-122 per mL venous blood and plasma in each healthy volunteer
(n = 20). Pearson R values are 0.89 (P < 0.0001), 0.88 (P < 0.0001)
and 0.92 (P < 0.0001), respectively (Pearson’s correlation test).
Blood drop values represent the mean copy number measured in
three drops, error bars represent standard errors of the mean
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Whenmeasured in capillary blood, the miR-122 Ct values
were all within the quantifiable range of the PCR assay that
had a linear calibration curve up to a Ct of 36. Intraindividual
variability was tested by comparing three different blood
drops taken from the same volunteer and resulted in an
average CV of around 50%. Respectively, the intra-assay and
interassay CVs of the PCR assay were only 0.94% and 3.4%,
therefore the CV across the blood drops probably represents
the variable volumes of the blood drops obtained during the
collection procedure. The intraindividual CV of blood drop
volume obtained from a finger has been reported to be 83%
[29]. This is comparable to the intraindividual CV of miR-
122 measured in our study. In a future POC assay, the
variability of sample volume could be reduced by automated
microchip sample processing technologies [30, 31] as already
applied in test strips for international normalized ratio (INR)
POC testing in the context of warfarin dosing [32].
Furthermore, as the circulating concentration of miR-122
increases up to a 100 fold in DILI patients [14], a CV of 50%
would be expected to have little effect on the detection of
DILI.
The concentration of capillarymiR-122measured in blood
drops strongly correlated with blood and plasma obtained
from venepuncture. This provides reassurance that our data
reflect circulating concentrations. Furthermore, capillary
miR-122was significantly higher in blood drops frompatients
with DILI compared to healthy volunteers with amedian fold
increase of 86 and a ROC curve area under the curve of 0.96.
These data confirm that the dynamic changes and the
sensitivity to report DILI is similar between blood drops and
earlier reported results from serum/plasma venous samples
[14, 15]. A challenge in using circulating miRNAs as
Table 2
Clinical parameters of the patient cohort with drug-induced liver injury (DILI).














1 82 F 3475 2 50 74 29 Paracetamol 1.58 × 108
2 44 F 10 543 6.9 47 101 106 Paracetamol 4.51 × 109
3 54 F 1210 8.9 66 236 162 Nitrofurantoin 4.09 × 107
4 24 F 1608 1.4 79 239 224 Paracetamol 1.58 × 108
5 29 M 1143 1.7 52 43 17 Paracetamol 5.64 × 107
6 25 M 1653 1.9 72 147 58 Paracetamol 1.66 × 109
7 45 M 1131 1.5 65 79 34 Paracetamol 3.50 × 109
8 35 M 1101 1.8 57 141 32 Paracetamol 1.16 × 107
ALT, alanine aminotransferase; INR, international normalized ratio; serum creatinine; ALP, alkaline phosphatise; bilirubin and aetiology of DILI are
presented
Figure 3
Receiver operator characteristic curve analysis with respect to blood
drop miR-122 as a discriminator of drug-induced liver injury patients
from healthy volunteers. Area under the curve (AUC), statistical
significance and sensitivity (SENS) at 90% specificity (95%CI) are
presented
Figure 2
Copy number of miR-122 per blood drop from healthy volunteers
(n = 20) and drug-induced liver injury patients (n = 8). Data are
presented as a Tukey plot. In healthy volunteers, the mean copy
number measured in three drops was used
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biomarkers for human pathology is that the contribution of
different tissues to the circulating pool is often unknown.
Most miRNAs are expressed in multiple cell types, by contrast
miR-122 is highly specific for the liver [33, 34]. miR-122 is not
expressed in platelets, T-cells, B-cells, granulocytes or
erythrocytes, which contain a wide variety of other miRNA
species [35]. This makes miR-122 suitable for accurate
measurement in whole blood without need for plasma or
serum isolation.
There is an urgent need for improved DILI monitoring in
the developing world where cotreatment of HIV and TB is a
common cause [5]. However, despite the need, DILI
monitoring in resource-limited settings is often restricted by
practical concerns. The requirement for expensive tools and
highly trained technicians can mean testing is only done in
centralized or regional laboratories [24]. Moreover, many
patients undergoing TB treatment in resource-limited
settings have a negative association with venepuncture itself,
do not have a primary care physician and do not value regular
visits to a health care professional for health maintenance,
which reduces potential participation in DILI monitoring
[36]. A rapid POC test for measuring miR-122 from a single
blood drop would mean that the patient undergoing TB
and/or HIV treatment could use the assay at home (or near
home). This study has demonstrated that a blood drop can
be used as the matrix to measure miR-122. Recently,
substantial effort has been spent in developing highly
sensitive, rapid, reliable and low-cost methods for measuring
miRNAs in minimal sample volumes. Electrochemical DNA
hybridization sensors have potential as detection techni-
ques in a POC test because this technology can detect
specific miRNAs in the attomolar range without PCR
amplification [37]. Other promising miRNA detection
methods include nanoparticle-based optical technologies
[38], surface plasmon resonance [39, 40] and amplification-
free fluorescence-based assays [41, 42]. As miR-122 is a
relatively high-concentration, organ-specific, circulating
miRNA with a large dynamic range in disease it represents
an ideal target for assay development with line of sight on
a commercial product tackling a global health need.
This is an early phase proof of concept study that
predominately used paracetamol toxicity as the model of
DILI (seven of eight patients). Work is now required to
determine whether capillary miR-122 has clinical utility in
DILI caused by other drugs, especially antimicrobials. In
conclusion, this work supports the potential use of miR-122
as biomarker of human DILI when measured in a blood drop
from a finger prick. This could be used by novel POC
technologies to produce a minimally invasive, near patient,
diagnostic for DILI that has enhanced sensitivity and
specificity compared to current tests.
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Co-ingestion of ethanol is common in patients presenting to hospital after a 
deliberate overdose (232, 233), and so its effects on new biomarkers must be 
determined. In order to test the effect of acute ethanol ingestion on miR-122-5p, 18 
healthy volunteers were recruited and a small but significant increase in miR-122-5p 
was found after consumption of recreational levels of ethanol (2.2-fold increase). In 
previous studies miR-122-5p increased 100- to 1000 fold in response to 
hepatocellular injury (77, 231). It is doubtful, therefore, in mixed overdoses of APAP 
and ethanol that elevations of miR-122-5p above around 2-fold could be due to 
ethanol ingestion alone. These data indicate that ethanol co-ingestion is unlikely to 
be a significant contributor to the massive increases in miR-122-5p seen after APAP 
overdose. This is essential information for the further development of miR-122-5p as 
a biomarker of APAP-mediated hepatocellular injury. 
An essential part of biomarker development is the definition of normal reference 
ranges that allows patients with disease to be identified with a level of accuracy that 
is fit for purpose given the biomarker’s context of use. In this project it was 
demonstrated that Ago2-bound miR-122-5p is substantially reduced in patients with 
ESRD on HD who have standard liver function tests (such as ALT) within the normal 
range. Furthermore, HD increases miR-122-5p, which may reflect hepatocyte injury 
given the concomitant increase in ALT and miR-885-5p and the lack of correlation 
with measures of dialysis adequacy. These data need to be considered when 
interpreting miR-122-5p concentrations in patients with ESRD on dialysis. 
The third scenario studied in this chapter demonstrated, for the first time, that 
capillary miR-122-5p can be measured in a single blood drop and can be used as 
sensitive and specific biomarker of DILI. This facilitates point-of-care measurement 
out with hospital, such as in the developing world where the burden of DILI is 
substantial. Recently, substantial effort has been spent in developing highly sensitive, 
rapid, reliable and low cost methods for measuring miRNAs in minimal sample 
volumes. Electrochemical DNA hybridization sensors have potential as detection 
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techniques in a POC test because this technology can detect specific miRNAs in the 
attomolar range without PCR amplification (239). Other promising miRNA detection 
methods include nanoparticle-based optical technologies (240), surface plasmon 
resonance (241, 242) and amplication-free fluorescence-based assays (243, 244). As 
miR-122-5p is a relatively high concentration, organ specific circulating miRNA with a 
large dynamic range in disease it represents an ideal target for proof-of-concept assay 
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Chapter 4: Circulating paracetamol metabolites are toxicokinetic early 




miR-122-5p is a highly sensitive and specific marker that enables early stratification 
of patients by hepatocyte injury. To further improve risk assessment of patients 
presenting with a paracetamol overdose improved quantification of the toxic burden 
is required. Paracetamol concentration itself is a sub-optimal predictor of toxic NAPQI 
formation due to inter individual differences in pharmacology (245, 246). Therefore, 
circulating paracetamol metabolites were studied.  
The primary objective of this study was to define the relationship between circulating 
paracetamol metabolites and ALI using serial samples collected in The Scottish and 
Newcastle Antiemetic Pretreatment for Paracetamol Poisoning study (SNAP) (247) 
(the discovery cohort). There was subsequent validation in samples taken at first 
presentation in two non-SNAP hospitals as part of the Markers and Paracetamol 
Poisoning (MAPP) study (the validation cohort). The secondary objective was to 
explore the effect of ondansetron on paracetamol metabolism to provide a 
mechanistic explanation for the increase in liver injury with this commonly used anti-
emetic.  
 
The results of this study are published as: 
Vliegenthart, ADB, Kimmitt, RA, Seymour, JH, Homer, NZ, Eddleston, M, Gray, A, 
Webb, DJ, Lewis, SC, Bateman, DN, Dear, JW. Circulating Acetaminophen Metabolites 
Accurately Predict Hepatotoxicity And Represent New Clinical Toxicokinetic 





4.2 Contributions by the candidate 
 
Producing and validating the dataset; Performing all data analysis apart from the post 
hoc logistic regression modelling presented in table 4; Producing the figures; 
Preparation and revision of the manuscript. 
  
Circulating Acetaminophen Metabolites Are
Toxicokinetic Biomarkers of Acute Liver Injury
ADB Vliegenthart1, RA Kimmitt1, JH Seymour1, NZ Homer1, JI Clarke2, M Eddleston1, A Gray3,
DMWood4,5, PI Dargan4,5, JG Cooper6, DJ Antoine2, DJ Webb1, SC Lewis7, DN Bateman1 and
JW Dear1
Acetaminophen (paracetamol-APAP) is the most common cause of drug-induced liver injury in the Western world. Reactive
metabolite production by cytochrome P450 enzymes (CYP-metabolites) causes hepatotoxicity. We explored the toxicoki-
netics of human circulating APAP metabolites following overdose. Plasma from patients treated with acetylcysteine (NAC)
for a single APAP overdose was analyzed from discovery (n 5 116) and validation (n 5 150) patient cohorts. In the discov-
ery cohort, patients who developed acute liver injury (ALI) had higher CYP-metabolites than those without ALI. Receiver
operator curve (ROC) analysis demonstrated that at hospital presentation CYP-metabolites were more sensitive/specific for
ALI than alanine aminotransferase (ALT) activity and APAP concentration (optimal CYP-metabolite receiver operating char-
acteristic area under the curve (ROC-AUC): 0.91 (95% confidence interval (CI) 0.83–0.98); ALT ROC-AUC: 0.67 (0.50–0.84);
APAP ROC-AUC: 0.50 (0.33–0.67)). This enhanced sensitivity/specificity was replicated in the validation cohort. Circulating
CYP-metabolites stratify patients by risk of liver injury prior to starting NAC. With development, APAP metabolites have
potential utility in stratified trials and for refinement of clinical decision-making.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 Acetaminophen overdose is common. Decisions regarding
the need for treatment are frequently based on measurement of
the blood acetaminophen concentration. However, acetamino-
phen must be metabolized to cause liver injury. Acetaminophen
metabolites are present in the circulation after therapeutic dos-
ing and overdose.
WHAT QUESTION DID THIS STUDY ADDRESS?
 Are circulating acetaminophen metabolites elevated with
acute liver injury and can they predict injury better than acet-
aminophen parent drug concentration?
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
 Patients who developed acute liver injury had higher acet-
aminophen metabolites derived from the cytochrome P450
pathway that mediates toxicity. Hospital presentation metabo-
lites were more sensitive and specific for liver injury compared
with the parent drug.
HOW THIS MIGHT CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE
 Acetaminophen metabolites can predict liver injury and have
potential utility in stratified trials and for refinement of clinical
decision-making.
Acetaminophen (paracetamol, APAP) overdose is a common rea-
son for attending the hospital and the leading cause of acute liver
failure in the Western world.1 In the United States, over 400,000
Emergency Department visits relating to APAP overdose were
recorded between 2006 and 2010.2 Annually in the UK, APAP
overdose results in 100,000 Emergency Department presenta-
tions and 50,000 hospital admissions,3 and is the direct cause of
death in around 150 people.4
The mechanism of acute liver injury (ALI) after APAP over-
dose is well defined and can be translated from rodents to
humans using mechanistic biomarkers.5 APAP is predominantly
metabolized into nontoxic glucuronide (APAP-Glu) and sulfate
(APAP-Sul) conjugates. A small fraction is metabolized by cyto-
chrome P450 (CYP) enzymes into the reactive metabolite N-acetyl-
p-benzoquinone imine (NAPQI). When NAPQI is formed it
reacts with the cysteine sulfhydryl group on glutathione (GSH).
Most APAP-GSH is subsequently converted into APAP-cysteine
(APAP-Cys) and APAP-mercapturate (APAP-Mer) conjugates.6
APAP metabolites are detectable in plasma from healthy volun-
teers after therapeutic doses and in patients after APAP over-
dose.7–10 They rapidly increase after ingestion of a therapeutic
dose, with APAP-Glu having a higher concentration than the
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parent drug from 1–2 hours after ingestion.6 Urinary metabolites
of APAP can identify subjects with liver injury in the context of
therapeutic dosing.11
In overdose, glutathione can become depleted and NAPQI can
then bind to sulfhydryl groups in cellular proteins.6 This may
lead to oxidative stress, mitochondrial injury, hepatocyte necrosis,
and acute liver failure. The protein binding of NAPQI results in
APAP protein adducts that can be quantified by measurement of
APAP-Cys that is released from the protein fraction of serum or
plasma following protease enzyme treatment.12 This is a distinct
pool of APAP-Cys to the in vivo glutathione-derived metabolite
that is present in the nonprotein fraction of the circulation.
Glutathione-derived APAP-Cys is removed by dialysis in studies
designed to quantify circulating APAP protein adducts.13–15
APAP protein adducts are released from necrotic hepatocytes,
although this remains controversial.16 The focus of the present
study was the metabolism of APAP as opposed to quantification
of cell death. Therefore, we measured APAP-Cys in the nonad-
duct fraction of plasma.
The current antidote, acetylcysteine (NAC), replenishes cellu-
lar GSH and is effective at preventing liver injury if administered
soon after overdose.17,18 NAC could also directly bind to
NAPQI, although this is not a significant pathway in rodents.19
The decision to start treatment with NAC is commonly based
on the dose ingested and a timed blood APAP measurement,
which is interpreted using a binary treat/no treat nomogram
with the threshold for treatment at a level of low risk. Current
clinical practice, therefore, treats a number of patients who would
not come to harm if they did not receive NAC.20 Despite this
conservative approach there are still patients who develop acute
liver injury (ALI). Targeted therapies that reduce cell death and
aid tissue regeneration are in development.21,22 To facilitate strat-
ified clinical trials there is an unmet need for new biomarkers of
liver injury. These need to be accurate at early timepoints, when
current markers lack sensitivity and specificity.23
Although the efficacy of NAC has been established for over 35
years, the optimal dosing regimen is still undetermined. The Scot-
tish and Newcastle Antiemetic Pretreatment for Paracetamol
Poisoning study (SNAP) compared the conventional intravenous
NAC regimen with an identical NAC dose given in a modified
(shorter) regimen.24 Patients who had ingested a single acute
overdose were randomized to one of four treatment arms: modi-
fied NAC regimen pretreated with the intravenous antiemetic
ondansetron (ondansetron-modified) or pretreated with placebo
(saline) (placebo-modified); or the conventional NAC regimen
with or without ondansetron (ondansetron-conventional and
placebo-conventional). The primary finding of the SNAP study
was that the modified regimen resulted in substantially reduced
vomiting, anaphylactoid reactions, and treatment interruptions.
Although that study was not powered for efficacy, there was no
significant difference in liver injury between modified and con-
ventional regimens. However, unexpectedly, significantly more
ondansetron-treated patients developed an elevation in serum ala-
nine aminotransferase (ALT) activity compared to placebo. Giv-
en that APAP overdose and NAC therapy are commonly
accompanied by nausea and vomiting, it is important to under-
stand whether ondansetron worsens liver toxicity as even small
increases in ALT could result in extra NAC treatment and avoid-
able increases in length of hospital stay.
The primary objective of this study was to define the relation-
ship between circulating APAP metabolites and ALI. The sec-
ondary objective was to explore the effect of ondansetron on
APAP metabolism to provide a mechanistic explanation for the
increase in liver injury with this commonly used antiemetic.
RESULTS
The relationship between APAP metabolites and ALI (defined as
an increased serum ALT activity of 50% or more) was investigat-
ed using serial samples collected in the SNAP trial (the discovery
cohort). There was subsequent validation in samples taken at first
presentation to two hospitals as part of the Markers and Paracet-
amol Poisoning (MAPP) study (the validation cohort). An over-
view of APAP metabolism is presented in Figure 1, with the
metabolites measured in this study indicated. Patient screening
and recruitment to the original SNAP trial, and the current dis-
covery cohort, is presented in Figure 2. The characteristics of
those patients with blood samples available for this study were
similar across SNAP treatment groups aside from the higher inci-
dence of liver injury in ondansetron-treated patients (Supple-
mentary Table 1), which mirrors the whole SNAP trial cohort.
Patients with and without ALI in the SNAP “discovery”
cohort and the MAPP “validation” cohort are compared in
Tables 1 and 2, respectively. In the time window of this study all
patients in the discovery cohort received the same total dose of
NAC, given either by the conventional or modified protocol. In
both cohorts the increase in ALT was modest in those patients
with ALI, with a median peak serum ALT activity of 154 U/L
(65–909) and a median peak International Normalized Ratio
(INR) of 1.4 (1.3–1.6) in the discovery cohort and 252 U/L
(22–1256) and 1.2 (1.1–1.6) in the validation cohort. This
increase in INR may reflect APAP inhibition of vitamin K-
dependent activation of clotting factors rather than liver synthet-
ic dysfunction.25 There was no change in kidney function with
ALI in either cohort as reported by change in serum creatinine
concentration.
APAP metabolite kinetics
APAP parent drug concentration measured by liquid chromatog-
raphy, tandem mass spectrometry (LC-MS/MS) correlated signif-
icantly with the value from the clinical laboratory APAP assay.
The Pearson r value (95% confidence interval (CI)) was 0.88
(0.84–0.92), P < 0.0001 with a correlation coefficient (R2) of
0.78 (Supplementary Figure 1A). In the discovery cohort, the
plasma APAP and metabolite concentrations at pretreatment
and at 12 h and 20.25 h after the start of NAC treatment are
presented in Supplementary Figure 1B. APAP-Glu was the
metabolite with the highest concentration followed by APAP-
Sul, APAP-Cys, APAP-Mer, and APAP-GSH. All metabolites
decreased after the start of treatment, and only APAP-Glu was
higher in concentration than APAP parent drug.
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Discovery cohort (SNAP). APAP half-life was longer in patients
who developed liver injury compared to those with no injury:
3.11 h (2.38–4.38) vs. 2.36 h (2.02–2.68), P 5 0.004 (Figure 3a).
The concentrations of the APAP metabolites in patients without
and with ALI are presented in Supplementary Figure 2. To
compare the relative amount of metabolites formed by CYP
activity compared to non-CYP conjugation, the AUC(0-20.25h) of
CYP metabolites (APAP-Cys, APAP-Mer, APAP-GSH) was
expressed as a fraction of the total AUC(0-20.25h) (CYP/total(%)).
Patients who developed liver injury had a significantly higher
AUC(0-20.25h) (CYP/total(%)) compared to those without liver
injury (74 (58–746) vs. 47 (30–77), P 5 0.003) (Figure 3b).
AUC(0-20.25h) (CYP/total(%)) had a significant correlation with
peak hospital stay ALT (Figure 3c).
APAP parent drug is used in clinical practice to stratify
patients at hospital presentation. To explore the prognostic
potential of metabolites formed by CYP activity the plasma con-
centration of the CYP metabolites (APAP-Cys, APAP-Mer,
APAP-GSH) at pretreatment (0 h) were expressed as a fraction
of the total metabolites (CYP/total (%)). Patients who developed
liver injury had a significantly higher CYP/total (%) at pretreat-
ment compared to those who did not develop liver injury, 2.21%
(1.05–4.50) vs. 0.87% (0.58–1.43), P 5 0.0004 (Figure 3d). The
absolute concentration of APAP-Cys was significantly higher pre-
treatment with NAC in those patients with subsequent ALI
(Supplementary Figure 2). Pretreatment CYP/total (%)
remained higher in those patients who developed liver injury
when the discovery cohort was censored by time from overdose
to blood sampling (<8 h: ALI 3.12% (1.00–8.11) vs. no ALI
0.91% (0.59–1.40), P 5 0.006; >8 h: ALI 2.16% (1.18–4.43) vs.
no ALI 0.75% (0.50–1.70), P 5 0.05).
The performance of each metabolite in the discovery cohort,
alone and combined, was compared with regard to predicting
Figure 1 Pathways of acetaminophen (APAP) metabolism. APAP-sulphate (APAP-Sul); APAP-glucuronide (APAP-Glu); glutathione (GSH); APAP-glutathione
(APAP-GSH); APAP-cysteine; (APAP-Cys); APAP-mercapturate (APAP-Mer). *Measured in this study.
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ALI at pretreatment using receiver operator characteristic analysis
(ROC) (Table 3). The CYP metabolites had a superior predic-
tive performance in comparison with the current markers (ALT
and APAP parent drug had ROC-AUC of 0.67 (0.50–0.84) and
0.50 (0.33–0.67), respectively) (Supplementary Figure 3a–d). In
this discovery cohort the optimal metabolite combination was
the ratio of APAP-Cys (CYP mediated) and APAP-Sul (non-
CYP mediated), with an ROC-AUC of 0.91 (0.83–0.98). This
metabolite combination at presentation had a significant correla-
tion with peak ALT activity (Supplementary Figure 3e).
Validation cohort (MAPP). The validation cohort consisted of 150
patients recruited from two geographically distinct hospitals, dif-
ferent from the site of recruitment for the discovery cohort. In
blood samples collected at first presentation to hospital after sin-
gle APAP overdose (before NAC was commenced), CYP/total
(%) in those patients who developed liver injury was significantly
higher compared to those who did not develop liver injury
(0.95% (0.46–1.78) vs. 0.53% (0.34–0.84), P 5 0.02) (Supplemen-
tary Figure 3f). APAP-Cys and APAP-Mer were significantly
higher in those patients with subsequent ALI (Supplementary
Figure 2).
Consistent with the results from the discovery cohort, CYP
metabolites had superior predictive performance in comparison
with the current standard markers (Table 3). In the validation
cohort the sum of all the CYP metabolites had the largest ROC-
AUC (0.83 (0.71–0.94)). As in the discovery cohort, APAP and
ALT had no predictive value as assessed by ROC analysis (APAP
ROC-AUC 0.57 (0.41–0.73); ALT ROC-AUC 0.51 (0.35–0.67)).
Effect of ondansetron on APAP metabolism
In the SNAP trial, patients pretreated with ondansetron had a
higher incidence of liver injury that may reflect an effect on
APAP metabolism. However, when liver injury patients were
excluded, there was no difference in APAP half-life with ondan-
setron treatment compared to placebo, 2.48 h (2.07–2.97) vs.
2.23 h (1.97–2.56), P 5 0.10. There was also no difference in
AUC(0-20.25h) (CYP/total (%)) when ondansetron was compared
to placebo (ondansetron: 54 (34–93) vs. placebo 43 (25–70),
P 5 0.15).
Figure 2 Study profile. The number of patients screened, suitable for NAC, eligible, and randomized into the original SNAP trial together with the number
of patients (116) and their respective treatment arms in whom APAP metabolites were measured.
APAP-Cys/APAP-Sul was higher in the pretreatment blood
sample from patients randomized to ondansetron compare to
placebo. Post hoc analysis of the SNAP trial by logistic regression
modeling demonstrated that when APAP-Cys/APAP-Sul was
added to the stratified randomization process the incidence of
ALI in the ondansetron treated patients was not different from
placebo (Table 4).
Effect of modified NAC regimen on APAP metabolism
There was no difference in APAP half-life or AUC(0-20.25h)
(CYP/total(%)) between SNAP trial conventional and modified
NAC treatment (half-life: 2.19 h (1.97–2.54) vs. 2.44 h (2.08–
2.84), P 5 0.08. AUC(0-20.25h) (CYP/total (%)) 42 (32–89) vs.
53 (26–76), P 5 0.95).
DISCUSSION
This study demonstrates that the cytochrome P450 enzyme-
mediated mechanism of APAP toxicity described in rodent
models translates to humans. The key novel findings were that a
higher percentage of circulating metabolites formed by cyto-
chrome P450 enzymes (CYP metabolites) were present in
patients with liver injury and these metabolites were superior to
both ALT and APAP with regard to early ALI risk stratification.
The potential value of CYP metabolites to future clinical trials
was demonstrated by their incorporation post-hoc into the SNAP
trial. This showed that the reported increase in ALI with ondan-
setron was no different than placebo. This work has the potential
to be built on and produce an important change in the manage-
ment of APAP overdose—a very common medical emergency
with suboptimal tools for patient stratification.
We measured five APAP metabolites (two non-CYP-mediated
and three CYP-mediated) alongside APAP parent drug. APAP
half-life was 2–2.5 h in patients who did not develop ALI and was
prolonged to over 3 h in people with ALI. The prolongation of
APAP half-life was smaller than reported in previous studies
Table 1 Patient characteristics of the discovery cohort divided by absence or presence of acute liver injury according to the British
National Formulary 200937
>50% ALT rise No > 50% ALT rise P-value
Number 14 102
Median (IQR) age (years) 28 (21-32) 37 (26-48) 0.03
Median (IQR) weight (kg) 62 (56-71) 70 (59-80) 0.27
Number of females 11 (79%) 61 (55%) 0.17
Median (IQR) time from ingestion to treatment (h) 6.7 (7.8-10.7) 7.2 (8.0-10.0) 0.63
Number with ingestion to treatment <8hr 8 (57%) 65 (64%) 0.63
Median (IQR) ingested acetaminophen (mg/kg) 332 (190-393) 222 (165-313) 0.06
Number who ingested acetaminophen 16g 9 (64%) 44 (43%) 0.14
Median (IQR) admission alanine aminotransferase (U/L) 24 (18-82) 18 (13-26) 0.04
Median (IQR) peak alanine aminotransferase (U/L) 154 (65-909) 18 (14-27) < 0.0001
Median (IQR) admission INR 1.0 (1.0-1.2) 1.0 (0.9-1.0) 0.01
Median (IQR) peak INR 1.4 (1.3-1.6) 1.1 (1.0-1.2) < 0.0001
Median (IQR) admission billirubin (lmol/l) 12 (7-17) 7 (5-9) 0.009
Median (IQR) admission GGT (U/l) 19 (12-42) 25 (16-42) 0.25
Median (IQR) admission creatinine (lmol/l) 69 (59-81) 65 (59-74) 0.44
Median (IQR) peak creatinine (lmol/l) 70 (59-81) 67 (60-79) 0.68
Median (IQR) change in creatinine (%) -5.4 (-22.8-3.1) -6.0 (-12.6-1.7) 0.46
Alcohol ingested 1 (7%) 59 (58%) < 0.0001
Other drugs ingested 9 (64%) 67 (66%) 0.92
Nutritional deficiency 2 (14%) 17 (17%) 0.82
Debilitating disease 0 (0%) 2 (2%) 0.60
Chronic alcohol use 0 (0%) 44 (43%) 0.002
Identified as high risk 2 (14%) 57 (56%) 0.004
Number who received ondansetron 11 (79%) 46 (45%) 0.02
Number who received modified NAC 7 (50%) 57 (56%) 0.68
P-value for difference between groups was determined by Mann-Whitney test or chi-square test.
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(half-life up to 6.9 h), which is likely due to their patients having
more severe ALI, as indicated by an ALT activity of 1,000 U/l.6
The present study suggests that mild ALI is associated with a
reduction in the capacity to metabolize APAP. This increase in
half-life might reflect an intrinsic lower capacity to metabolize
APAP that results in liver injury after overdose due to increased
production of NAPQI. Alternatively, liver injury may cause a low-
er metabolic capacity. In this study there was no evidence of a dif-
ference in renal function between those patients with and without
ALI, which otherwise could have affected metabolite clearance.
APAP-Glu and APAP-Sul (formed through phase II non-CYP
metabolism) were the highest concentration APAP metabolites in
the circulation.6,26,27 In previously published studies, about one-
third of APAP was metabolized into APAP-Sul and two-thirds
into APAP-Glu. The APAP-Sul pathway becomes saturated even
at therapeutic doses26,27 and the higher capacity of the APAP-Glu
pathway is likely to explain the higher circulating concentration of
APAP-Glu, which is in agreement with earlier reports.6,7
Current practice worldwide is to measure plasma or serum
APAP as a central part of risk stratification after overdose. How-
ever, APAP per se is relatively nontoxic without CYP-mediated
metabolism.28,29 The CYP generated reactive metabolite,
NAPQI, mediates ALI following APAP overdose.30 Therefore,
biomarkers that report activity of CYP-mediated APAP metabo-
lism may, theoretically, refine patient care pathways. A priori, it
could be hypothesized that APAP-GSH, APAP-Cys, and/or
APAP-Mer would be either higher in those with liver injury
because of increased CYP metabolism or lower because of
reduced glutathione bioinactivation of NAPQI. This study
demonstrates that patients with ALI have a relatively higher cir-
culating fraction of CYP metabolites compared to phase II
metabolites. Importantly, from a clinical perspective, prior to
NAC treatment the fraction of CYP-mediated metabolites was
higher in people who subsequently developed ALI. Although all
patients included in this study received NAC treatment following
measurement of their plasma APAP concentration, the absolute
value of APAP had no predictive value for the development of
subsequent ALI. We chose not to interpret APAP with regard to
time from overdose—such as by creating multiple nomogram
lines31—to facilitate head-to-head comparison with metabolites
measured in the same sample. By contrast with APAP, the CYP
metabolite APAP-Cys was able to predict the onset of ALI with
an ROC-AUC of 0.75 in the discovery cohort and an ROC-
AUC of 0.82 in the validation cohort. APAP-Cys is commonly
used as a surrogate measure of circulating APAP-protein adducts.
In this study the protein fraction was removed prior to mass spec-
trometry, which distinguishes it from the protocol used for
adduct measurement. Therefore, the data presented in this article
are likely to accurately reflect APAP-Cys derived from glutathi-
one conjugation with NAPQI. When the ratio of APAP-Cys
and APAP-Sul was calculated, prediction accuracy was further
increased to an ROC-AUC of 0.91 in the discovery cohort. The
optimal measure of CYP metabolism remains to be determined
by future larger studies.
Multiple new biomarkers of hepatocyte injury,5 inflamma-
tion,32 tissue regeneration,21 and kidney injury33 have recently
been identified. These markers have high sensitivity and specific-
ity for reporting injury or assessing prognosis (depending on the
Table 2 Patient characteristics of the validation cohort divided by absence or presence of acute liver injury (>50% increase in ALT)
>50% ALT rise No. >50% ALT rise P-value
Number 19 131
Median (IQR) age (years) 41 (19-65) 36 (22-48) 0.60
Number of females 12 (63%) 86 (72%) 0.83
Median (IQR) time from ingestion to sampling (h) 5.0 (4.0-8.0) 5.5 (4.0-13.25) 0.65
Number with ingestion to treatment <8hr 13 (57%) 94 (64%) 0.76
Median (IQR) ingested acetaminophen (gram) 13 (22-35) 15 (9-21) 0.01
Number who ingested acetaminophen 16g 11 (58%) 58 (44%) 0.27
Median (IQR) admission alanine aminotransferase (U/L) 18 (12-34) 18 (13-28) 0.86
Median (IQR) peak alanine aminotransferase (U/L) 252 (22-1256) 19 (14-28) < 0.0001
Median (IQR) admission INR 1.0 (1.0-1.0) 1.1 (1.0-1.2) 0.0004
Median (IQR) peak INR 1.1 (1.0-1.1) 1.2 (1.1-1.6) < 0.0001
Median (IQR) admission billirubin (lmol/l) 8 (6-15) 5 (5-9) 0.04
Median (IQR) admission GGT (U/l) 26 (15-40) 17 (13-47) 0.88
Median (IQR) admission creatinine (lmol/l) 59 (48-68) 57 (51-68) 0.99
Median (IQR) peak creatinine (lmol/l) 64 (55-78) 61 (55-70) 0.70
Median (IQR) change in creatinine since admission (%) 2.3 (-5.9-16.7) -2.0 (-12.6-8.2) 0.14
P-value for difference between groups was determined by Mann-Whitney test or chi-square test.
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context of use). CYP metabolites complement these markers by
offering potential refinement of risk stratification beyond the
measurement of APAP parent drug. It has been proposed that the
product of the APAP concentration and serum ALT activity can
determine the risk of liver injury independent of time from drug
ingestion.34 A combination of CYP metabolites and one or more
highly sensitive liver injury markers (such as miR-122) promises to
more accurately identify patients at risk of liver injury despite
NAC treatment. Using this new combination in routine clinical
practice still requires development. However, in the context of
clinical trials these markers may offer value in the near future. The
potential for refinement of clinical trials was demonstrated when
the SNAP trial results were reanalyzed with the pre-ondansetron
treatment ratio of APAP-Cys/APAP-Sul included. In this refined
analysis the apparent increase in ALI reported with ondansetron
was not different from placebo. This is because the more sensitive
CYP pathway biomarker demonstrated that, by chance, more
patients with a toxic metabolite profile were randomized to ondan-
setron compared to placebo. Future clinical trials of novel thera-
peutic strategies could be enhanced by measurement of CYP
metabolites that may identify patients who will develop ALI
despite treatment with NAC. For both CYP metabolites and other
novel biomarkers to be useful in clinical trials, a key roadblock to
be overcome is the development and validation of point-of-care
assays that can provide measurements within the timeframe for
patient identification and trial recruitment.35
Our data are from an early-phase discovery study that only
included patients treated with NAC (because they had serial
blood tests). Future work will include those patients deemed
not to require treatment after overdose based on interpreta-
tion of the currently used biomarkers. In this study we inter-
preted the APAP metabolite data at first presentation without
regard for time from ingestion. In the future, nomograms may
be developed that are analogous to the APAP treatment lines.
The increase in ALT used to define our primary outcome of
ALI (50% rise) was modest. This was chosen by the SNAP
trialists before this randomized clinical trial started and so was
also used in this follow-up biomarker discovery study. The
incidence of larger increases in ALT (such as >1,000 U/L)
was too low in both our discovery and validation cohorts for
robust analysis. Therefore, future studies will be needed to
define the relationship between CYP metabolites and more
severe injury.
In summary, circulating APAP metabolites formed by CYP
enzymes are toxicokinetic biomarkers that stratify patients by







































































c r = 0.31 (0.12-0.48)
R2 = 0.10
P = 0.002
Figure 3 Discovery cohort. (a) APAP half-life in patients developing acute liver injury (ALI, as defined by>50% ALT increase) (n 5 14) and those with no injury
(no ALI) (n 5 102). (b) Area under the curve (AUC) for the proportion of total metabolites formed by CYP enzyme activity (CYP/Total(%)) from time 0 to 20.25 h
after starting NAC in liver injury (ALI) (n 5 14) and nonliver injury (No ALI) patients (n 5 102). (c) Correlation between the AUC for the proportion of total metabo-
lites formed by CYP enzyme activity (CYP/Total(%)) from time 0 to 20.25 h after starting NAC and peak hospital stay serum alanine transaminase (ALT) activity
(n 5 116). (c) At pretreatment before NAC and ondansetron or placebo. Metabolites formed by CYP enzyme activity are expressed as a proportion of total circulat-
ing metabolites (CYP/total (%)) in liver injury (n 5 14) and nonliver injury patients (n 5 102). In (a,b,d): boxes show median 6 IQR, whiskers represent range.
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development, there is the potential for enhanced patient identifi-
cation for entry into clinical trials of novel treatment pathways
and refined clinical decision-making.
METHODS
Patients
All patients were treated with NAC for a single acute APAP overdose.
To determine the need for NAC treatment, plasma APAP concentration
was measured by the Paracetamol Assay from Cambridge Life Sciences
(Cambridgeshire, UK) in the clinical biochemistry laboratories at each
center. The APAP concentration was interpreted using the contempora-
neous UK APAP treatment nomogram.
Discovery cohort. Patients from the SNAP trial (EudraCT number
2009-017800-10) were recruited at the Royal Infirmary of Edinburgh
(RIE), UK. Details of the full SNAP protocol are reported in Tha-
nacoody et al.36 In brief, patients were eligible for entry into the SNAP
trial if they presented within 36 h of a single acute APAP overdose and
required treatment with NAC, based on standard UK guidance for man-
agement. Full informed consent was obtained and the study was
approved by the UK Medicines and Healthcare products Regulatory
Agency and the Scotland A Research Ethics Committee, UK (ref. no.
10/MRE00/20).
Plasma EDTA blood samples were collected before (“pretreatment”),
12 h and 20.15 h after the start of conventional or modified NAC treat-
ment (with intravenous ondansetron or placebo treatment immediately
after the pretreatment blood draw). Plasma was separated and the sam-
ples were stored at –808C until analysis. For all study participants, demo-
graphics and blood results were recorded.
Validation cohort. Adult patients (16 and over in Scotland, 18 and over
in England) were recruited to the MAPP study if they fulfilled the study
inclusion and exclusion criteria. Full informed consent was obtained from
every participant and ethical approval for this study was from the South
East Scotland Research Ethics Committee and the East of Scotland
Research Ethics Committee via the South East Scotland Human Biore-
source. Research nurses at each site identified participants on admission to
hospital. The inclusion criteria were: a history of APAP overdose that the
treating clinician judged to warrant treatment with intravenous NAC as
per the contemporaneous UK guidelines; the first blood sample collected
within 24 h of last APAP ingestion and the patient had the capacity to
consent. Patients were excluded if any of the following applied: patient
detained under the Mental Health Act (UK); patient has known cognitive
impairment; inability to provide informed consent for any reason or an
unreliable history of overdose. Patients having taken a single acute APAP
overdose were recruited at St. Thomas Hospital London, UK (n 5 59)
and Aberdeen Royal Infirmary, UK (n 5 91).
Primary endpoint
The primary endpoint was ALI; predefined by SNAP as a rise in serum
ALT activity of 50% or more at 20.25 h compared to the hospital admis-
sion value.36
Table 3 Predictive accuracy of current and new biomarkers compared to ROC-AUC 5 0.5

























0.91 (0.83-0.98) < 0.0001 0.71 (0.42-0.92) 50 96 0.76 (0.63-0.88) 0.0003 0.43 (0.35-0.52) 38 92
CYP% 0.78 (0.67-0.90) 0.0006 0.36 (0.13-0.65) 33 91 0.66 (0.51-0.82) 0.02 0.11 (0.06-0.17) 14 87
Sum CYP
metabolites
0.75 (0.61-0.88) 0.003 0.48 (0.38-0.58) 40 93 0.83 (0.71-0.94) < 0.0001 0.44 (0.36-0.53) 39 92
APAP-CYS 0.75 (0.61-0.88) 0.003 0.36 (0.13-0.65) 33 91 0.82 (0.71-0.94) < 0.0001 0.44 (0.35-0.52) 39 92
INR 0.70 (0.54-0.86) 0.03 0.23 (0.05-0.54) 24 89 0.71 (0.57-0.85) 0.005 0.07 (0.03-0.13) 9 87
ALT 0.67 (0.50-0.84) 0.04 0.29 (0.08-0.58) 28 90 0.51 (0.35-0.67) 0.86 0.16 (0.03-0.40) 19 88
APAP-Sul 0.65 (0.48-0.82) 0.06 0.50 (0.23-0.77) 41 93 0.53 (0.38-0.67) 0.75 0.11 (0.06-0.17) 14 87
APAP-Glu 0.63 (0.44-0.82) 0.11 0.36 (0.13-0.65) 33 91 0.61 (0.47-0.76) 0.11 0.11 (0.06-0.17) 14 87
APAP-GSH 0.61 (0.46-0.76) 0.19 0.21 (0.05-0.51) 22 89 0.67 (0.61-0.74) 0.004 0.41 (0.21-0.64) 37 91
APAP-Mer 0.59 (0.40-0.77) 0.29 0.21 (0.05-0.51) 22 89 0.76 (0.62-0.90) 0.0003 0.26 (0.19-0.34) 27 89
APAP LC/MS 0.50 (0.33-0.67) 0.97 0.14 (0.02-0.43) 16 88 0.57 (0.41-0.73) 0.32 0.05 (0.02-0.11) 7 87
APAP hospital lab 0.55 (0.37-0.73) 0.78 0.00 (0.00-0.04) 0 87 0.58 (0.42-0.73) 0.29 0.09 (0.04-0.15) 12 87
The positive and negative predictive values (PPV and NPV, respectively). Table with ROC-AUC (area under the curve with 95% CI), sensitivity (at 90% specificity) with 95%
CI, and statistical significance for different metabolites measured at pretreatment in the discovery and hospital presentation in the validation cohort. P-value represents
significance level are also presented for each metabolite/biomarker.
Table 4 Effect of APAP-Cys/APAP-Sul on acute liver injury in




Odds ratio (95% CI),
P value for developing ALI
Full SNAP trial, adjusteda as
in Lancet paper21
0.303 (0.108, 0.851), 0.024
Full SNAP trial, unadjustedb 0.332 (0.124, 0.886), 0.028
This study subset of SNAP,
unadjusted
0.211 (0.055, 0.801), 0.022
This subset, adjusted for
APAP-Cys/APAP-Sul
0.465 (0.097, 2.226), 0.338
aAdjusted by the variables in the minimization algorithm, and center. bObtained
with a model in which only treatment and regimen were included.
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Chemicals and reagents
High-performance liquid chromatography (HPLC)-grade methanol and
water were from Fisher Scientific (Loughborough, UK). Acetic acid and
formic acid were from Sigma-Aldrich (Gillingham, UK). APAP was
from Apollo (Denton, Manchester, UK). APAP-Mer, APAP-GSH,
APAP-Sul, APAP-d4 (APAP-d4), and APAP-sulphate-d3 (APAP-SUL-
d3) were from Santa Cruz Biotechnology (Heidelberg, Germany).
APAP-Cys and APAP-Glu were from CGeneTech (Indianapolis, IN).
Sample preparation and analysis by LC-MS/MS
APAP and metabolites were extracted from plasma by liquid–liquid
extraction with acidified methanol. Briefly, 10 lL plasma was enriched
with 10 ng APAP-d4 (APAP-d4) and 10 ng APAP-SUL-d3 as internal
standards and 0.8 mL methanol (w/0.2% acetic acid) was added, vor-
texed, and incubated for 20 min on ice. After centrifugation (3000g, 10
min, 108C) to pellet protein in the sample, the supernatant was reduced
to dryness under nitrogen at 408C and reconstituted in mobile phase
(200 lL water/methanol (65:35, v/v)) and centrifuged for a second
time.
Analysis was carried out by LC-MS/MS. Liquid chromatographic sep-
aration was achieved using an Aria CTC autosampler and Allegros
pump on an ACE Excel 2 SuperC18 column (150 3 3 mm; 2 lm) pro-
tected by a Kinetex KrudKatcher (Phenomenex, UK) at 208C and
detected on a TSQ Quantum Discovery triple quadrupole mass spec-
trometer (Thermo Fisher Scientific, UK) operated by selective reaction
monitoring. The mobile phase consisted of 0.1% formic acid in water
and 0.1% formic acid in methanol at a flow rate of 0.3 mL/min. Gradi-
ent elution was achieved with a total run time of 9 min from 35% to
5%. The mass spectrometer was operated in polarity switching electro-
spray mode (3008C, 3 kV). In positive mode, transitions monitored for
were m/z 152 ! 110.0, 93.1 at 20 and 13 V and m/z 156.1 ! 114.1,
97.1 at 15 and 22 V for APAP and APAP-d4, respectively. For the posi-
tively ionized APAP metabolites, APAP-Cys, APAP-Mer, and APAP-
GSH, m/z 271.1 ! 182.0, 207.6 at 8 and 9 V, m/z 313.0 ! 140.1,
208.1 at 28 and 16 V and m/z 457.2! 140 at 33 V were monitored.
For the negatively ionized APAP metabolites APAP-Sul, APAP-Glu,
and the internal standard APAP-SUL-d3 m/z 229.8 ! 107.0, 150.1
at 36 and 15 V, m/z 326.0 ! 113.0, 150.0 at 28 and 16 V and
m/z 233.0! 109.5, 181.4 at 30 and 5 V were monitored.
Statistical analysis
All data are presented as median and interquartile range (IQR), except
for ROC data, where 95% CIs are quoted. Comparisons were made
using the Mann–Whitney U-test. All LC/MS-MS data were trans-
formed from mass to molar concentrations before analyses were per-
formed. APAP plasma half-life was estimated using a nonlinear fit,
assuming first-order kinetics. All calculations and ROC analysis were
performed using GraphPad Prism software (GraphPad Software, La
Jolla, CA). Logistic regression models were run using SAS v. 9.4 (Cary,
NC).
Additional Supporting Information may be found in the online version of
this article.
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miR-122-5p is highly sensitive for detecting hepatocyte injury and allows for early 
stratification of patients. A marker that sensitively quantifies the body’s ‘toxic 
burden’ with regard to paracetamol metabolites could further improve risk 
assessment at hospital presentation and during NAC treatment. 
This study characterised the toxicokinetics of paracetamol metabolites in a discovery 
cohort of carefully phenotyped patients from a randomized clinical trial. The key 
findings were replicated in a separate validation cohort recruited at two different 
hospital sites. The key novel findings were that a higher percentage of circulating 
metabolites formed by cytochrome P450 enzymes (CYP metabolites) were present in 
patients with liver injury and these metabolites were superior to both ALT and 
paracetamol with regard to early patient stratification. The potential value of CYP 
metabolites to future clinical trials was demonstrated by their post-hoc incorporation 
into the SNAP trial. This resulted in the reported increase in ALI with ondansetron 
being no different to placebo.  
Compared to the miRNAs that were able to detect liver injury, paracetamol 
metabolites are able to quantify the toxic burden. In patients requiring NAC 
treatment, the circulating paracetamol concentration was not able to predict who is 
more at risk of liver injury (although the decision to treat with NAC had been made 
in all patients). Measuring circulating metabolites formed by the toxic pathway 
allowed prediction of who was at risk of developing liver injury.  
This work along with the miRNA work has the potential to be built on in order to 








Chapter 5: Retro-orbital blood acquisition facilitates circulating 




After identifying microRNAs in human hepatotoxicity, the next step was to develop a 
translational hepatotoxicity model in zebrafish. Due to the clinical relevance, 
paracetamol was chosen as first liver toxic compound. In order to measure circulating 
miRNAs in zebrafish, a method had to be developed for bloodletting. The paper in 
this chapter describes how a new bloodletting method from zebrafish was developed 
and compared to the previously described ‘tail cut’ or ‘lateral incision’ (LI) 
bloodletting method. This technique was then used to measure miR-122-5p in adult 
zebrafish exposed to paracetamol. 
 
The results of this study are published as: 
Vliegenthart AD, Starkey Lewis P, Tucker CS, Del Pozo J, Rider S, Antoine DJ, Dubost V, 
Westphal M, Moulin P, Bailey MA, Moggs JG, Goldring CE, Park BK, Dear JW. Retro-orbital 
blood acquisition facilitates circulating microRNA measurement in zebrafish with 
paracetamol hepatotoxicity. Zebrafish 2014;11:219-226. (75) 
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Abstract
Paracetamol is the commonest cause of acute liver failure in the Western world and biomarkers are needed that
report early hepatotoxicity. The liver-enriched microRNA (miRNA), miR-122, is a promising biomarker cur-
rently being qualified in humans. For biomarker development and drug toxicity screening, the zebrafish has
advantages over rodents; however, blood acquisition in this model remains technically challenging. We de-
veloped a method for collecting blood from the adult zebrafish by retro-orbital (RO) bleeding and compared it to
the commonly used lateral incision method. The RO technique was more reliable in terms of the blood yield and
minimum amount per fish. This new RO technique was used in a zebrafish model of paracetamol toxicity.
Paracetamol induced dose-dependent increases in liver cell necrosis, serum alanine transaminase activity, and
mortality. In situ hybridization localized expression of miR-122 to the cytoplasm of zebrafish hepatocytes. After
collection by RO bleeding, serum miR-122 could be measured and this miRNA was substantially increased by
paracetamol 24 h after exposure, an increase that was prevented by delayed (3 h poststart of paracetamol
exposure) treatment with acetylcysteine. In summary, collection of blood by RO bleeding facilitated measure-
ment of miR-122 in a zebrafish model of paracetamol hepatotoxicity. The zebrafish represents a new species for
measurement of circulating miRNA biomarkers that are translational and can bridge between fish and humans.
Introduction
At therapeutic doses, paracetamol (acetaminophen) isa safe analgesic drug used by millions of people world-
wide. However, in overdose, paracetamol is hepatotoxic, be-
ing the most common cause of acute liver failure in the United
States and Europe.1–3 The mechanism of paracetamol hepato-
toxicity is well described; in overdose, the reactive metabolite
N-acetyl-p-benzoquinone imine (NAPQI) is generated in
excess and cellular glutathione (GSH) is depleted, NAPQI
then binds covalently to cellular proteins resulting in oxi-
dative stress and consequent hepatocyte necrosis.4 The cur-
rent antidote, acetylcysteine (AC), replenishes cellular
GSH and is highly effective if administered within 8 h of
overdose. However, this treatment is time-consuming and
commonly results in adverse drug reactions. Therefore,
there is a pressing need for new biomarkers that identify
hepatotoxicity soon after overdose to stratify patients and
improve the targeting of treatment to those at most risk of
adverse outcomes.
microRNAs (miRNAs) are small (*22 nucleotides long)
nonprotein coding RNA species involved in post-transcriptional
gene product regulation. In the blood, miRNA is protected
from degradation by microvesicles5 and RNA binding protein
complexes.6 As they are amplifiable and tissue restricted,
miRNAs represent a new reservoir for biomarker discovery.
The liver-enriched miRNA, miR-122, is a circulating bio-
marker for paracetamol-induced liver toxicity in rodents and
humans.7,8 It has greater specificity for liver injury than serum
alanine transaminase (ALT) activity9 and in humans and
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rodents is elevated soon after overdose when the ALT activity
is still normal.10 miRNAs are highly conserved across species
and so represent bridging biomarkers that facilitate translation
of toxicity signals from animal models to human clinical trials.
The zebrafish is used to study the drug effects on organ
systems such the heart, CNS, and gastrointestinal tract.11,12
Recent studies have demonstrated that paracetamol exposure
induces hepatotoxicity in zebrafish.13 The zebrafish has many
mammalian homologs at multiple loci and several advantages
as a vertebrate model compared with rodents and other higher
order species. These include lower financial costs, convenient
drug delivery, genetically tractable and visually accessible or-
gans.11,14,15 However, the small size of the adult fish means that
the circulating blood volume is low, which makes blood ac-
quisition technically challenging. A number of blood collection
techniques exist for zebrafish, such as a lateral incision (LI) in
the dorsal aorta; yet, significant limitations remain with regard
to the volume of blood that can be collected. For measurement
of circulating biomarkers, such as miRNA, there is a need for
new approaches to maximize the blood yield. With regard to
the clinical translatability of circulating miRNA, it is important
to note that the zebrafish liver expresses miR-122, which has an
identical nucleotide sequence (UGGAGUGUGACAAUGGU
GUUUG) to the rodents and humans.16
To date, zebrafish miRNA expression has been studied only in
tissues, and no data have been published on circulating miRNA.
In this article, we describe a new method for blood collection
based on retro-orbital (RO) sinus bleeding, a technique com-
monly used in rodents.17 This technique was used to collect
blood for measurement of circulating miR-122 in a clinically
relevant zebrafish model of paracetamol hepatotoxicity.
Materials and Methods
Ethical approval
All experiments were conducted in accordance with the
Animals (Scientific Procedures) Act 1986 in a UK Home
Office approved establishment.
Materials
Paracetamol, MS-222 (tricaine methanesulfonate), and
ethylenediaminetetraacetic acid (EDTA) were obtained from
Sigma-Aldrich (Gillingham, United Kingdom). The MiRNeasy
and the MinElute Cleanup kit were obtained from Qiagen
Benelux B.V. (Venlo, the Netherlands). Specific reverse tran-
scription (RT) and polymerase chain reaction (PCR) primers
were obtained from Applied Biosystems (Foster City, CA)
(assay number 002245 for miR-122, 004468_mat for let-7d).
Zebrafish
Fish were 5–24 months old. In all studies, the age of fish
was the same across experimental groups. All fish were
maintained at 28.5C, pH 7.2, and conductivity of &400 lS.
Fish were euthanized with 4 mg/mL MS-222 before all blood
and tissue collection procedures. All experimental proce-
dures were performed at room temperature (23C – 0.5C).
Blood collection
To study the relationship between the fish size and blood
yield, after euthanasia, each fish was weighed and the total
body length (BL) was measured (from the tip of the snout to
the origin of the caudal fin). Two methods of blood collection
were compared: the established LI technique and a new RO
approach. LI was performed as previously described.18 In
brief, after euthanasia, fish were dried and then the tail was
cut at the caudal peduncle with a surgical knife. Blood was
collected, with the aid of a pipette, into an eppendorf tube
containing heparin solution (0.5 lL of 25 mg/mL). For RO
bleeding, following euthanasia, fish were quickly dried and
then one eye was removed using a pair of fine forceps. The
heparin (0.5 lL of 25 mg/mL stock) or EDTA (0.5 lL of 2%
stock) solution was pipetted onto the eye socket to prevent the
blood from clotting. Once the orbital space had filled with
blood, it was pipetted off and collected in an eppendorf tube.
After this step, pressure was applied to the fish from the tail
toward the head to accumulate more blood into the orbit for
collection. This last step was repeated until no more blood
could be collected.
Paracetamol toxicity model
Zebrafish were exposed to paracetamol (20–40 mM), dis-
solved in system water, for 3 h (or system water alone for
negative controls). This was followed by a change of system
water for 2–21 h with or without AC (3 mM). This brief ex-
posure to high-concentration paracetamol followed by delayed
AC treatment was used to replicate a human single, acute
overdose. The drug concentrations were based on published
data.13 Experiments were terminated 5–24 h after the start of
paracetamol exposure (5–24 hours post exposure [hpe]).
All histology samples were placed in Dietrich’s fixative
and left to fix for at least 24 h before processing, cutting, and
hematoxylin staining using standard protocols. All fish were
sectioned sagittally along the midline to allow examination of
the hepatic tissue. Hepatic lesions were scored by a boarded
pathologist (author J.D.P.), who was blinded to the treatment
groups. Zebrafish blood was obtained by the RO technique
and pooled as described in the results. Serum was separated
by centrifugation and the ALT activity was measured as
described by Bergmeyer et al.,19 utilizing a commercial kit
(Alpha Laboratories Ltd., Eastleigh, United Kingdom)
adapted for use on a Cobas Fara centrifugal analyzer (Roche
Diagnostics Ltd., Welwyn Garden City, United Kingdom).
The paracetamol concentration was measured by an aryl
acylamidase enzymatic assay in the Royal Infirmary of
Edinburgh Clinical Biochemistry laboratory.
miR-122 localization by in situ hybridization
miR-122 was localized using double-DIG-labeled miR-
CURY LNA miRNA detection probes (Exiqon A/S, Vedbaek,
Denmark) specific for miR-122. The in situ hybridization
procedure was performed on a fully automated Ventana
Discovery Ultra (Roche diagnostics AG, Rotkreuz, Switzer-
land). All reagents were provided by Roche Diagnostics.
Briefly, whole zebrafish sections were deparaffinized at 62C
for 12 min before the proteinase K digestion step (Exiqon A/S,
Vedbaek, Denmark) treatment (37C, 24 min). The anti-miR-
122 probe (25 pmoles) was then incubated at 54C for 3 h with
deparaffinized sections. Sections were then washed with
3 · 8-min cycles of saline sodium citrate at increasing strin-
gency per cycle (2.0 · , 1.0 · , 0.5 · ). The secondary antibody
(alkaline phosphatase-linked Sheep anti-DIG, dilution 1:500
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in antibody diluent) was then incubated at 37C for 32 min.
Chromogenic detection was performed using the BlueMap
kit as per the manufacturer’s instructions. The substrate was
allowed to develop for 6 h before counterstaining with
Red Stain II for 4 min. Slides were manually washed be-
fore mounting on laboratory-grade glycerol gelatin (Sigma-
Aldrich, Buchs, Switzerland). Slides were scanned using a
Nanozoomer 2.0-HT digital slide scanner (Hamamatsu pho-
tonics, Hamamatsu, Japan). Images were captured using
NDP.view2 software (Hamamatsu photonics).
miRNA measurement
For miRNA analysis, zebrafish blood was obtained by the
RO technique and pooled as described in Results. Serum was
separated by centrifugation and miRNA was extracted using
a miRNeasy kit (Qiagen, Venlo, Netherlands), after which
the small RNA fraction was purified using a MinElute
kit (Qiagen, Venlo, Netherlands).8 miRNAs were measured
using TaqMan-based quantitative PCR.
The small RNA elute was reverse transcribed using spe-
cific stem-loop reverse-transcription RT primers (Applied
Biosystems, Foster City, CA) for each target miRNA species,
following the manufacturer’s instructions. In the reverse-
transcription reaction, 2 lL of RNA was used to produce the
complementary DNA (cDNA) template in a total volume of
15 lL. Then, 1.33 lL of cDNA was used in the PCR mixture
with specific PCR primers (Applied Biosystems) in a total
volume of 20 lL. Levels of miRNA were measured using the
Light Cycler 480 (Roche, Basel, Switzerland). All samples
were assayed in duplicate. miRNA levels were normalized
to the levels of let-7d, which has been reported to be an
appropriate internal normalizer in humans.20 At the time
of writing, the optimum normalizer for zebrafish was not
described.
Statistical analysis
Statistical analysis was performed with GraphPad Prism
software (GraphPad Software, Inc., La Jolla, CA). Differ-
ences in blood yield between the LI and RO techniques and
biomarker differences between the experimental groups were
analyzed with the Student’s unpaired t test. For correlation
analysis, a Pearson’s correlation test was used. Nominal
statistical significance was set at p < 0.05.
Results
Blood yield was higher with the RO technique
The volume of blood obtained by RO (N = 52) and LI
(N = 37) techniques was compared (Fig. 1); the RO technique
resulted in significantly higher blood yields than the LI
FIG. 1. (A) Blood yield for the retro-orbital (RO) technique (N = 52) and for the lateral incision (LI) technique (N = 37).
Each point represents an individual fish. Horizontal bars represent the mean. Error bars represent standard deviation.
***p < 0.0001. Scatter graphs of RO blood yield in relation to body length (B), body weight (C), and age (D). Each point
represents an individual fish. Pearson R values (statistical probabilities) are 0.63 ( p < 0.0001), 0.67 ( p < 0.0001), and 0.46
( p = 0.001) for length, weight, and age, respectively.
MICRORNA BIOMARKERS IN FISH 221
technique (mean per fish – SD: 5.3 – 2.6 lL vs. 2.8 – 2.0 lL,
p < 0.0001). Furthermore, the LI technique did not result in
successful blood collection from every fish, with 6 from 37
providing insufficient or no blood. In comparison, the RO
technique resulted in blood collection from every fish, with a
minimum yield of 2 lL.
Individual fish age, BL, and body weight (BW) were not
significantly different between the RO and LI groups
(mean – SD: age 52.2 – 30.3 vs. 53.9 – 32.48 weeks, p = 0.81,
BL 28.5 – 4.5 vs. 27.8 – 3.6 mm, p = 0.44, BW 518.6 – 284.1
vs. 492.7 – 181.9 mg, p = 0.62, for RO vs. LI, respectively).
Within the RO group, blood yield correlated significantly
with all three parameters. However, BL and BW were more
strongly correlated with blood yield than age: BL (R = 0.63,
p < 0.0001), BW (R = 0.67, p < 0.0001), and age (R = 0.46,
p = 0.001) (Fig. 1).
Paracetamol-induced liver toxicity in adult zebrafish
Next, the RO blood collection technique was applied to a
zebrafish model of paracetamol hepatotoxicity. Paracetamol
dissolved in the system water entered the zebrafish circula-
tion. In a pooled serum sample from 10 fish, the serum
paracetamol concentration was 962 mg/L immediately fol-
lowing a 3-h exposure to paracetamol (30 mM). Exposure to
40 mM paracetamol for 3 h resulted in 4 out of 10 fish dying
3–6 hpe. In the 30 mM group, 1 out of 30 fish died at 2.5 hpe,
and 3 out of 30 fish died at 20–23 hpe (Fig. 2). No fish died
after 20 mM of paracetamol exposure ( p = 0.02 for mortality
following paracetamol exposure). Exposure to 20 mM and
40 mM paracetamol for 3 h resulted in hepatocyte necrosis at 24
hpe (Fig. 2). There was a dose–response relationship in the
mean number of necrotic foci per liver section (mean –
standard error of the mean: control 0.13 – 0.1, 20 mM 1.5 – 0.7,
40 mM 2.7 – 0.7), and both treatment groups induced a signif-
icant increase in necrosis compared with control ( p = 0.02 and
p < 0.001 for 20 and 40 mM paracetamol, respectively) (Fig.
2). Other histological features included pericapsular mac-
rophage clustering, pigment-laden macrophages, and cyto-
plasmic granularity of hepatocytes. The former two features
were noted in both cases and controls, suggesting these are
background findings. Cytoplasmic granularity of hepato-
cytes appeared to be associated with paracetamol exposure.
At 24 hpe, there was a paracetamol-induced dose-dependent
increase in the serum ALT activity (Fig. 2).
miR-122 localized to zebrafish hepatocytes
In situ hybridization with the miR-122 probe revealed
positive intra-cytoplasmic staining in zebrafish. ISH-positive
staining was noted in variable numbers of hepatocytes scat-
tered throughout the hepatic parenchyma, and was charac-
terized by one or more focal deposits within the cytoplasm
(Fig. 3).
FIG. 2. Effect of paracetamol exposure on adult zebrafish. Paracetamol treatment was for 3 h, all measurements made 24
hpe. (A) Histological images of adult zebrafish liver at the indicated paracetamol concentrations; both treatment groups
displayed liver necrosis. (B) Mean foci of necrosis per liver section at the indicated paracetamol concentrations. N = number
of fish per treatment group. Error bars represent SEM, *p < 0.05, ***p < 0.001. (C) Serum ALT activity in pooled samples
from each treatment group. N = the number of pooled fish for ALT measurement. (D) Survival curves for experimental
groups N = 10/group. There was a significant difference between treatment groups, p = 0.02. ALT, alanine transaminase;
hpe, hours post exposure; SEM, standard error of the mean.
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Paracetamol hepatotoxicity was associated
with increased circulating miR-122
Measurement of miRNA in pooled serum from adult
zebrafish was possible, and this was facilitated by the in-
creased blood yields from RO bleeding. Exposure to para-
cetamol (20–40 mM for 3 h) resulted in a dose-dependent
increase of miR-122 concentration, measured at 24 hpe (Fig.
4). This increase was still apparent when raw ct values were
displayed without normalization to the miRNA let-7d (Fig.
4). A paracetamol concentration of 30 mM was chosen to
study the effect of AC as this concentration induced a
FIG. 3. miR-122 in-situ hybridization. (A) Whole zebrafish section demonstrates localization to the liver. (B, C) Liver
microphotographs: widespread intracytoplasmic deposition of ISH substrate in the hepatocytes of a fish (arrows indicate
focal deposits). Scale bar: 50 lm.
FIG. 4. (A) Circulating miR-122 24 hpe to 3 h of paracetamol at the concentrations indicated. miR-122 was normalized to
let-7d. N = number of fish pooled for microRNA measurement. (B) Circulating miR-122 24 hpe to 3 h of paracetamol at the
concentrations indicated. Raw ct values are presented without normalization. N = number of fish pooled for microRNA
measurement. (C) Serum ALT activity and miR-122 24 hpe to 3 h of paracetamol (30 mM) followed by 21 h of AC (3 mM)
or water. ALT and miR-122 are expressed as fold change compared to control. Values are mean, error bars are SEM.
Zebrafish were equally divided across three replicate experiments giving the indicated total numbers per group (N).
*p < 0.05, **p < 0.001 for comparison of miR-122/let-7d values between groups indicated. AC, acetylcysteine.
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significant increase in circulating miR-122 at 24 hpe (miR-
122/let-7d: mean – SEM, control 0.1 – 0.005, paraceta-
mol 1.0 – 0.2. p = 0.01) with lower mortality than 40 mM.
Zebrafish were divided across 3 replicate experiments giving
total numbers per group as presented in Figure 4. Blood was
pooled within groups from each experiment. Expressed with
reference to each experiment’s system water control, there
was an eightfold larger increase of miR-122 compared with
ALT activity for the same paracetamol dose at 24 hpe (fold
change relative to control, 30 mM paracetamol [mean –
SEM]: 1.4 – 0.3 ALT, 11.5 – 2.7 miR-122). (Fig. 4). After 3 h
of exposure to paracetamol, the fish were treated with AC
(3 mM) in the water or water alone for 21 h. With AC, 1 out of
30 fish died (3.3%), whereas 4 out of 30 fish died (13.3%) in
the absence of AC. Consistent with delayed AC treatment
preventing liver injury, AC prevented the paracetamol-
induced increase in circulating miR-122 (miR-122/let-7d:
mean – SEM, paracetamol 1.0 – 0.2, paracetamol and AC
0.2 – 0.05. p = 0.009). Figure 5 presents the temporal profile
of circulating miR-122 and ALT activity at 5–24 hpe to
30 mM paracetamol for 3 h. This demonstrates that miR-122
was not significantly elevated until 24 hpe. With this dose of
paracetamol, there was no significant increase in the serum
ALT activity.
Discussion
For zebrafish to be useful in circulating biomarker discovery
and validation studies, it is vital to maximize the yield of blood
from every fish. In this study, we demonstrated that a new RO
technique was more efficient than the commonly used LI ap-
proach in terms of blood yield. We developed a zebrafish model
for paracetamol-induced hepatotoxicity, in which we used the
new RO blood draw technique to, for the first time, measure
circulating miRNA in zebrafish. We noted that circulating
liver-enriched miRNA (miR-122), was elevated in a dose-
dependent pattern as a result of paracetamol hepatotoxicity.
This is consistent with findings in humans and rodents.
In the present study, the LI blood collection technique
yielded a mean of 2.8 lL of blood per fish, but no blood or
blood volumes of less than 1 lL were obtained from around
19% of fish. These results are consistent with previous
studies.21,22 The new RO technique yielded a higher mean of
5.3 lL of blood per fish and a maximum of 14 lL. Ad-
ditionally, the RO technique resulted in a minimum of 2 lL
from all fish used in this study. When calculating the number
of fish that need to be pooled (with a power of 80%) to ensure
a sample of 40 lL of blood, for the RO technique, 13 fish
would be needed, whereas 36 fish would be needed if the LI
technique is used. Therefore, fewer animals may be needed
for a successful experiment if the RO technique is used,
which is in compliance with the principle of reduction in the
number of experimental animals (www.nc3rs.org.uk).
The fish age, length, and weight correlated significantly
with the amount of blood drawn by the RO technique (longer,
heavier, and older fish yielded higher volumes of blood).
However, the size correlated more strongly with blood yield
than fish age, which makes the fish size a more useful pre-
dictor of successful blood acquisition. In our study, relatively
small fish were mostly used; *22–30 mm in length. How-
ever, a few larger fish, up to 40 mm, were included, which is a
size that is rarely exceeded in captivity.23 These large fish
yielded up to 14 lL of blood. The largest reported blood yield
was from the study of Pedroso et al.,18 who reported a yield of
up to 20 lL; however, the fish size was not disclosed in their
report and the anesthetic agent used might have increased the
blood yield. Pedroso et al.18 used ice-cold water, which slows
fish metabolism,24,25 however, the UK Animals (Scientific
Procedures) Act 1986, does not allow this approach. Jen-
sen,26 who, like our study, used MS-222 to anesthetize the
fish before the LI technique, reported blood yields of 2–8 lL,
which is in line with our LI results. Recently, a new technique
has been described in which fish were centrifuged in a per-
forated eppendorf tube after the administration of a LI.27
They reported comparable blood yields (5.5–11 lL) to the
RO approach. However, centrifugation may lead to blood
contamination with other body fluids, whereas the RO blood
collection approach results in a reduced risk of contamina-
tion. Zang et al.,28 described a recovery method that allows
for serial blood sampling from adult zebrafish, but it takes 1
to 2 weeks for fish to recover normal hemoglobin values after
taking a small blood sample of 2 lL. This delayed recovery
may limit the value of serial blood sampling in toxicity
studies.
Paracetamol was associated with hepatocyte necrosis in
the liver of zebrafish. This is consistent with previous studies
in zebrafish that have demonstrated paracetamol-induced
formation of NAPQI through the enzymatic action of
CYP3A6529; hepatic GSH depletion and necrotic cell
death.13 In the present study, the histological evidence of
liver injury was accompanied by modestly increased serum
ALT activity and clearly increased mortality. The zebrafish
FIG. 5. Serum ALT activity and miR-122 5–24 hpe to
3 h of paracetamol (30 mM). ALT and miR-122 are ex-
pressed as fold change compared to controls run at each
time point. Values are mean, error bars are SEM. Zebra-
fish were equally divided across three replicate experi-
ments giving the indicated total numbers per group (N).
**p < 0.001 for comparison of miR-122/let-7d values be-
tween groups indicated.
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liver expressed miR-122 as detected by ISH. To the best of
our knowledge, this is the first study to localize zebrafish miR-
122 by in situ hybridization and to measure miRNA in
zebrafish serum, facilitated by the increased blood volumes
collected by the RO technique. In paracetamol-exposed fish,
there was a clear, dose–response elevation in circulating miR-
122. This is consistent with release from the injured liver as is
described in rodents and humans.7,8 Furthermore, circulating
miR-122 is elevated in humans and rodents soon after a
paracetamol overdose at a time when ALT is still normal, and
therefore, miR-122 appears more sensitive than ALT for re-
porting hepatotoxicity.7,10 In the present study, 24 h after
paracetamol exposure, when there was histologically proven
hepatocyte necrosis, there was an eightfold larger increase of
miR-122 than ALT, suggesting a greater sensitivity for re-
porting tissue injury. More work is needed to fully define the
kinetics of circulating miRNA in fish using different dosing
regimens for paracetamol and other hepatotoxic drugs.
However, this study suggests that miRNA may have signifi-
cant advantages over ALT measurement in zebrafish.
Delayed AC treatment (administered after paracetamol
exposure for 3 h) prevented the increase in circulating miR-
122 at 24 hpe. This is, to the authors’ knowledge, the first
demonstration that effective antidote treatment is reported by
a circulating miRNA biomarker. miRNAs are very promising
disease biomarkers because they are stable in blood, some
display tissue-restricted expression, they rarely undergo
postprocessing modification, and they are readily amplifiable
signals. Another major strength of miRNA is that they are
translational across species, and this study adds zebrafish to
the list of species (rodents and humans) that report hepato-
toxicity by elevation in circulating miR-122.
The results of this study suggests that with further devel-
opment, zebrafish may be valuable as a model to identify and
explore drug-induced liver injury using miR-122 as a read-out
of toxicity that is directly translatable to rodents and humans.
The value of such a zebrafish model lies in the simplicity of
drug administration, low financial cost, and ease of genetic
manipulation. In the present study, we measured the serum
paracetamol concentration, which was 962 mg/L immediately
following a 3-h exposure to paracetamol (30 mM), a clear
evidence that drug in the water enters the fish circulation. This
paracetamol concentration is within the range reported in
humans and would be expected to produce hepatotoxicity if
untreated in clinical practice.
There are limitations to the model that will be a focus of
further work. Although RO bleeding increased the blood yield
per fish, there was still a need to pool samples to measure
biomarkers. Future work will focus on refining techniques
to allow miRNA measurement on single fish to produce a
significant reduction in numbers needed for experiments.
Zebrafish could represent a high-throughput screen, but mea-
surement of miRNA is time-consuming by PCR. There is a
need for a rapid point of care assay for miR-122 to speed up the
time for results both in preclinical and clinical studies. In this
study, we normalized miR-122 using circulating let-7d, as per
our published human studies. This is a new field, and further
work is needed to determine the optimal normalizing approach
for zebrafish blood miRNA.
In summary, collection of blood by RO bleeding facilitated
the measurement of circulating miR-122 in a model of
paracetamol hepatotoxicity. The adult zebrafish represents a
new species for the measurement of circulating miRNA
biomarkers that can bridge from fish to humans.
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For zebrafish to be useful in circulating biomarker discovery and validation studies, it 
is vital to maximize the yield of blood from every fish. In this study, we demonstrated 
that a new ‘retro orbital’ (RO) technique was more efficient than the commonly used 
LI approach in terms of blood yield. We developed a zebrafish model for paracetamol-
induced hepatotoxicity in which we used the new RO blood draw technique to, for 
the first time, measure circulating miRNA in zebrafish. We noted that circulating liver 
enriched miRNA (miR-122-5p), was elevated in a dose dependent pattern as a result 
of paracetamol hepatotoxicity.  
This is consistent with findings in humans and rodents. In summary, collection of 
blood by RO bleeding facilitated measurement of circulating miR-122-5p in a model 
of paracetamol hepatotoxicity. The adult zebrafish represents a new species for 














After developing a model for hepatotoxicity in adult zebrafish, the next step was to 
develop a model for hepatotoxicity in zebrafish larvae. Larvae were chosen because 
they are easier to handle than adult fish, they are optically clear making them suitable 
for imaging and till 5 dpf they replace controlled animals.  
Firstly, liver histology was studied in zebrafish larvae after exposure to paracetamol. 
Subsequently triptolide (TP), the active compound in Tripterygium wilfordii Hook F, a 
medicinal plant with a long history of use in traditional medicine was used. TP is 
purported to have multiple pharmacological effects including anti-inflammatory, 
anti-cancer, neuroprotective and contraceptive activities (248, 249). However, its use 
is limited by its high incidence of hepatotoxicity (250) and in vitro data suggest that 
inhibition of RNA synthesis may be the mechanism of toxicity (251). 
In the study described in this chapter novel imaging tools were used to characterize 
a new model of DILI due to TP in zebrafish larvae. Histological examination, 
quantification of miR-122-5p per larva, selective plane illumination microscopy 
(SPIM) and time-lapse imaging by 2D microscopy to characterise the time course of 
liver injury were performed. The transcriptional changes induced by TP were 
investigated by RNA-sequencing and this confirmed mRNA synthesis inhibition and 
identified nitric oxide production as a protective pathway in the injury pathogenesis.  
 
6.2 Contributions by the candidate 
 
Study design; Execution of paracetamol and triptolide exposure experiments; 
performing miRNA measurements; time-lapse microscopy; Performing PCR for 
sequencing validation and measuring inflammatory associated gene expression; Data 
57 
 





6.3.1 Preliminary studies 
 
First, it was determined whether paracetamol and TP induced liver injury in zebrafish. 
Larvae were exposed to paracetamol or TP for 48 hours from 3 to 5 dpf. This exposure 
caused mortality with a dose-response relationship with a 100% death rate reached 
with 10 mM paracetamol versus 2 μM for TP (Figure 5A). Histological examination of 
larvae revealed injury specifically to the liver. There was a dose response relationship 
between TP and hepatocyte vacuolation, hepatocyte disarray and oncotic necrosis 
whereas there was no dose-response relationship with paracetamol (Figure 5B). 
Paracetamol did not induce hepatocyte necrosis despite causing death. Out of 38 
zebrafish larvae treated with TP (0.8μM) only 3 did not have histological evidence of 
liver injury. There was no discernible histological injury to other organs. Because of 
these results TP was chosen as compound to further characterize its hepatotoxicity 





Figure 5. Effect of paracetamol and triptolide on zebrafish larvae after 48 hours (3-
5dpf) exposure. (A) Survival of zebrafish larvae after paracetamol or TP exposure at 
the concentrations indicated. Each dot represents mean mortality of 30 larvae. (B) 
Scatter plots (mean) of histology scores for hepatocyte vacuolation, hepatocyte 
disarray and oncotic necrosis after paracetamol or TP exposure at the concentrations 
indicated (For paracetamol control N = 11, 2 mM N= 17, 4 mM N=21, 6 mM N = 8, For 
Hepatocyte vacuolation
















































































































TP control N=12, 0.4 μM N=20, 0.6 μM N=18 and 0.8 μM N=18). There was no necrosis 
induced by paracetamol.  
 
6.3.2 Studies with triptolide 
 
The studies with triptolide are being prepared to submit for publication as: 
Characterization of triptolide induced hepatotoxicity in zebrafish larvae. AD Bastiaan 
Vliegenthart, Chunmin Wei, Charlotte Buckley, Cécile Berends, Carmelita MJ de 
Potter, Jorge Del Pozo, Carl Tucker, Al Ivens, David J Webb and James W Dear. 
  
 1 
Title: Characterization of triptolide-induced hepatotoxicity by imaging and 
transcriptomics in a novel zebrafish model 
 
Running title: Triptolide hepatotoxicity in zebrafish 
 
Authors:  AD Bastiaan Vliegenthart*,¶, 
 (bastiaanvliegenthart@hotmail.com) 
   Chunmin Wei*,†,¶,    (mini9636@126.com) 
Charlotte Buckley*,   
 (charlotte.b.buckley@gmail.com) 
Cécile Berends*,    (cecileberends@gmail.com) 
Carmelita MJ de Potter*,   (c.m.j.depotter@students.uu.nl) 
Sarah Schneemann*  
 (s.a.schneemann@students.uu.nl) 
Jorge Del Pozo‡,    (Jorge.Del.Pozo@ed.ac.uk) 
Carl Tucker§,     (Carl.Tucker@ed.ac.uk) 
John J Mullins*,    (j.mullins@ed.ac.uk) 
David J Webb*,    (d.j.webb@ed.ac.uk) 
James W Dear*.   (james.dear@ed.ac.uk) 
 
¶ these authors contributed equally 
Affiliations: 
* Edinburgh University/BHF Centre for Cardiovascular Science, The Queen’s 
Medical Research Institute, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK. 
† Center for Drug Evaluation, China Food and Drug Agency, No1 Fuxing Road, 
Beijing, 100083, China. 
‡ Easter Bush Pathology, Royal (Dick) School of Veterinary Studies, The University 
of Edinburgh, Easter Bush campus, Roslin, Midlothian EH25 9RG, UK. 
§ Biomedical Research Resources, The College of Medicine and Veterinary 
Medicine, The 





Corresponding author:  James W. Dear  
University/BHF Centre for Cardiovascular Science,  
University of Edinburgh, Queen’s Medical Research 
Institute, 47 Little France Crescent, Edinburgh, EH16 
4TJ  
james.dear@ed.ac.uk  
Tel: (+44) 131 242 9214 




Triptolide is a vine extract used in traditional Chinese medicines and associated with 
hepatotoxicity. In vitro data suggest that inhibition of RNA synthesis may be the 
mechanism of toxicity. For studying drug-induced liver injury the zebrafish has 
experimental, practical and financial advantages compared with rodents. The aim of 
this study was to explore the mechanism of triptolide toxicity using zebrafish as the 
model system. The effect of triptolide exposure on zebrafish larvae was determined 
with regard to mortality, histology, expression of liver specific microRNA-122 and 
liver volume. Fluorescent microscopy was used to track toxicity in the Tg(-
2.8lfabp:GFP)as3 zebrafish line. Informed by microscopy, RNA-sequencing was used 
to explore the mechanism of toxicity. Triptolide exposure resulted in dose-dependent 
mortality, a reduction in the number of copies of microRNA-122 per larva, 
hepatocyte vacuolation, disarray and oncotic necrosis, and a reduction in liver 
volume. These findings were consistent across replicate experiments. Time-lapse 
imaging indicated the onset of injury was 6 hours after the start of exposure, at which 
point, RNA-sequencing revealed that 88% of genes were downregulated. Immune 
response associated genes were upregulated in the triptolide-treated larvae including 
nitric oxide synthase (NOS). Inhibition of NOS increased mortality. Triptolide 
induces hepatotoxicity in zebrafish larvae. This represents a new model of drug-
induced liver injury that complements rodents. RNA sequencing, guided by time-
lapse microscopy, revealed early down regulation of genes consistent with previous 
in vitro studies, and facilitated the discovery of mechanistic inflammatory pathways. 
 
Key words:  Triptolide, hepatotoxicity, zebrafish, microRNA-122, imaging, nitric 
oxide synthase  
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Introduction 
Traditional Chinese Medicines (TCMs), including herbal drugs, have been used for 
thousands of years (Zhang et al., 2012). Currently, TCMs are used around the world 
with 70-95% of the population in certain developing countries relying on it for their 
primary medical care (Parveen et al., 2015;  Robinson and Zhang, 2011). In the 
United States, in 2004, around 1 in 5 adults reported taking a herbal product during 
the past 12 months (Barnes et al., 2004). Despite this high global use of TCM, 
evidence for efficacy is limited (Bent, 2008;  Parveen, Parveen, Parveen and Ahmad, 
2015). On the other hand, some TCMs clearly cause toxicity (Bunchorntavakul and 
Reddy, 2013;  Teschke et al., 2012). As there is little evidence of efficacy, it is 
important to understand safety/toxicity, in order to protect users from unacceptable 
harms.  
An archetypal example of a medicinal plant with a long history of use in TCM is 
Tripterygium wilfordii Hook F, also known as “thunder duke vine” (Kupchan et al., 
1972). Its major active ingredient is triptolide (TP), a diterpene triepoxide. TP has 
been reported to have multiple pharmacological activities, including neuroprotective, 
anti-inflammatory and contraceptive effects (Chen, 2001;  Liu, 2011;  Zheng et al., 
2013;  Ziaei and Halaby, 2016). Unfortunately, the relatively high incidence of 
toxicity, predominately to the liver, and a narrow therapeutic window, has limited the 
clinical development of TP (Li et al., 2014). A synthetic pro-drug of TP, F60008, has 
entered phase 1 clinical trials in patients with advanced solid tumours. However, out 
of 20 study participants, two died. One subject died without clear cause and the other 
most likely died from neutropenic sepsis. Further development of F60008 was 
stopped due to these two deaths and marked variability in its pharmacokinetics 
(Kitzen et al., 2009).  
TP is extensively metabolized, with less than 1% of a single dose being recovered in 
bile, urine or faeces within 48 hours (Shao et al., 2007). After administration of TP to 
rats, its concentration was at least 3 fold higher in liver compared to the plasma, 
kidney, lung, spleen or testicular concentration. This is consistent with unequal tissue 
distribution (Xue et al., 2012). In rats, the primary phase I metabolic pathway of TP 
is hydroxylation into mono-hydroxylated triptolides that can subsequently undergo 
phase II metabolism into glucuronides and sulfates (Du et al., 2014;  Li et al., 2008). 
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CYP3A was identified to be primarily responsible for hydroxylation and 
dexamethasone, a CYP3A inducer, increased TP metabolism in rat liver microsomes 
(Ye et al., 2010) and reduced TP-induced hepatotoxic effects (Ye, Li, Yan, Mao, Cai, 
Xu and Yang, 2010). Conversely, a single dose of TP that caused only mild toxicity 
in wild-type mice resulted in severe toxicity and death in cytochrome P450 gene 
deleted mice (Xue et al., 2011). These findings suggest that TP itself is toxic (not 
dependent on metabolism) and the higher degree of toxicity in the liver may be due 
to a higher TP distribution to this organ.  
TP is a reactive electrophile containing three epoxide groups that can bind to cellular 
macromolecules (Attia, 2010). It has been reported that TP can covalently bind to a 
subunit of the transcription factor II human complex (TFIIH) and cause inhibition of 
its DNA-dependent ATPase activity, which leads to the inhibition of RNA 
polymerase II mediated transcription (Titov et al., 2011). Another group confirmed 
that TP inhibited total RNA and mRNA de novo synthesis. Up to 98% of genes were 
down regulated in a human non-small cell lung cancer line after exposure to TP. TP 
also depleted RPB1, the main RNA polymerase II subunit. These in vitro data 
suggest that inhibition of RNA synthesis may explain the pharmacology and 
toxicology of TP (Vispe et al., 2009).  
In order to better understand drug-induced liver injury (DILI), new tools and models 
are needed. Zebrafish are a promising animal model for studying DILI with many 
advantages over rodents (Vliegenthart et al., 2014b). Advantages include convenient 
drug delivery, high fecundity, lower financial costs, optical clarity of larvae allowing 
real-time imaging of toxicity and suitability for high-throughput screening that is not 
possible with other vertebrate systems (Lieschke and Currie, 2007;  McGrath and Li, 
2008;  Zon and Peterson, 2005). Recently, we have established a DILI model in 
zebrafish using paracetamol as the toxic agent (Vliegenthart et al., 2014a). The main 
difference between the mammalian and zebrafish liver is the structural organization 
of the liver tissue. Instead of having the large bile ducts, portal veins and hepatic 
arteries organised in portal tracts, these are randomly allocated throughout the liver 
parenchyma in the zebrafish. The tri-lobed liver of the zebrafish is similar to other 
mammals with regard to biological function. This includes processing of lipids, 
vitamins, proteins, carbohydrates and the synthesis of serum proteins (Menke et al., 
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2011). The metabolic properties of zebrafish regarding xenobiotics, including drugs, 
also have many similarities with mammals (Vliegenthart et al., 2014b). 
 
In this study we applied novel imaging tools to characterize a new model of DILI due 
to TP in zebrafish larvae. We performed histological examination, selective plane 
illumination microscopy (SPIM) and time-lapse imaging by 2D microscopy to 
characterise the time course of liver injury. The transcriptional changes induced by 
TP were investigated by RNA-sequencing. The results were consistent with mRNA 
synthesis inhibition and identified nitric oxide production as a protective pathway in 
the injury pathogenesis.  
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Materials and Methods 
Fish lines and husbandry 
Experiments were conducted in accordance with the United Kingdom Animals 
(Scientific Procedures) Act 1986 in a United Kingdom Home Office-approved 
establishment. Zebrafish (Danio rerio) were maintained at 28.50C, as previously 
described by Westerfield (Westerfield, 2007). Established lines used were WIK and 
Tg(-2.8lfabp:GFP)as3 (Her et al., 2003), where GFP is green fluorescent protein. 
Chemical exposure 
The wild-type WIK line was used for all experiments apart from imaging. Unless 
otherwise stated larvae were maintained at 28.5°C in 50mL conditioned water (CW). 
Larvae were exposed to TP (National Institutes for Food and Drug Control, China, 
>98% pure) dissolved in CW at concentrations described in the results section. For 
the experiments testing the effect of TP on survival, 30 larvae were treated per 50mL 
dish for 48 hours (3-5dpf). The concentrations tested were 0 µM (3 dishes), 0.8 µM 
(3 dishes), 1.0 µM (3 dishes), 1.2 µM (3 dishes), 1.4 µM (2 dishes), 1.6 µM (2 
dishes) and 2 µM (2 dishes). For the experiments testing the effect of TP on copies of 
microRNA-122 (miR-122) per larvae, 30 larvae were treated per 50mL dish for 48 
hours (3-5dpf). The concentrations tested were 0 µM (3 dishes), 0.2 µM (3 dishes), 
0.4 µM (3 dishes) and 0.8 µM (3 dishes). For the effect of TP on histology 30 larvae 
were treated per 50mL dish up to 48 hours (3-5dpf). The concentrations tested were 0 
µM (3 dishes), 0.2 µM (3 dishes), 0.4 µM (3 dishes) and 0.8 µM (3 dishes), the 
number of fish of which successful histology scoring could be obtained per treatment 
are given in the results. For all imaging experiments larvae were treated for 48 hours 
(3-5dpf) with a concentration of 0, 0.4, 0.8, 1.2 or 1.6 µM in agarose conditions as 
indicated in the methods of each technique. For the sequencing experiment 5dpf 
larvae (N=30) were treated per 50mL dish for 6 hours with a TP concentration of 0 
µM (8 dishes) or 1.6 µM (8 dishes). For the NOS inhibitor studies 3dpf larvae 
(N=30) were treated per 50mL dish for 24 hours. With either TP concentration of 
0µM, 1.0 µM, or 1.6 µM with or without NOS inhibitor. 
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Experiments determining the effect of nitric oxide synthase inhibition on TP were 
blinded such that the investigator scoring larval mortality did not know the treatment 
groups. When necessary, larvae were anaesthetised with MS-222 (tricaine 
methanesulfonate - 40 μg ml−1) dissolved in CW. Mortality was assessed in a blinded 
fashion with no response to stimuli as the measured endpoint. 
For adult zebrafish experiments 6 fish (3 treatment and 3 control) aged 12 months 
were used. Fish were exposed for 10 hours to triptolide (1.6 µM in conditioned 
water) or conditioned water alone. Then fish were fixed for histopathology. A 
veterinary pathologist, who was blinded to treatment allocation, assessed the liver 
sections.  
Histology 
Larvae were submerged in 10% formalin and left to fix for at least 24 hours at 4°C 
before processing. Larvae were prepared for histology as described by Sabaliauskas 
et al. (Sabaliauskas et al., 2006) resulting in agarose blocks containing zebrafish 
larvae. The agarose blocks were then embedded in paraffin blocks using a Thermo 
Electron Excelsior tissue processor (Thermo, UK). This was achieved by serial 
immersion in the following: 70% ethanol (1h), 90% ethanol (1h), absolute ethanol 
(1h x4), xylene (1h x2), wax (1.3h x 3). The blocks were sectioned at 4μm and 
placed on a glass slide that was then incubated at 52℃ for at least an hour. Tissue 
sections were then dewaxed and rehydrated using an autostainer (ST5010 
Autostainer XL, Leica Microsystems, UK) through three x 5min cycles of xylene, 
two x 3min cycles of 100% ethanol, one x 2min cycles of 95% ethanol and one x 
5min wash of distilled H2O (dH2O) and were then left to stand in dH2O until the next 
procedure. After rehydration, for haematoxylin and eosin (H&E), slides were stained 
in the same autostainer by sequential immersion in haematoxylin (5min), dH2O 
(5min), Scott’s tap water (2min), dH2O (5min), and eosin (3min). Stained slides were 
then dehydrated (dH2O wash (45s), 70% ethanol (30s), 95% ethanol (30s x2), 100% 
ethanol (1min x2), ethanol/xylene (1min), and xylene (1min x3)), and cover slipped 
using Pertex Mounting Medium (CellPath Ltd, UK). Fish were sectioned sagittally 
along the midline to facilitate examination of the liver.  
Histology was scored by an accredited (DiplECVP) veterinary pathologist (author 
JDP), who was blinded to the treatment groups. A semi-quantitative scoring system 
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was used to grade the pathological changes noted in these livers. Briefly, each feature 
of interest was ranked as follows: 0=absent; 1=1-25% of total area examined; 2=26-
75%; 3=76-100%. The features of interest were hepatocyte vacuolation, hepatocyte 
swelling, hepatocyte disarray, and oncotic necrosis. 
 
Imaging 
Fluorescent microscopy and selective plane illumination microscopy (SPIM) were 
performed with fluorescent liver reporter zebrafish Tg(−2.8fabp10:GFP)as3. Time-
lapse recording of zebrafish embryos was performed using an EVOS FL Cell 
Imaging System (Life Science, USA). Up to 5 larvae (72 days post-fertilisation 
(dpf)) were oriented in 700 μL agar (0.75%, wt/vol) containing 84 mg/L MS-222. 
Once the agar was set, 750 μL of CW with TP (concentration as indicated in results) 
and MS-122 (84 mg/L) was added on top of the agar and the time-lapse recording 
was started. The incubator was set to 27°C and pictures were taken hourly. ImageJ 
software (National Institutes of Health, Bethesda, USA) was used to determine 
maximum GFP intensity in each image. 
Selective Plane Illumination Microscopy (SPIM)  
A custom built SPIM system was used. This was based on the design previously 
published (Taylor et al., 2012). A Vortran VersaLase multiple wavelength system 
with 3 laser diodes (405nm, 488nm and 561nm) was coupled to the SPIM 
illumination arm using a single mode optical fibre. The appropriate laser power was 
set using Stradus VersaLase software, and a power meter (Thorlabs Inc, PM100D) 
was used to verify collimated beam power. The resulting beam was then focused 
onto the sample (10X 0.3 NA Nikon CFI Fluor water dipping objective) to produce a 
light sheet. Imaging of the sample was through a 12X 0.8NA Nikon CFI LWD Plan 
Fluor water dipping objective (N16LWD-PF) and the resulting beam sent to three 
QI-Click Mono CCD cameras (Q-Imaging Inc) via a series of dichoric filters CFP 
Em/BW 479/40 nm (MF479-40), GFP Em/BW 525/39 nm (MF525-39), TxRed 
Em/BW 630/69 nm (MF630-60) (Thorlabs Inc). The entire system was controlled 
through a written interface operating in the Python language.  
 
 9 
SPIM Image Acquisition and Analysis 
Fish were age matched and selected from the same batch of eggs. Images were 
acquired from the same orientation at 1.5µm intervals, at 3, 4 and 5dpf. A Matlab 
script was written to determine liver volume. Files were automatically segmented 
based on signal intensity (kept consistent across groups), a mask applied and the 
signal intensity and area of the mask calculated. This was summed over the volume 
of the stack and the pixel size used to calculate the volume. Rendering of 3D SPIM 
image datasets was performed using Amira 3D for Life Sciences v5.5.0; imported 
fluorescence images were kept consistent throughout time points and treatments and 
an isosurface was created for liver volume and structure visualisation.   
RNA extraction 
Total RNA was extracted from pooled zebrafish larvae (30 larvae per sample) for 
qPCR and RNA-sequencing. Larvae were fixed in Qiazol after which they were 
disrupted using a tissue disruptor. Subsequently total RNA was extracted using the 
miRNeasy mini kit (Qiagen, Venlo, Netherlands) eluted in 30 μl RNAse free water.  
PCR analysis 
For microRNAs 1 μg of total RNA from pooled larvae was reverse transcribed into 
cDNA using the miScript II RT Kit (Qiagen, Venlo, Netherlands) following 
manufacturer’s instructions. The synthesized cDNA was ten-fold diluted and used for 
cDNA template in combination with the miScript SYBR Green PCR Kit (Qiagen, 
Venlo, Netherlands) using the specific miScript assays (Qiagen, Venlo, Netherlands). 
Absolute quantification of microRNA was achieved by generating a standard curve 
using synthetic target. Standard curves were generated by reverse transcribing known 
concentrations of miScript microRNA mimics (Qiagen, Venlo, The Netherlands) in 
0.1X TE buffer spiked with 10 ng/μl Poly-C (Sigma-Aldirch, Gillingham, UK). The 
resulting cDNA was measured using serial dilutions on 3 different plates to 
demonstrate minimal variability. The final concentration was divided by the number 
of larvae used within the pooled sample to obtain the average microRNA copy 
number per larva.  
For mRNA, 1 μg of total RNA from pooled larvae was reverse transcribed into 
cDNA using the QuantiTect Reverse Transcription Kit (Qiagen, Venlo, Netherlands) 
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following manufacturer’s instructions. The synthesized cDNA was ten-fold diluted 
and used for cDNA template in combination with the QuantiTect SYBR Green PCR 
Kit (Qiagen, Venlo, Netherlands) using the specific QuantiTect primer assays 
(Qiagen, Venlo, Netherlands). Real-time PCR was performed on a Light Cycler 480 
(Roche, Basel, Switzerland) using the recommended cycling parameters. 
RNA-sequencing 
For this experiment 5dpf wild type (WIK) zebrafish were used and exposed to 
triptolide or vehicle control (DMSO). Each treatment group had 8 biological 
replicates, each replicate consisted of 30 pooled fish. For quality control RIN values 
were measured on the Agilent Technologies 2100 Bioanalyzer using the Eukaryote 
Total RNA Nano kit. All samples had a RIN of > 9.5. RNA Sequencing was 
performed using the Illumina® NextSeq® 550 system with 2x75bp paired end runs. 
RNA libraries were prepared for each sample with the Truseq® Stranded Total RNA 
Sample Prep LT Kit. Libraries were checked for size, purity and concentration with a 
high sensitivity DNA chip on the Agilent Technologies 2100 Bioanalyzer. 
The raw sequences were quality assessed using FASTQC. Based on the output of the 
FASTQC analysis, the raw fastq sequences required no further pre-processing to 
remove contaminating primers and sequences were not collapsed within each sample.  
The most recent Ensembl release (Rel84, March 2016) of zebrafish transcript 
sequences was downloaded using BioMart (Smedley et al., 2015). Alignments (end-
to-end, very-sensitive settings) to the reference set were performed using bowtie2 
(Langmead and Salzberg, 2012). A requirement for concordant read pair mapping 
was applied, and all other alignments discarded. Alignments were stored in indexed 
BAM files. Raw "tag counts" (i.e. sequences aligning) per sample were normalised to 
the sample with the lowest number of alignments, and counts converted to log2; 
"abundance normalised" data were not further quantile normalised for linear model 
fitting purposes.  
Gene ontology enrichment analysis 
Gene ontology (GO) and Kyoto encyclopaedia of genes and genomes (KEGG) 
enrichment analysis for over or under representation of GO terms or KEGG 
pathways were done by using a hypergeometric test for likelihood due to chance, 
reporting anything more significant than the cut-off P-value of 0.001. 
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Statistical analysis 
Statistical differences in copies of microRNA per fish, histology scores, liver 
volume, difference in gene expression obtained by PCR and death rate were 
performed using Graphpad Prism (GraphPad Software, La Jolla California, USA). 
For RNA-seq pairwise comparisons of the two sample groups were performed on the 
normalised tag counts using linear modelling with the Bioconductor limma package 
(Ritchie et al., 2015). Nominal statistical significance was set at P < 0.05, unless an 





Triptolide-induced liver toxicity in zebrafish larvae 
First, we determined whether TP induced liver injury in zebrafish. Larvae were 
exposed to TP for 48 hours from 3 to 5 dpf. This exposure caused mortality with a 
dose-response relationship (Figure 1A). Histological examination of larvae revealed 
injury specifically to the liver. There was a dose response relationship between TP 
and hepatocyte vacuolation, oncotic necrosis and hepatocyte disarray subsequent to 
cell death (Figures 1C-D & Supplementary Figure 1). These histological features 
were diffusely present throughout the liver tissue. Out of 38 zebrafish larvae treated 
with TP (0.8μM) only 3 did not have histological evidence of liver injury. There was 
no discernible histological injury to other organs. To confirm that TP is hepatotoxic 
in adult zebrafish we exposed fish aged 12 months to TP (1.6 µM) or vehicle control 
for 10 hours. There was hepatocyte necrosis in TP exposed adult zebrafish 
(Supplementary Figure 2). 
 
Our previous work has demonstrated that zebrafish release the liver specific 
microRNA, miR-122, from injured hepatocytes (Vliegenthart, Starkey Lewis, 
Tucker, Del Pozo, Rider, Antoine, Dubost, Westphal, Moulin, Bailey, Moggs, 
Goldring, Park and Dear, 2014a). TP exposure resulted in a significant decrease in 
the number of copies of miR-122 per larva (Figure 1B). Building on these data, 
SPIM was used to quantify liver volume in the zebrafish line Tg(-2.8lfabp:GFP)as3 
(Figure 2). Images were captured for vehicle control (N=10) and TP-treated fish 
(N=6) at 5 dpf after 54 hours of drug/vehicle exposure. Control livers increased in 
size from 3 to 5 dpf and, at 5 dpf, had a higher mean liver volume of 85.4 (SD 0.6) 
mm3 compared with no fluorescent signal for TP, P = 0.0002 (Figure 2). 
 
Onset of TP -induced hepatotoxicity could be determined by Time-lapse microscopy 
Time-lapse microscopy was used to characterise the time course of injury and 
identify an early time point for RNA sequencing. The fish line Tg(-2.8lfabp:GFP)as3 
enabled quantification of the fluorescence intensity of the liver during TP exposure 
(Figure 3A). After 6 hours, the fluorescent intensity of TP-treated fish started to 
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decrease compared to control fish, suggesting that this time may represent the onset 
of hepatocyte injury (Figure 3B). Histological examination supported the data from 
time-lapse microscopy. There was statistically significant hepatocyte vacuolation and 
swelling 6 hours post-exposure to TP (Figure 3C). 
 
RNA-seq revealed pathways involved in triptolide exposure 
RNA-seq was performed on 5 dpf larvae after exposure to TP for 6 hours, an early 
time-point identified by microscopy and histology as being before the onset of 
fulminant hepatocyte death. A total of 16 sequencing experiments were performed 
(control N=8 and treatment N=8). Each replicate consisted of 30 pooled larvae, 
therefore 480 larvae were included in total. 
A total of 57,264 transcripts were identified of which 16,926 were statistically 
significantly differentially expressed with an adjusted P-value of 0.01 or less.  Of the 
differentially expressed transcripts, 1995 were upregulated and 14,931 
downregulated. Of these significant transcripts, 1433 (12%) were more than 2-fold 
upregulated and 4675 (88%) were more than 2-fold downregulated (Figure 4A). 
Unsupervised clustering separated the control group from the TP exposed group 
(Figure 4B). The top 10 most up- and down-regulated genes based on fold change are 
presented in table 1. 
Gene ontology (GO) enrichment analysis revealed 32 significantly enriched terms in 
biological process, 16 enriched terms in cellular component and 17 enriched terms in 
molecular function (Supplementary Table 1). The most significant enriched GO 
terms were translation (P = 4.35x10-51) in the biological process ontology, structure 
constituent of ribosome (P = 3.13x10-64) in the molecular function ontology and 
ribosome (P = 9.09x10-61) in the cellular component ontology. KEGG pathway 
analysis revealed 6 upregulated pathways of which ribosome (P = 1.87x10-72) and 
cardiac muscle (P = 8.01x10-7) pathways were the most significant. Another 18 
downregulated KEGG pathways were identified, of which spliceosome (P = 4.19x10-
5) and notch signaling (P = 0.0008) were the most significant (Table 2). 
Multiple inflammation associated genes were upregulated and validated by qPCR. 
Nitric oxide synthase 2b (NOS2b) was 4.0 fold increased (P<0.0001) in the TP 
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treated fish compared to control along with other genes involved in an inflammatory 
response including TNF-α (32.9 fold, P<0.0001), IL-1b (7.6 fold, P < 0.0001), IL-6 
(4.0 fold, P < 0.0001), IL-10 (2.3 fold, P = 0.01) and CCR2 (5.6 fold, P < 0.0001) 
(Figure 5A-E). 
To further validate the sequencing results, 14 transcripts chosen from differentially 
regulated pathways and genes involved in the immune response were measured by 
qPCR. The fold change obtained by RNA-sequencing correlated with the fold change 
measured by qPCR with a Pearson’s r of 0.93, P < 0.0001 (Figure 5G). 
Nitric oxide synthase is involved in triptolide toxicity 
Finally, in order to explore a mechanistic role for NOS2b in TP-induced toxicity, the 
effect of the non-selective nitric oxide synthase (NOS) inhibitor L-NAME and the 
selective inducible NOS (iNOS) inhibitor aminoguanidine was determined. Neither 
compound caused any effect on zebrafish survival when applied alone. Co-treatment 
with TP and either L-NAME or aminoguanidine significantly increased larval 
mortality (Figure 6). 
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Discussion 
TP, the primary active compound in Tripterygium wilfordii, has a long history of use 
because of its purported neuroprotective, anti-inflammatory and contraceptive effects 
(Chen, 2001;  Liu, 2011;  Zheng, Zhang and Wang, 2013;  Ziaei and Halaby, 2016). 
Due to its high incidence of hepatotoxicity, its utility in clinical medicine is limited 
(Li, Jiang and Zhang, 2014). 
Zebrafish larvae are as proliferative and easily accessible as in vitro cell culture 
models while providing in vivo complexity comparable to larger vertebrate models 
(Vliegenthart, Tucker, Del Pozo and Dear, 2014b). In addition, zebrafish have 
substantially lower cost and the larvae are optically clear so are suitable for high 
throughput screening (Lieschke and Currie, 2007;  McGrath and Li, 2008;  Zon and 
Peterson, 2005). This unique combination of characteristics makes the zebrafish an 
attractive model species for studying DILI. 
To investigate whether zebrafish larvae could be used as a tool to study TP-induced 
DILI, larvae were exposed to increasing concentrations of TP. Larvae died with a 
dose-response relationship in the micromolar range and histological examination 
revealed that TP induced highly reproducible hepatic necrosis without affecting other 
organs. The plasma concentration of triptolide in humans (Cmax) is reported to be 
around 0.15 – 0.4μM.(Yao et al., 2006) In rats, a plasma concentration of 1.5μM has 
been reported to be associated with histological liver cell necrosis.(Shao, Wang, Xie, 
Zhu, Sun and A, 2007) These human and rodent studies are consistent with the 
concentrations that produce hepatotoxicity in our zebrafish larvae, which supports 
the translational relevance of our fish model. Ours is the first study confirming that 
TP-induced hepatotoxicity can be modelled in zebrafish larvae. The administration of 
TP is straightforward and the resultant liver injury is reproducible and tractable. This 
is in contrast to paracetamol, an archetypal compound used to induce hepatocyte 
necrosis, which is variable with regard to histological liver injury in larvae and 
requires millimolar water concentrations for an effect (Vliegenthart, Starkey Lewis, 
Tucker, Del Pozo, Rider, Antoine, Dubost, Westphal, Moulin, Bailey, Moggs, 
Goldring, Park and Dear, 2014a). The enhanced ability of TP to induce liver toxicity 
is likely due to a combination of its pharmacokinetics and its ability to induce injury 
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without need for metabolism. We believe that the data from these studies with 
triptolide confirm the benefits of zebrafish as a model organism to screen for DILI. 
 
We previously reported that miR-122 increases in the circulation of patients with 
DILI with superior sensitivity and specificity compared to the currently used clinical 
biomarker alanine aminotransferase (ALT) (Vliegenthart et al., 2015). Using in situ 
hybridisation, we reported that miR-122 is specifically expressed in the zebrafish 
liver and is released into the circulation with DILI. As in humans, in zebrafish miR-
122 can be used as a more sensitive and specific biomarker than ALT (Vliegenthart, 
Starkey Lewis, Tucker, Del Pozo, Rider, Antoine, Dubost, Westphal, Moulin, Bailey, 
Moggs, Goldring, Park and Dear, 2014a). The present study reports that the number 
of copies miR-122 per zebrafish larvae is decreased with TP-induced DILI, 
indicating that miR-122 can also be utilised as a biomarker for DILI in whole 
zebrafish larvae. 
By exploiting the optical transparency of the zebrafish larvae in combination with the 
liver specific fluorescent reporter transgenic fish line, Tg(-2.8lfabp:GFP)as3, we were 
able to capture 3D images by using SPIM of the fish liver during TP-induced DILI. 
This confirmed that the liver volume (as reported by fluorescence) is substantially 
reduced with injury. Because of low bleaching, high acquisition speed and high 
depth penetration, SPIM is well suited for imaging intact fully functioning zebrafish 
larvae. These characteristics make SPIM suited for time-lapse imaging of biological 
processes over long periods of time (Huisken and Stainier, 2009;  Weber and 
Huisken, 2011). This is potentially valuable in studies of development (Kaufmann et 
al., 2012), functional imaging of multiple brain regions (Panier et al., 2013) and 
heart function (Mickoleit et al., 2014). This is the first study confirming that SPIM 
has sufficient depth penetration to image the zebrafish liver from 3 to 5 dpf. SPIM is 
a tool that could be further exploited in the field of studying liver development and 
injury in zebrafish. 
Fluorescent time-lapse microscopy allowed us to characterise the time course of 
injury and identified an early time point for RNA sequencing, which demonstrated 
that TP has similar effects on RNA transcription as in vitro models. TP covalently 
binds to a subunit of TFIIH that leads to inhibition of RNA polymerase II 
 17 
transcription initiation (Titov, Gilman, He, Bhat, Low, Dang, Smeaton, Demain, 
Miller, Kugel, Goodrich and Liu, 2011). RNA expression studies using microarrays 
have shown that both total RNA and mRNA de novo synthesis were lowered in a TP 
treated cancer cell line compared to control. Among the down regulated genes was 
RPB1, the main RNA polymerase II subunit (Vispe, DeVries, Creancier, Besse, 
Breand, Hobson, Svejstrup, Annereau, Cussac, Dumontet, Guilbaud, Barret and 
Bailly, 2009). These in vitro data indicate that inhibition of RNA synthesis could 
explain TP hepatotoxicity. In our study, the RNA-sequencing data also demonstrated 
that TP leads to a general downregulation of gene expression, with 88% being 
downregulated in TP treated larvae compared to vehicle control. Notably, this effect 
on gene expression was measured at an early time-point before fulminant hepatic 
necrosis had started. Therefore, we propose that inhibition of RNA synthesis may be 
the mechanism that causes liver toxicity. In line with this hypothesis, gene ontology 
analysis revealed that, in general, GO terms involved in RNA transcription, such as 
nucleic acid metabolic processes, transcription, regulation of gene expression and 
RNA biosynthesis, were significantly reduced. Also KEGG pathways involved in 
RNA transcription went down, including spliceosome and RNA polymerase. GO 
terms in biological processes involved in protein synthesis - such as translation, 
cellular protein metabolic process and protein metabolic process - were increased. 
We speculate that upregulation of processes involved in protein synthesis might be a 
response to lower template mRNA; an attempt by the organism to maintain 
equilibrium. 
Other upregulated GO terms were involved in the immune response, defense 
response, response to other organisms, immune system process, response to viruses 
and response to lipopolysaccharide. PCR confirmed that multiple inflammatory 
markers were increased in the TP-treated fish compared to control, with the cytokine 
TNF-α being increased 32.9 fold. This suggests that, besides a general 
downregulation of transcription, inflammation potentially has a role in TP-induced 
DILI. In DILI, the liver injury caused by the drug or its metabolites is often an 
initiating event for an immune response which determines the extent of liver injury 
(Ju and Reilly, 2012). Liver necrosis with inflammatory cell infiltration has been 
reported in TP-induced hepatotoxicity (Fu et al., 2011) and Th17/Treg imbalance has 
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been associated with the exacerbation of liver inflammation in TP-induced 
hepatotoxicity (Wang et al., 2014).  
Three NOS isoforms have been identified in humans: a neuronal NOS1, an inducible 
NOS2 and an endothelial NOS3 enzyme. One NOS1 and two NOS2 (NOS2A and 
NOS2B) genes have been reported to be present in the zebrafish genome. Both 
liposaccharide stimulation and tail cut injury induces the NOS2 isoforms in zebrafish 
(Lepiller et al., 2009). Knockdown of NOS2b reduced leukocyte attraction to ventral 
fin wounds (Wittmann et al., 2015). These data indicate that NOS2b is involved in 
inflammation. Our results suggest that inhibition of NOS2b in our model increased 
TP toxicity. This is consistent with a protective role for NOS2b. The protective role 
of NOS has also been reported in a model of paracetamol liver injury in mice 
(Hinson et al., 2002). Various other models have also demonstrated that NO protects 
the liver against oxidative stress induced by ethanol, (Nanji et al., 1995), H2O2 (Kim 
et al., 1995) and CCl4 (Zhu and Fung, 2000).  
In conclusion, TP induces hepatic necrosis in zebrafish larvae and inhibits RNA 
synthesis in line with previous published data. The hepatocyte necrosis induces an 
inflammatory response, which partially determines outcome. TP is a model 
compound for inducing DILI in zebrafish. Zebrafish have experimental properties 




Supplementary Data description 
Supplementary Figure 1. Effect of triptolide on zebrafish larvae after 48 hours (3-
5dpf) exposure. Magnified histological images at x400 of zebrafish larvae liver after 
water exposure to triptolide at the concentrations indicated. Three representative fish 
are presented for each dose. Note the presence of dose dependent increase in 
hepatocyte vacuolation (A), necrosis (with nuclei breaking down (B) and karyolysis 
(C)) and the presence of disarray (red lines). The latter two features are absent from 
the control group. Scale bar = 20µm. 
Supplementary Figure 2. Histological images of adult zebrafish after exposure to 
triptolide (1.6 μM) for 10 hours. (A) Subgross view. Liver is indicated by the red 
arrow. The area displaying hepatic necrosis is indicated by the circle. (B) Arrows 
denote lesions consistent with hepatic necrosis after triptolide exposure. (C) Control 
adult zebrafish after exposure to vehicle control. Normal liver, with no areas of 
necrosis. 
Supplementary Table 1. Significantly enriched GO terms in response to triptolide in 
zebrafish larvae (with P < 0.001 cutoff). 
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Figure 1. Effect of triptolide on zebrafish larvae after 48 hours (3-5dpf) exposure. 
(A) Survival of zebrafish larvae after TP exposure at the concentrations indicated. 
Each dot represents mean mortality of 30 larvae. (B) Copies of miR-122 per larva 
after 48 hours of exposure at the concentrations indicated (from 3-5 dpf). (C) 
Histological images of zebrafish larvae after exposures of the TP concentrations 
indicated. 3 representative fish are presented per TP dose. (D) Box plots (min to 
max) of histology scores for hepatocyte vacuolation, hepatocyte disarray and oncotic 
necrosis after TP exposure at the concentrations indicated (control N=12, 0.4 μM 
N=20, 0.6 μM  =18 and 0.8 μM N=18).  
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Figure 2. 3D images of livers captured by SPIM. 3dpf zebrafish larvae were exposed 
to 1.6μM triptolide or vehicle control. After 6 hours of exposure the first image was 
captured and subsequent images were taken at 4 and 5 dpf. 
 
  
























Figure 3. Time-course of triptolide-induced liver injury. (A) Fluorescent images of 
control and TP exposed fish obtained during time-lapse experiments at the indicated 
time from start of exposure. (B) Relative fold change of fluorescent intensity from 
baseline during TP exposure with the doses indicated. (N=15 larvae for each dose) 
(C) Box plots (min to max) of histology scores of hepatocyte vacuolation, hepatocyte 
disarray and hepatocyte swelling during exposure to TP (0.8 μM) for the time 
durations indicated (control N=17, 2h N=10, 6h N=9, 24h N=16, 48 h N=20).  
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Figure 4. RNA-sequencing of zebrafish larvae exposed to triptolide. RNA-seq was 
performed on 5 dpf larvae after exposure to triptolide (1.6μM) for 6 hours. A total of 
16 sequencing experiments were performed (control N=8 and treatment N=8). Each 
individual experiment consisted of 30 pooled larvae, therefore 480 larvae were 
included in total. (A) Proportion of down-regulated and up-regulated genes. (B) 
Volcano plot of adjusted p value versus log2 fold change of triptolide treated fish 
versus control. (C) Clustered heatmap with the top 200 most variable genes.  
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Figure 5. Inflammatory gene expression in zebrafish larvae treated with triptolide 
(1.6μM) for 6 hours. A-F, Relative gene expression of various inflammatory 
associated genes measured by PCR. (N=8 pooled sample of 30 larvae for each group, 
each dot represents one pooled sample and line represents mean). G, correlation 
between fold change of 14 genes obtained by RNA-seq versus PCR. All genes 



















































































































































































































Figure 6. Effect on mortality of co-treatment with (A) L-NAME or (B) 
aminoguanidine. 3dpf old larvae were exposed for 24h to triptolide and/or the NOS 
inhibitor indicated. Each dose was tested on at least 60 larvae. Mortality was 
assessed blinded to the treatment groups. Fisher’s exact test was used for statistical 





















































Table 1. Top 10 most up regulated and down regulated genes. RNA-sequencing of 
zebrafish larvae exposed to triptolide (1.6μM) for 6 hours compared to vehicle 
control.  
 
ID Symbol Fold change 
Adjusted 
P value 
ENSDART00000128835 NA 26.2 2.39*10-8 
ENSDART00000154981 wu:fi47d06 21.7 1.80*10-8 
ENSDART00000103858 LOC557782 20.3 2.29*10-8 
ENSDART00000025847 TNF-α 19.3 2.24*10-8 
ENSDART00000037557 admp 19.0 3.16*10-7 
ENSDART00000062715 NA 17.4 3.17*10-06 
ENSDART00000157090 LOC557782 17.0 1.30*10-7 
ENSDART00000129697 ifnphi3 16.1 1.97*10-7 
ENSDART00000146927 LOC100330560 14.8 3.74*10-10 
ENSDART00000019296 gdf9 14.6 3.33*10-09 
ENSDART00000145976 hsp47 -6.8 1.28*10-05 
ENSDART00000138941 shox2 -6.9 9.08*10-06 
ENSDART00000048182 v2rh32 -7.0 1.07*10-06 
ENSDART00000134215 grik1a -7.0 3.09*10-05 
ENSDART00000169378 mmp13a -7.0 0.0001 
ENSDART00000101289 zgc:153395 -7.2 0.0002 
ENSDART00000054588 spon2b -7.5 0.0003 
ENSDART00000132490 NA -8.2 1.65*10-09 
ENSDART00000082333 LOC792903 -8.5 1.22*10-8 
ENSDART00000078154 npas4 -8.8 1.03*10-8 
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Table 2 KEGG pathways. RNA-sequencing of zebrafish larvae exposed to triptolide 
(1.6μM) for 6 hours compared to vehicle control. 
Up/Down (trip vs Ctrl) Pathway Description P-Value 
Up Ribosome 1.87E-86 
Up Cardiac muscle contraction 8.01E-07 
Up Oxidative phosphorylation 0.002544 
Up Steroid hormone biosynthesis 0.006209 
Down Spliceosome 4.19E-08 
Down Notch signaling pathway 0.000845 
Down Progesterone-mediated oocyte maturation 0.004103 
Down Ubiquitin mediated proteolysis 0.005622 






The purpose of the studies described in this chapter was to characterize TP induced 
toxicity in zebrafish larvae. Larvae died with a dose-response relationship in the 
micromolar range and histological examination revealed that TP-induced highly 
reproducible hepatic necrosis without affecting other organs. This is the first study 
confirming that TP-induced hepatotoxicity can be modelled in zebrafish larvae. The 
administration of TP is straightforward and the resultant liver injury is reproducible 
and tractable. This is in contrast to paracetamol, an archetypal compound used to 
induce hepatocyte necrosis, which is variable with regard to histological liver injury 
in larvae and requires millimolar water concentrations for an effect. The enhanced 
ability of TP to induce liver toxicity is likely due to a combination of its 
pharmacokinetics and its ability to induce injury without need for metabolism. It is 
proposed that the data from these studies with triptolide confirm the benefits of 
zebrafish as a model organism to screen for DILI. 
In previous chapters it was reported that upon DILI, miR-122-5p is released from the 
liver and increases in the circulation of humans and adult zebrafish. The present study 
reports that the number of copies miR-122-5p per zebrafish larva is decreased with 
TP-induced DILI, indicating that miR-122-5p can also be utilised as a biomarker for 
DILI in whole zebrafish larvae. 
By exploiting the optical transparency of the zebrafish larvae, in combination with 
the liver specific fluorescent reporter transgenic fish line, Tg(-2.8lfabp:GFP)as3, I 
captured 3D images by using SPIM of the fish liver. This confirmed that the liver 
volume was substantially reduced with injury. Fluorescent time-lapse microscopy 
allowed the characterisation of the time course of injury and identified an early time 
point for RNA sequencing, which demonstrated that TP has similar effects on RNA 
transcription as in vitro models (251). PCR confirmed that multiple inflammatory 
markers were increased in the TP treated fish compared to control, with the cytokine 
TNF-α being increased 32.9 fold. This suggests that besides a general down regulation 
of transcription, inflammation potentially has a role in TP-induced DILI. Various 
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models for inflammation indicate that the zebrafish nitric oxide synthase 2b (NOS2b) 
is involved in inflammation and has a protective role in the liver (252, 253). NOS2b 
was upregulated with TP induced toxicity and chemically blocking NOS2b increased 
TP toxicity. 
In conclusion, TP induces hepatic necrosis in zebrafish larvae and inhibits RNA 
synthesis in line with previous published data. The hepatocyte necrosis induces a 











Chapter 7: General Conclusions 
 
The studies presented in first part of this thesis aimed to identify the circulating 
miRNAs that are most sensitive at detecting paracetamol induced liver injury in 
humans. Subsequently the leading miRNA candidate was taken forward to further 
qualify in clinically-relevant scenarios.  
Circulating miR-122-5p was the most sensitive miRNA for detecting and predicting 
liver injury in patients after paracetamol overdose at first presentation at the 
hospital.  
In healthy volunteers, ethanol ingestion led to a significant but not clinically relevant 
rise in circulating miR-122-5p of 2.2 fold. The circulating miR-122-5p concentration 
was reduced in patients with ESRD but not in patients with CKD when comparing to 
healthy volunteers. Circulating miR-122-5p increased after dialysis to healthy levels. 
These conclusions need to be considered when interpreting liver injury using miR-
122-5p in patients with ESRD because a lower baseline concentration might conceal 
the signal. 
Furthermore, it was determined that the lead miRNA, miR-122-5p, measured in 
capillary blood obtained from a finger prick yielded sufficient miR-122-5p for robust 
quantification and faithfully reflected the concentration in venous blood and plasma. 
Capillary miR-122-5p reported paracetamol induced ALI with high sensitivity and 
specificity and a comparable dynamic range as observed in chapter 2. This leads to 
the conclusion that miR-122-5p measured in capillary blood obtained from a finger 
prick can be used as biomarker for DILI. 
Besides identifying a circulating miRNA that can be used as a sensitive biomarker for 
liver injury, the toxicokinetics of circulating paracetamol metabolites were explored 
to determine if they could be used to quantify the toxic burden and so further refine 
patient risk stratification.  
The results of chapter 4 show that in patients presenting at the hospital after 
paracetamol overdose, the relative fraction of toxic paracetamol metabolites formed 
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by P450 (CYP%) was higher in patients that subsequently developed liver injury. In 
these patients, the ratio of APAP-Cys and APAP-Sul (APAP-Cys/APAP-Sul) had the 
most sensitivity for predicting subsequent liver injury. This leads to the conclusion 
that paracetamol metabolites could further refine risk assessment at the front door 
and guide requirement for NAC treatment. 
In the second part of this thesis a new blood letting method was developed that 
allowed for the measurement of circulating miR-122-5p in adult zebrafish. 
Subsequently it was tested if circulating miR-122-5p is increased with paracetamol 
induced liver injury in zebrafish. In paracetamol exposed zebrafish, there was a clear, 
dose-response elevation in circulating miR-122-5p. The conclusions from this chapter 
adds zebrafish to the list of species that report hepatotoxicity by elevation in 
circulating miR-122-5p. 
The next aim was to develop a hepatotoxicity model in zebrafish larvae for which TP, 
a hepatotoxic compound popular in traditional medicine, was used. The 
administration of TP to zebrafish larvae induced highly reproducible liver injury. This 
indicates that TP could be used as a model compound to further develop tools for 






The findings of the studies in this thesis have raised further questions that need to be 
addressed.  
For novel markers for which new assays are being developed and validated, normal 
reference limits need to be determined. These reference limits need to be generated 
in healthy reference samples from which the lower 2.5th and upper 97.5th percentile 
cut points must be determined to define abnormality. Approximately 200 individuals 
is a reasonable sample size to obtain the lower 2.5th and upper 97.5th percentile cut 
points with high confidence per reference group (254). Results in chapter 3 indicated 
that ESRD patients on HD have a lower concentration of circulating miR-122-5p. For 
this reason, reference ranges should also be determined for patients with reduced 
renal function. When determining the reference range, samples should be measured 
by a validated assay complying with Good Clinical Laboratory practice standards 
(255). 
In chapter 2 and 4, it was reported that miR-122-5p and paracetamol metabolites 
were able to predict the onset of ALI determined by an ALT rise. Besides using these 
markers to determine who is at high risk for developing DILI, they could also be 
utilised to identify a low risk group who do not need treatment. This would improve 
patient care by reducing over treatment and it would reduce healthcare costs. The 
limitation of the studies that measured miR-122-5p at the front door as risk 
assessment for developing DILI is that each patient received NAC treatment (231). 
Some patients with a miR-122-5p concentration that is perceived as low risk could 
have developed DILI if no NAC treatment was given. A clinical study is needed to 
determine if miR-122-5p could be used to identify patients at low risk that do not 
need treatment. In this study I suggest that only patients that have a plasma 
paracetamol concentration within the nomograms “100 mg l-l” and the “200 mg l-l” 
line receive NAC if their miR-122-5p concentration indicates high risk for developing 
DILI. All other patients should receive placebo during which they are monitored for 
developing DILI and receive NAC if DILI occurs during placebo treatment. A power 
calculation using historical data on determining how many patients develop DILI with 
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an initial plasma paracetamol concentration within the nomograms “100 mg l-l” and 
the “200 mg l-l” line needs to determine how many patients would need to be 
included to test the hypothesis that miR-122-5p can be used to determine which 
patients require NAC treatment or not. The limitation of this study is that a point of 
care test needs to be available. 
It also needs to be assessed whether these markers are able to predict which patients 
will need a liver transplant to avoid death. In a previous report, circulating miR-122-
5p concentration, on the first day of patient admission, was 2 fold higher in patients 
reaching KCC compared to those who did not satisfy KCC, however this did not reach 
statistical significance (77). In order to test whether miR-122-5p and paracetamol 
metabolites fulfil the TBP attributes of quantitative relationship with disease severity 
and if they could distinguish benign and clinical relevant increase in ALT, studies need 
to be performed with a higher number of patients reaching serum ALT of ≥ 1000 IU/L 
and patients reaching Kings College Criteria (KCC) despite NAC treatment. In the 
studies performed in this thesis only a small number of patients reached an ALT of ≥ 
1000 IU/L and none reached KCC. Being able to stratify patients as early as possible 
with regard to clinical outcome would assist clinical management of paracetamol 
poisoning and improve the decision making with regard to liver transplantation. If 
these markers could predict severe DILI, they would also allow clinical trials of new 
therapeutics in a group enriched for people with a poor clinical outcome. 
Certain medications have been demonstrated to have an effect on specific circulating 
miRNA concentrations (256). Regular use of medications is common in patients with 
paracetamol overdose, predominantly benzodiazepines, antidepressants, 
neuroleptics, paracetamol, oral contraceptives, beta-agonists, opioid analgesic and 
anticonvulsants (257). Also, concomitant overdosing of other drugs than paracetamol 
is common of which benzodiazepines, opioid analgesics, acetylsalicylic acid and 
NSAIDs predominate (258). There are no data regarding the effect of these drug 
classes on miR-122-5p. In order to further qualify miR-122-5p as biomarker, the 
effects of these drug classes need to be investigated. However, it should be noted 
that miR-122-5p retains its sensitivity and specificity for predicting ALI across a range 
of mixed overdoses.  
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Future studies should investigate the clearance mechanisms of miR-122-5p when 
combined with its circulating carrier, Ago2. Such studies would include defining the 
contribution of the kidney. The results from chapter B demonstrated that the Ago2 
bound form of miR-122-5p is substantially reduced in patients with ESRD. 
Mechanisms that underlie this are yet to be defined but may include reduced 
production of microRNA. However, if this were the case, the extra-cellular vesicle 
(ECV) bound fraction would also be expected to fall. Neal et al. have reported that 
ESRD is associated with increased circulating RNAse activity (235). The Ago2 bound 
form of miR-122-5p may be more sensitive to enzymatic digestion compared with 
ECV encapsulated miR-122-5p. A priori it could be hypothesised that the ECV fraction 
would differ between patients with ESRD and healthy controls because as it has 
clearly demonstrated that systemically injected ECVs are excreted in urine (259, 260). 
This would suggest that their clearance may be altered in ESRD. However, the miR-
122-5p concentration in this fraction did not change. Defining the kinetics of miR-122 
will be a priority if it is to be adopted into clinical practice and drug development.  
The results from this thesis amongst other publications suggest that zebrafish could 
potentially be used as an effective economical method for early hepatotoxicity 
screening in drug development  (205). In order to confirm this and make it useful in 
drug development, an automated assay needs to be developed that can test a high 
number of compounds in a high throughput fashion. The VAST (Vertebrate 
Automated Screening Technology) BioImager platform could be an ideal platform. 
The VAST system allows for fast automatic loading of larvae from multiwall plates in 
a capillary tube after which it is automatically oriented along the desired axis from 
which it is imaged (261). This system in combination with the fluorescent reporter 
Tg(-2.8lfabp:GFP)as3 that was able to track TP induced hepatotoxicity by liver volume 
and fluorescent intensity might be an effective system for screening compound 
libraries for DILI at an early stage during drug development. This system will need to 
be benchmarked and compared to the currently used high content screens used in 
drug development that primarily uses cell lines (205), by testing a wide variety of 
known hepatotoxic and non-hepatotoxic compounds. 
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The results in this thesis report that TP can induce specific and reproducible 
hepatotoxicity in zebrafish larvae. In the future it should be tested if there is a dosing 
regimen that can induce hepatotoxicity in zebrafish larvae from which they can 
recover. Zebrafish exhibit a strong regenerative capacity (262), with for instance the 
heart being able to fully regenerate within 2 months after 20% ventricular resection 
(263). Some models for liver regeneration in zebrafish exist such as partial 
hepatectomy by removal of one lobe (264) and liver ablation by using bacterial nitro 
reductase (NTR) in transgenic zebrafish with a liver specific promotor for NTR (265). 
However, these models have limitations due to their complexity and low throughput. 
If a dosing regimen with TP could be found that results in liver injury in a short time 
by simply adding drug to the water after which it can recover in clean system water 
it would offer useful system in the area of screening compounds and drugs for their 
effects upon liver regeneration (266). 
The development of circulating miRNAs as biomarkers in DILI is an exciting and 
valuable field to focus research efforts on. Exploiting these small RNA molecules has 
a great potential to improve paracetamol overdose management and the detection 
of DILI in clinical drug development. The work presented in this thesis confirmed that 
miR-122-5p was the optimum circulating miRNA for predicting the onset of DILI at 
first presentation to the hospital. The work presented in this thesis has highlighted 
the limitations and challenges related to the development and qualification required 
in biomarker research and have addressed this by exploring specific clinical scenarios. 
In conclusion, miRNAs can be used as specific markers for hepatotoxicity in humans 
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Supplementary Table 1. Patient demographics and clinical chemistry results in the 
training and test set.  
 






Training set Test set 
APAP-TOX APAP-no TOX APAP-TOX APAP-no TOX 
Number 27 27 41 40 
Sex (male:female) 10:17 11:16 13:28 15:25 
Age years (IQR) 39 (26-54) 38 (25-55) 39 (31-49) 38 (29-49) 
ALT IU/l (IQR) 2150 (487-4444) 16 (13-26) 3661 (2454-6306) 20 (12-25) 
INR (IQR) 1.5 (1.3-2.1) 1.1 (1.0-1.2) 3.4 (2.3-6.2) 1.1 (1.0-1.1) 
Creatinine µmol/L (IQR) 66 (58-170) 62 (55-80) 157 (66-230) 64 (56-69) 
Creatinine >110 
µmol/L (number) 
8 0 22 0 
 3 
Supplementary Table 2. Patient demographics and clinical chemistry results in 
patients with acetaminophen induced liver injury with normal renal function 
(APAP-ALI no AKI) and with abnormal renal function (APAP-ALI with AKI) 
  
  APAP-ALI no AKI APAP-ALI with AKI 
Number 38 30 
Sex (male:female) (14:24) (14:16) 
Age years (IQR) 40 (27-58) 41 (31-49) 
ALT IU/l (IQR) 2307 (651-3455) 4083 (2920-7398) 
INR (IQR) 1.9 (1.4-2.8) 3.4 (2.1-6.1) 
Creatinine µmol/L (IQR) 61 (56-73) 209 (120-286) 
 
 
ALT, alanine aminotransferase (ALT); INR, International Normalized Ratio. Data 
are presented as median values. *** P < 0.0001; ** P < 0.001 (Mann Whitney test). 
  
 4 
Supplementary Table 3. Normfinder assessment of 50 most stable expressed 
microRNA, including stability value. 
 






















































Supplementary Table 4. Patient demographics of the early acetaminophen overdose 
patient cohort. 
 
Number 67  
Sex (male:female) 34:33 
Age years  39 (26-49) 
Amount of acetaminophen ingested g  16 (12-30) 
Time from ingestion to first blood sample hr  6 (4-16) 
Admission acetaminophen concentration mg/L  101 (24-139) 
Admission serum creatinine µmol/L  66 (56-77) 
Admission billirubin µmol/L  6 (4-11) 
Admission ALT activity IU/L  20 (14-34) 
Admission ALP activity IU/L  72 (56-89) 
Admission GGT activity IU/L  31 (20-73) 
Admission INR  1.0 (1.0-1.1) 
Number with admission ALT<ULN 58 
Number with peak ALT > 3x ULN 13 
Number with peak ALT > 1000 IU/L 5 
Number with admission INR > 1.5 1 
Number with peak INR > 1.5 6  
ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGT, gamma glutamyl 
transpeptidase; INR, International Normalized Ratio; ULN, upper limit of normal. Data are 














































miR-122-5p Increase Yes Yes No Yes Yes 
miR-885-5p Increase Yes No No Yes No 
miR-151a-3p Increase Yes Yes No No No 













































Supplementary Fig. 1. Heatmap displaying cluster analysis of >3-fold 
increased/decreased circulating miRNAs in acetaminophen no toxicity (APAP-
no TOX) and acetaminophen toxicity (APAP-TOX) patients from the training 





Supplemental Fig 2. Graphical representations of the Ct values of 6 endogenous 
normalizers and ALT. Samples are from the APAP-early cohort. The coefficient of 






miRNA PCR RNA isolation and Sample Quality Control 
 
RNA was isolated from 200 µl plasma samples using the miRNeasy Serum/Plasma 
Kit (Qiagen, Venlo, Netherlands). RNA was eluted in a fixed volume of 14 µl and 
stored at -800C. Samples were evaluated for suitability by using the miScript PCR 
System (Qiagen, Venlo, Netherlands). Briefly, 1.5 µl of each eluate was reverse 
transcribed into cDNA using the miScript II RT Kit with miScript HiSpec Buffer. 
The reactions were incubated for 60 minutes at 37°C followed by a heat inactivation 
step for 5 minute at 95°C. One µl of each 10 µl cDNA synthesis was then diluted 
eleven-fold and assessed for a) the presence of common miRNA and for the absence 
of RT-PCR inhibitors using the miScript SYBR Green PCR Kit and the miScript 
miRNA QC PCR Array. Real-time PCR was performed on an ABI-7900HT (Applied 
Biosystems, Foster City, CA) using the recommended miScript cycling parameters.  
 
Phase I: Determine Expressed miRNAs 
 
A collection of 18 randomly chosen training set APAP no TOX samples and 18 
randomly chosen training set APAP-TOX samples were combined into two control 
pools and two liver injury sample pools, respectively, with each pool containing 
RNA from 9 samples. cDNA synthesis and real-time PCR were performed using the 
miScript PCR System. Briefly, 7.5 µl of total RNA eluate from each of the four 
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pooled samples was reverse transcribed into cDNA using the miScript II RT Kit with 
miScript HiSpec Buffer. Each cDNA synthesis was diluted to a final volume of 550 
µl using RNase-free water. For real-time PCR analysis of miRNA expression, diluted 
cDNA (1 µl per 4 wells) was analyzed using the miScript SYBR Green PCR Kit and 
the Human miRNome miScript miRNA PCR Array (miRBase V18, 1809 miScript 
Primer Assays). Real-time PCR was performed on an ABI-7900HT (Applied 
Biosystems, Foster City, CA) using the miScript cycling program. A miRNA was 
deemed to be expressed if its Ct value was less than 35 with a single, sharp melt peak 
in at least one of the four pools. A total of 356 miScript Primer Assays (or roughly 
20% of the miRNome) were selected for Phase II screening. 
 
Phase II: Determine Differentially Expressed miRNAs 
 
cDNA synthesis, cDNA preamplification, and real-time PCR were performed as 
described earlier for each of the 54 samples. Each cDNA synthesis was diluted 5-fold 
and one-tenth was preamplified using the miScript Microfluidics PreAMP Kit in 
combination with a Custom miScript PreAMP Primer Mix containing the 356 
miScript Primer Assays identified as ‘expressed’ in Phase I. Twelve cycles of 
preamplification was performed using the manufacturer recommended 384-plex 
preamplification protocol. Amplified cDNA was diluted to a final volume of 125 µl 
using RNase-free water and assessed in real-time PCR using the miScript 
Microfluidics PCR Kit and a Custom miScript miRNA PCR Array containing the 
356 expressed assays from Phase I. Real-time PCR was performed on a Fluidigm 
BioMark HD (Fluidigm, San Francisco, US) using the miScript cycling program for 
the Fluidigm BioMark, which consists of an initial thermal mix stage (50°C for 2 
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minutes, 70°C for 30 minutes, and 25°C for 10 minutes) followed by a hot start at 
95°C for 15 minutes and 40 cycles of 94°C for 15 seconds, 55°C for 30 seconds, and 
70°C for 30 seconds. For data processing, Ct values were calibrated for RNA 
recovery using the cel-miR-39-3p assay (which detects a synthetic miRNA spiked in 
to each sample during sample prep), and any miRNA assay with a Ct > 23 was 
deemed to be not expressed. For data analysis, the ΔΔCt method of relative 
quantification was used. The Ct values used for calculating the fold changes were 
normalized using the Global Ct mean.  The miRNAs included in the Ct mean were 
expressed in all samples at a Ct < 23. The Ct values used for the random forest 
analysis were normalized using invariant miRNAs.   
 
Random forest analysis of profiling test set data 
 
Classifier training was performed using APAP-no TOX (27 samples) versus APAP-
TOX (26 samples). The random forest classification method was used for two 
independent steps: (1) selection of the most predictive 16 miRNAs from the full set 
of experimentally selected 92 miRNAs and 1 snoRNA, and (2) training a final 16-
miRNA classification model. 
 
Step 1: selection of 16 miRNAs.  To select 16 miRNAs from the 93 measured 
without feature selection bias, we drew 250 bootstrap subsamples of the full training 
set, without replacement.  The subsamples were chosen to contain about 80% of the 
smaller TOX class and an equal number of no-TOX samples.  This gave 20 APAP-
noTOX versus 20 APAP-TOX. For each subsample, random forest classifier was 
trained, saved by the gene importance rank (by sorting according to the marginal 
 12 
decrease in out-of-bag prediction accuracy when the gene's expression measurements 
are scrambled), saved by predictions on the left-out samples and then the random 
forest model was discarded.  After all 250 iterations were complete, 93 genes were 
sorted by their median importance rank across all 250 bootstrap trainings, and the top 
16 genes were selected.  In addition to using the 250 bootstrap subsamples to obtain 
the 16 potentially most predictive genes, we also used the samples left out of training 
in each subsample to assess class separation magnitude and model error. 
 
Step 2: final classifier training.  Using the final 16 genes only, we trained a new 
random forest classifier using all training set samples, and saved this for use in class 
prediction on new samples.   The performance of this final 16 gene classifier was 
tested using our independent test set samples.  The classifier gives the probability 
that each sample is APAP-TOX.  This classification was performed blind to the true 
sample grouping. 
 
MicroRNA measurement by PCR 
 
 
miRNA timecourse, miRNA in Ago2 fraction and miRNA in mice 
 
 
RNA was isolated from 50 µl plasma samples using the miRNeasy Serum/Plasma 
Kit (Qiagen, Venlo, Netherlands). RNA was eluted in a fixed volume of 14 µl, after 
which 2 µl was reverse transcribed using the TaqMan MicroRNA Reverse 
Transcription Kit using stem-loop primers (Applied Biosystems, Foster City, CA) for 
each target miRNA species following the manufacturer’s instructions. Then, 1.33 µL 
of cDNA was used in the PCR mixture using the specific PCR probes (Applied 
Biosystems, Foster City, CA). Levels of miRNAs were measured using the Light 
Cycler 480 (Roche, Basel, Switzerland).  
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miRNA measurement - APAP - early  
 
RNA was isolated from 50 µl plasma samples using the miRNeasy Serum/Plasma 
Kit (Qiagen, Venlo, Netherlands). RNA was eluted in a fixed volume of 14 µl, after 
which 5 µl of each eluate was reverse transcribed into cDNA using the miScript II 
RT Kit (Qiagen, Venlo, Netherlands) following manufacturers instructions. The 
synthesized cDNA was ten-fold diluted and used for cDNA template in combination 
with the miScript SYBR Green PCR Kit (Qiagen, Venlo, Netherlands) using the 
specific miScript assays (Qiagen, Venlo, Netherlands). Real-time PCR was 
performed on a Light Cycler 480 (Roche, Basel, Switzerland) using the 
recommended miScript cycling parameters.  Ct values greater than 35 were 
considered to be negative for that miRNA.  
 
Supplemental Figure 1. 
 
 




Supplementary material legends 
 
Supplementary Figure 1. Discovery cohort. (A) Correlation between plasma 
APAP concentration (APAP) measured by LC-MS/MS and measured in the 
clinical chemistry laboratory as part of routine clinical care. Correlation 
coefficient (95% confidence interval), R squared and P value are given. N=116 
(B) In patients recruited to SNAP trial the time course of the mean plasma 
concentration of each APAP metabolite. Error bars represent standard 
deviation.  N=116. 
 
Supplementary Figure 2. APAP metabolite concentrations in patients with no 
acute liver injury (ALI) and ALI, in discovery (N=116) and validation cohorts 
(N=150). (A) APAP-CYS, (B) APAP-Mer, and (C) APAP-GSH represent the 
concentration of CYP mediated metabolites. (D) APAP-Glu and (E) APAP-Sul 
represent the concentrations of non CYP mediated metabolites. Boxes show 
median±IQR, whiskers represent range. Mann Whitney test was used to 
calculate statistical differences. 
 
Supplementary Figure 3. Predictive accuracy of current and new biomarkers. 
Example ROC curves for the most sensitive and specific APAP metabolites in the 
discovery (A) and validation (B) cohorts. ROC curves for APAP parent drug are 
presented for the discovery (C) and validation (D) cohorts. (E) Correlation 
between the APAP-Cys/APAP-Sul metabolite ratio at hospital presentation in 
the discovery cohort and peak hospital stay serum alanine transaminase (ALT) 
activity (N=116). (F) At hospital presentation in the validation cohort. 




Metabolites formed by CYP enzyme activity are expressed as a proportion of 
total circulating metabolites (CYP/total (%)) in liver injury (ALI) (N=19) and 
non-liver injury (No ALI) patients (N=131).  Boxes show median±IQR, whiskers 
represent range. 
 
Supplementary Table 1. Discovery cohort patient characteristics divided by 
SNAP treatment groups. †according to the British National Formulary 2009. 
*p=0.02 ondansetron vs. placebo. No patients were taking enzyme-inducing 















Number 34 30 25 27 




31 (21-48) 36.5 (28.6-46) 29 (23.5-42.5) 
Median (IQR) 
weight (kg) 
69 (62-79.3) 64.5 (54-82) 71 (60.8-79.5) 68 (61.5-79.5) 
Number of females 22 (65%) 16 (55%) 15 (58%) 20 (74%) 
Median (IQR) time 
from ingestion to 
treatment 










167 (145-311) 238 (162-364) 239 (199-325) 
Number who 
ingested APAP ≥16g 
17 (50%) 10 (34%) 12 (46%) 14 (52%) 
Alcohol ingested 14 (41%) 15 (52%) 15 (58%) 16 (59%) 
Other drugs 
ingested 
20 (59%) 17 (59%) 19 (73%) 20 (74%) 
Opioids 3 3 7 4 
Anti-histamines 1 1 1 0 
Nutritional 
deficiency 
7 (21%) 6 (21%) 2 (8%) 4 (15%) 
Debilitating disease 1 (3%) 1 (3%) 0 (0%) 0 (0%) 
Chronic alcohol use 12 (35%) 10 (34%) 13 (50%) 9 (33%) 
Identified as high 
risk† 







20 (13-36) 18 (13-28) 22 (17-28.5) 
Number with acute 
liver injury (>50% 
ALT rise) 































































S r = 0.88 (0.84-0.92)
R squared = 0.78





Supplementary figure 2. 






























































Discovery cohort Validation cohort
B




























P = 0.0005 P = 0.02 P = 0.03
Discovery cohort Validation cohort
C































Discovery cohort Validation cohort
D
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Supplementary Figure 1. Effect of triptolide on zebrafish larvae after 48 hours (3-
5dpf) exposure. Magnified histological images at x400 of zebrafish larvae liver after 
water exposure to triptolide at the concentrations indicated. Three representative fish 
are presented for each dose. Note the presence of dose dependent increase in 
hepatocyte vacuolation (A), necrosis (with nuclei breaking down (B) and karyolysis 
(C)) and the presence of disarray (red lines). The latter two features are absent from 







































Supplementary figure 2. Histological images of adult zebrafish after exposure to 
triptolide (1.6 μM) during 10 hours. (A) Subgross view. Liver is indicated by the red 
arrow. The area whith hepatic necrosis is indicated by the circle. (B) Arrows denote 
lesions consistent with hepatic necrosis after triptolide exposure. (C) Control adult 
zebrafish after exposure to vehicle control. Normal liver, with no areas of necrosis.  
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Supplementary Table 1. Significantly enriched GO terms in response to triptolide in 
zebrafish larvae (with P < 0.001 cutoff). 
 






translation Up 4.35x10-51 
cellular protein metabolic process Up 2.31x10-13 
protein metabolic process Up 1.56x10-12 
cellular biosynthetic process Up 7.93x10-12 
biosynthetic process Up 8.50x10-12 
macromolecule biosynthetic process Up 4.12x10-10 
cellular macromolecule biosynthetic process Up 5.81x10-10 
gene expression Up 5.19x10-08 
generation of precursor metabolites and energy Up 5.81x10-07 
immune response Up 2.35x10-06 
regulation of cell cycle Up 2.41x10-06 
translational elongation Up 2.58x10-06 
defense response Up 9.92x10-06 
primary metabolic process Up 1.24x10-05 
response to other organism Up 1.83x10-05 
multi-organism process Up 2.69x10-05 
immune system process Up 5.92x10-05 
cellular metabolic process Up 9.07x10-05 
response to biotic stimulus Up 0.0001 
embryo development Up 0.0002 
carbohydrate catabolic process Up 0.0002 
hormone biosynthetic process Up 0.0003 
energy derivation by oxidation of organic 
compounds Up 0.0004 
metabolic process Up 0.0005 
glycolysis Up 0.0005 
glucose metabolic process Up 0.0006 
cellular carbohydrate catabolic process Up 0.0006 
alcohol catabolic process Up 0.0006 
respiratory electron transport chain Up 0.0006 
purine nucleotide biosynthetic process Up 0.0006 
response to virus Up 0.0009 
response to lipopolysaccharide Up 0.0009 
nucleic acid metabolic process Down 4.83x10-27 
cellular nitrogen compound metabolic process Down 2.61x10-23 
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nucleobase, nucleoside, nucleotide and nucleic 
acid metabolic process Down 3.95x10-23 
transcription Down 4.01x10-23 
regulation of transcription Down 2.65x10-22 
nitrogen compound metabolic process Down 4.84x10-22 
regulation of nucleobase, nucleoside, nucleotide 
and nucleic acid metabolic process Down 3.00x10-21 
regulation of gene expression Down 4.36x10-21 
regulation of nitrogen compound metabolic 
process Down 5.67x10-21 
regulation of macromolecule biosynthetic process Down 1.24x10-20 
regulation of biosynthetic process Down 1.35x10-20 
regulation of cellular biosynthetic process Down 1.80x10-20 
regulation of cellular metabolic process Down 1.18x10-19 
RNA metabolic process Down 5.84x10-19 
regulation of primary metabolic process Down 4.89x10-18 
regulation of macromolecule metabolic process Down 6.20x10-18 
gene expression Down 8.92x10-18 
regulation of metabolic process Down 1.99x10-17 
cellular macromolecule metabolic process Down 6.59x10-14 
regulation of RNA metabolic process Down 6.65x10-12 
regulation of transcription, DNA-dependent Down 8.54x10-12 
transcription, DNA-dependent Down 1.22x10-11 
nervous system development Down 1.52x10-11 
multicellular organismal development Down 1.82x10-11 
system development Down 2.66x10-11 
RNA biosynthetic process Down 2.68x10-11 
RNA processing Down 8.40x10-11 
multicellular organismal process Down 2.38x10-10 
developmental process Down 3.65x10-10 
macromolecule metabolic process Down 1.51x10-09 
regulation of cellular process Down 1.76x10-09 
anatomical structure development Down 2.51x10-09 
regulation of biological process Down 1.07x10-08 
cellular macromolecule biosynthetic process Down 2.01x10-08 
brain development Down 4.16x10-08 
organ development Down 4.46x10-08 
central nervous system development Down 5.35x10-08 
macromolecule biosynthetic process Down 5.73x10-08 
neurogenesis Down 2.13x10-07 
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cellular metabolic process Down 5.09x10-07 
generation of neurons Down 7.20x10-07 
biological regulation Down 1.09x10-06 
skeletal system development Down 1.15x10-06 
forebrain development Down 1.23x10-06 
neuron differentiation Down 1.32x10-06 
cellular developmental process Down 2.33x10-06 
cartilage development Down 2.83x10-06 
embryo development ending in birth or egg 
hatching Down 3.57x10-06 
chordate embryonic development Down 3.57x10-06 
cellular biosynthetic process Down 8.45x10-06 
cell fate commitment Down 9.71x10-06 
cell differentiation Down 1.36x10-05 
biosynthetic process Down 2.24x10-05 
cellular process Down 2.74x10-05 
cell fate specification Down 2.84x10-05 
mRNA processing Down 3.09x10-05 
sensory organ development Down 3.52x10-05 
ncRNA processing Down 4.28x10-05 
cellular component organization Down 4.66x10-05 
skeletal system morphogenesis Down 5.29x10-05 
ribosome biogenesis Down 8.59x10-05 
primary metabolic process Down 0.0001 
ribonucleoprotein complex biogenesis Down 0.0001 
embryonic skeletal system development Down 0.0001 
anatomical structure morphogenesis Down 0.0001 
regulation of signaling pathway Down 0.0001 
rRNA processing Down 0.0002 
ncRNA metabolic process Down 0.0002 
embryonic skeletal system morphogenesis Down 0.0002 
camera-type eye development Down 0.0002 
hindbrain development Down 0.0003 
eye development Down 0.0003 
mRNA metabolic process Down 0.0003 
neuron development Down 0.0003 
embryonic cranial skeleton morphogenesis Down 0.0004 
cellular response to stimulus Down 0.0004 
rRNA metabolic process Down 0.0004 
RNA modification Down 0.0005 
cellular membrane organization Down 0.0005 
membrane organization Down 0.0005 
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embryonic organ morphogenesis Down 0.0005 
generation of neurons in the forebrain Down 0.0005 
forebrain neuron differentiation Down 0.0005 
chromatin organization Down 0.0006 
neural crest cell differentiation Down 0.0006 
anterior/posterior pattern formation Down 0.0007 
peroxisome organization Down 0.0008 
cardioblast differentiation Down 0.0008 
regionalization Down 0.0008 
RNA splicing Down 0.0009 
neural crest cell development Down 0.0009 
pattern specification process Down 0.0009 
chromosome organization Down 0.0009 
Molecular 
Function 
structural constituent of ribosome Up 3.13x10-64 
structural molecule activity Up 2.09x10-41 
rRNA binding Up 6.47x10-08 
hydrogen ion transmembrane transporter activity Up 4.97x10-06 
actin binding Up 1.26x10-05 
monovalent inorganic cation transmembrane 
transporter activity Up 8.25x10-05 
inorganic cation transmembrane transporter 
activity Up 0.0002 
cytoskeletal protein binding Up 0.0002 
cytochrome-c oxidase activity Up 0.0004 
heme-copper terminal oxidase activity Up 0.0004 
oxidoreductase activity, acting on heme group of 
donors Up 0.0004 
oxidoreductase activity, acting on heme group of 
donors, oxygen as acceptor Up 0.0004 
cytokine receptor binding Up 0.0004 
cation transmembrane transporter activity Up 0.0004 
substrate-specific transmembrane transporter 
activity Up 0.0007 
ion transmembrane transporter activity Up 0.0009 
nucleic acid binding Down 7.69x10-22 
transcription regulator activity Down 1.36x10-16 
DNA binding Down 1.63x10-14 
sequence-specific DNA binding transcription 
factor activity Down 4.96x10-13 
sequence-specific DNA binding Down 1.28x10-09 
binding Down 1.71x10-08 
zinc ion binding Down 7.20x10-06 
ubiquitin thiolesterase activity Down 0.0002 
transferase activity, transferring phosphorus-
containing groups Down 0.0005 
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transition metal ion binding Down 0.0006 
Cellular 
Component 
ribosome Up 9.09x10-61 
ribonucleoprotein complex Up 3.48x10-46 
non-membrane-bounded organelle Up 7.41x10-33 
intracellular non-membrane-bounded organelle Up 7.41x10-33 
macromolecular complex Up 1.67x10-24 
cytoplasmic part Up 4.73x10-24 
cytoplasm Up 1.01x10-17 
ribosomal subunit Up 1.08x10-10 
small ribosomal subunit Up 4.86x10-08 
intracellular part Up 6.25x10-08 
intracellular organelle Up 3.82x10-07 
organelle Up 3.92x10-07 
eukaryotic translation elongation factor 1 complex Up 4.66x10-06 
intracellular Up 0.0002 
large ribosomal subunit Up 0.0005 
myosin filament Up 0.0008 
proton-transporting ATP synthase complex, 
catalytic core F(1) Up 0.0009 
nucleus Down 2.45x10-30 
membrane-bounded organelle Down 4.74x10-18 
intracellular membrane-bounded organelle Down 4.74x10-18 
intracellular Down 7.22x10-12 
intracellular organelle Down 8.23x10-12 
organelle Down 9.53x10-12 
intracellular part Down 4.24x10-09 
 
